Gene expression in the peripartum canine placenta by Kutzler, Michelle A. et al.
 
   AN ABSTRACT OF THE THESIS OF  
 
 
Elizabeth Jane Fellows for the degree of Master of Science in Animal Sciences presented 
on August 30, 2012 
Title: Gene Expression in the Peripartum Canine Placenta 
 
 
Abstract Approved: 
 
 
Michelle A. Kutzler 
 
This research investigated gene expression in the canine placenta during the peripartum 
period. Previous studies have recognized molecular changes that occur in the placenta 
around the time of placental release in other species, but no study has looked at gene 
expression in the late gestation canine placenta. Of particular significance for this thesis 
work is the groundwork laid for future studies modeling placental abnormalities in dogs 
(e.g. subinvolution of placental sites) and humans (e.g. preeclampsia, placenta accreta). 
Despite years of research in multiple species, the exact mechanisms and processes 
regulating trophoblast invasion and placental release remain unclear. Therefore, the 
specific objective of this research was to characterize gene expression changes that occur 
during the peripartum period in the dog using microarray and real-time RT-PCR. 
Following total RNA isolation, the microarray analysis was performed by hybridizing 
total RNA to the Canine 2.0 Array (Affymetrix, Santa Clara, CA). Microarray analysis 
was carried out using the limma and affy packages through the Bioconductor software in 
WKH5VWDWLVWLFDOHQYLURQPHQW'LIIHUHQWLDOH[SUHVVLRQZDVGHILQHGDVS)'5S
DQGDORJIROGFKDQJHRI)ROORZLQJF'1$V\QWKHVLVUHDO-time RT-PCR was 
performed using TaqMan primer and probes that were pre-made and pre-optimized for canine tissues (Applied Biosystems, Carlsbad, CA).  Microarray analysis showed 
differential expression in 18 genes between pre-term and pre-labor sample groups, 38 
genes that were differentially expressed between pre-term and parturient samples and no 
genes that were differentially expressed between pre-labor and parturient samples. 
Microarray analysis led to the identification of several candidate genes for closer 
investigation using real-time RT-PCR. These genes included MMP-1, MMP-2, MMP-9, 
TIMP-2, VEGF-A, Flt-1, CD44, DAG-1, IL-6 and CXCL10. All of these genes have 
been linked to trophoblast invasion or regression or placental release in a number of 
species including humans, cattle and rodents.  Using real-time RT-PCR, there was a 
significant difference in MMP-9 mRNA expression in pre-term samples compared to pre-
labor and parturient samples (p<0.05). However, there was no significant difference in 
mRNA expression of MMP-2, TIMP-2, VEGF-A, Flt-1 CD44, DAG-1, IL-6 or CXCL10. 
Future studies may focus on additional candidate genes identified by microarray that play 
a role in tissue remodeling at the end of canine gestation such as IL-8, EPHX2, PI3 and 
SERPINE1.  
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CHAPTER I 
 
 
 
INTRODUCTION 
 
 
 
1.1 GENETIC REGULATION OF TROPHOBLAST MIGRATION AND INVASION 
 
 
 
1.1.1  Significance 
 
  Determining the mechanisms of trophoblast invasion in various placental types is 
crucial for a better understanding of pathologic trophoblast processes and conditions. 
Clarifying the regulatory mechanisms of normal trophoblast invasion will allow a better 
understanding of abnormal trophoblast invasion. The etiologies of pathologic conditions 
involving shallow trophoblast invasion such as preeclampsia in humans (Brosens et al., 
1972; Pijnenborg et al., 1991) and uninhibited trophoblast invasion such as placenta 
accreta in humans (Davidson, 1944; Khong and Robertson, 1987) or subinvolution of 
placental sites (SIPs) in dogs (Al-Bassam et al., 1981; Fernández et al., 1998) remain 
elusive.  
 
1.1.2  Summary 
 
Trophoblast invasion is crucial for anchoring the embryo to the uterus (Gao et al., 
2001) and is essential for the successful development of the placenta in deciduate species. 
A general placental classification distinguishes between deciduate and adeciduate types. 
In the adeciduate placental type, the endometrium is left intact at parturition. This type of 
placenta is seen in larger domestic animals (e.g. ruminants, pigs, horses). The deciduate 
placental type is seen in primates and rodents, with a modified form seen in carnivores 
(Roberts, 1986). In this type of placenta, the endometrium is lost at parturition. In 2	 ﾠ
primates and rodents, deeper layers of the endometrium are lost, whereas this loss is more 
superficial in dogs (Jainudeen and Hafez, 1993).  
In addition to mechanical disruption and penetration of the endometrium, 
trophoblast invasion is an active process involving secretion of multiple factors (Fisher et 
al., 1985). Within the placenta, the trophoblast is the only cell with the ability to degrade 
the extracellular matrix within the endometrium (Pijnenborg et al., 1980; Fisher et al., 
1985). Many studies compare trophoblast invasion to tumor invasion. However, unlike 
tumor invasion, trophoblast invasion is regulated by time and space (Graham and Lala, 
1991; Bischof et al., 2000). A number of autocrine and paracrine factors regulate 
trophoblast invasion including matrix metalloproteinases, tissue inhibitors of 
metalloproteinases, components of the extracellular matrix, and cytokines (Bischof et al., 
2000; Bischof et al., 2002).  
 
1.1.3  Matrix Metalloproteinases and their Tissue Inhibitors 
 
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are crucial 
for the process of cell invasion. Matrix metalloproteinases are a family of over 20 zinc 
dependent proteases that can degrade the extracellular matrix (ECM) (McCawley and 
Matrisian, 2001). This family includes gelatinases (MMP-2, MMP-9), which degrade 
collagen type IV, a major component of the basement membrane. Other members of this 
family include collagenases (MMP-1, MMP-8, MMP-13), stromelysins (MMP-3, MMP-
7, MMP-10, MMP-11, MMP-12) and membrane-bound metalloproteinases (MT1-MMP, 
MT2-MMP, MT3-MMP, MT4-MMP) (Matrisian, 1990; Bischof and Campana, 2000). 
Membrane-bound metalloproteinases are important for the activation of latent MMPs 
such as pro-MMP-2 (Sato et al., 1994; Bjørn et al., 2000).  
Support for a role of MMPs in trophoblast invasion comes from the localization 
of these factors in trophoblasts of several species: sheep (Salamonsen et al., 1995; Riley 
et al., 2000), pigs (Menino et al., 1997), cows (Hashizume 2007) and goats (Uekita et al., 
2004). In the horse, MMPs are involved in chorionic girdle trophoblast invasion 3	 ﾠ
(Vagnoni et al., 1995). In humans, both mRNA and protein expression of MMP-9 
(Hurskainen et al., 1996; Huppertz et al., 1998; Xu et al., 2000) and MMP-14 have been 
reported in isolated first trimester trophoblasts (Huppertz et al., 1998; Xu et al., 2000). In 
addition, MMP-3 is also expressed in invasive human trophoblasts (Huppertz et al., 1998; 
Husslein et al., 2009) and MMP-7 (Vettraino et al., 1996) is present in intermediate 
trophoblasts and the decidua suggesting both of these MMPs influence trophoblast 
invasion of the spiral arteries.  
Matrix metalloproteinases, specifically MMP-2 and MMP-9, have been identified 
as rate-limiting enzymes for trophoblast invasion in mice (Behrendtsen et al., 1992; 
Alexander et al., 1996), non-human primates (Gao et al., 2001; Wang et al., 2001) and 
humans (Librach et al., 1991; Staun-Ram et al., 2004). In murine trophoblasts, MMP-2 
and MMP-9 mRNA expression show major spatial and temporal changes during 
implantation (Das et al., 1997). Furthermore, MMP-2 has been localized to specialized 
cell membrane extensions known as “invadiopodia”, involved with degradation of the 
extracellular matrix (Monsky et al., 1993). In vivo and in vitro studies have shown that 
MMP-2 (Isaka et al., 2003; Staun-Ram et al., 2004) and MMP-9 (Librach et al., 1991; 
Morgan et al., 1998; Luo et al., 2011) are critical for trophoblast invasion in humans; 
whereas MMP-2, MMP-9, and MMP-14 (MT1-MMP) are crucial for trophoblast 
invasion in rhesus monkeys (Wang et al. 2001).  
Tissue inhibitors of metalloproteinases (TIMPs) are involved with the regulation 
of trophoblast invasion through MMP inhibition. The activity of MMPs, specifically 
MMP-2 and MMP-9, is regulated at the transcriptional level by proenzyme activation as 
well as by TIMP-1 and TIMP-2 (Matrisian, 1990; Woessner, 1991). The TIMP family 
consists of four members: TIMP-1, TIMP-2, TIMP-3 and TIMP-4. Within the placenta, 
TIMP-1 has been identified in both trophoblasts and fibroblasts, while TIMP-2, TIMP-3 
and TIMP-4 are primarily secreted by trophoblasts (Riley et al., 1999). TIMP-1 has the 
ability to inhibit most MMPs (Gao et al., 2001; Goldman et al., 2003) and its expression 
is non-cell specific, suggesting its role is to protect the trophoblast from degradation by 
its own MMPs (Gao et al., 2001). TIMP-2 is most likely of maternal origin and inhibits 4	 ﾠ
invasion of first trimester human trophoblasts (Librach et al., 1991), possibly through 
regulation of MMP-2 (Itoh et al., 1998).  
The mRNA expression of TIMP-3 has been shown to correlate with MMP-9 
during early gestation at the peak of trophoblast invasion (Bass et al., 1997). A balance 
between MMP-9 and TIMP-3 activity is proposed to regulate the depth of trophoblast 
invasion in monkeys (Wang et al., 2001) and rodents (Das et al., 1997). In rhesus 
monkeys, TIMP-1, TIMP-2 and TIMP-3 mRNA expression is thought to be crucial for 
regulation of trophoblast invasion (Wang et al., 2001). Major spatiotemporal changes in 
TIMP-3 mRNA expression also occur during murine implantation (Das et al., 1997). In 
humans, both mRNA and protein expression of MMP-9, TIMP-1, TIMP-2 and TIMP-3 
have been localized to early gestation cytotrophoblasts (Hurskainen et al., 1996; 
Huppertz et al., 1998; Xu et al., 2000).  
 
1.1.4  KiSS-1 and its receptor KiSS-1R 
 
The product of the KiSS-1 gene and its receptor, KiSS-1R have been isolated at 
high levels from the human placenta (Ohtaki et al., 2001) and from trophoblast giant cells 
of the rat placenta (Terao et al., 2004). Prior to its localization in the placenta, KiSS-1 
was found to suppress MMP-9 expression in fibrosarcoma cells through reduced NK-ț%
binding to the MMP-9 promoter (Yan et al., 2001), suggesting a role of KiSS-1 in cell 
invasion. The expression of KiSS-1 and KiSS-1R have been found to be parallel, 
suggesting an autocrine mechanism of activation.  
There is still debate over the temporal expression of KiSS-1 and KiSS-1R in the 
placenta. In the rat, mRNA expression of KiSS-1 and KiSS-1R is seen in the trophoblast 
giant cells on embryonic day 12.5. After embryonic day 12.5, its expression gradually 
decreases until term (Terao et al., 2004). KiSS-1 and KiSS-1R have been found to be 
expressed at significantly higher levels in first trimester human trophoblasts than term 
cells using semi-quantiative RT-PCR and DNA microarray (Bilban et al., 2004), 
suggesting their role is more important in early pregnancy. However, in another study, 5	 ﾠ
using real-time RT-PCR, KiSS-1R mRNA levels were higher in first trimester human 
trophoblasts compared to term, while KiSS-1 mRNA levels did not significantly change 
during gestation (Janneau et al., 2002).  The decline of KiSS-1 and KiSS-1R expression 
from early gestation to term reported in multiple studies seems counterintuitive, but 
perhaps the role of KiSS-1 in early gestation is to regulate the depth of trophoblast 
invasion. 
Despite differences in temporal expression of KiSS-1 and KiSS-1R, the evidence 
suggests it may play a significant role in the inhibition of trophoblast invasion. 
Kisspeptin-10 (Kp-10), a product of the KiSS-1 gene, has been shown to inhibit 
trophoblast migration in vitro presumably by inhibiting protease activity of MMP-2 
(Bilban et al., 2004). Furthermore, the invasion ability of trophoblasts transfected with 
the KiSS-1 gene is significantly lower than non-transfected cells and controls (Zhang et 
al., 2011). In addition, activation of the KiSS-1 receptor inhibits cell invasion and 
addition of KiSS-1 peptide to cells transfected with the receptor inhibits their invasion 
(Stafford et al., 2002). 
 
1.1.5  Vascular Endothelial Growth Factor-A and its Receptor (Flt-1) 
 
Vascular endothelial growth factor subtype A (VEGF-A) and its receptor (Flt-1) 
are expressed in human trophoblasts (Shore et al., 1997; Lash et al., 1999; Lash et al., 
2003; Lash et al., 2010). Following the binding of VEGF-A, Flt-1 initiates a JNK 
signaling cascade (Shore et al., 1997). VEGF acts as a chemoattractant for first trimester 
human trophoblasts but not term trophoblasts, which suggests trophoblasts change their 
responsiveness to VEGF throughout gestation (Lash et al., 2003).  
Treatment of trophoblasts with exogenous VEGF increases trophoblast motility 
but not invasion (Lash et al., 1999), suggesting that VEGF may play a role in the 
initiation of cell invasion, but lacks the protease activity needed to carry out the necessary 
degradation to complete the invasion process. In addition, levels of soluble Flt-1 secreted 
by human cytotrophoblasts increase with gestational age, suggesting a limit on the 6	 ﾠ
bioavailability of placental VEGF-A as pregnancy progresses (Lash et al., 2010).  In 
human umbilical vein endothelial cells, VEGF has been shown to stimulate the 
expression of Flt-1 and MMP-1 (Sato et al., 2000). Additionally, VEGF treatment of 
human smooth muscle cells has also been shown to increase mRNA expression of MMP-
1, -3 and -9 as well as enhance invasion of these cells in vitro (Wang and Keiser, 1998). 
 
1.1.6  Interleukins 
 
Members of the interleukin family have been implicated in the regulation of 
trophoblast invasion in humans and non-human primates through the regulation of MMP 
expression (as reviewed by Bischof et al., 2000). Immunolocalization of IL-Į,/-ȕDQG
IL-6 in cells of the conceptus and at the implantation site in rhesus monkeys (Sengupta et 
al., 2003) supports a role for interleukins in the implantation process. Both interleukin- 
ȕ (IL- ȕ) (Librach et al., 1994) and IL-Į0HLVVHUHWDOE*RQ]DOH]HWDO
increase MMP-9 activity. Interleukin-6 (IL-6) may also be involved with the regulation 
of trophoblast invasion by stimulating the activation of MMP-2 and MMP-9, possibly 
through an increased secretion of leptin by cytotrophoblasts (Meisser et al., 1999a).  
Interleukin-ȕ (IL-ȕXS-regulates MMP-2, MMP-9, MT1-MMP, MT2-MMP 
and urokinase plasminogen activator (uPA) mRNA in first trimester trophoblasts 
(Karmakar and Das, 2002). In immortalized human trophoblast cell lines ED27, ED31, 
and ED77, expression of MMP-9 is stimulated by IL-ȕ0RUJDQHWDO,QDGGLWLRQ
recombinant IL-ȕWUHDWPHQWRIWURSKREODVWs increases MMP-3 mRNA expression 
(Husslein et al., 2009). IL-ȕKDs also been shown to stimulate invasion in vitro (Librach 
et al., 1994). 
It has been suggested that IL-ȕDFWVLQERWKDQDXWRFULQHDQGSDUDFULQHPDQQHUWR
influence proteases during pregnancy and may initiate a cascade that activates MT-
MMPs, which then activate other MMPs (Karmakar and Das, 2002). Alternatively, it has 
been suggested that IL-ȕGLUHFWO\SURPRWHVWURSKREODVWPRWLOLW\XVLQJWKHX3$3$,
system. IL-ȕLQGXFHVWKHVHFUHWLRQRIX3$3$,-1 (plasminogen activator inhibitor 7	 ﾠ
(PAI)-1 and PAI-2 by trophoblasts, influencing trophoblast invasion. In addition, up-
regulation of IL-1 receptor (IL-1R1) expression during extravillous trophoblast 
differentiation suggests IL-1R1 may also affect invasion of the trophoblasts (Prutsch et 
al., 2012).  
Interleukin-8 (IL-8) as well as its receptor CXCR1 are expressed in the 
immortalized first trimester trophoblast cell line HTR-8/SVneo and isolated 
F\WRWURSKREODVWV-RYDQRYLüHWDO,QYDVLRQDVVD\VDQG]\PRJUDSK\KDYHVKRZQ
that treatment of trophoblasts with IL-8 stimulates migration and invasion as well as 
increases proMMP-2 and MMP-OHYHOV,QDGGLWLRQĮ5 DQGȕ1 integrins have been 
linked to an increase in trophoblast invasion following IL-WUHDWPHQW-RYDQRYLüHWDO
2010). Therefore, the role of IL-8 in trophoblast invasion may be to stimulate expression 
of MMP-2, MMP-9 and integrins. 
 Incubation of the human placental choriocarcinoma cell line (JEG-3) with 
interleukin 15 (IL-15) causes a significant increase in MMP-1 concentration. This 
suggests a role for IL-15 in cell invasion through the regulation of MMP-1 production by 
trophoblasts. Furthermore, treatment of trophoblasts with IL-15 results in a significant 
increase in invasion and migration in vitro (Zygmunt et al., 1998).  
Trophoblasts express interleukin 10 (IL-10) receptor mRNA and IL-10 synthesis 
by trophoblasts is inversely related to MMP-9 secretion. Furthermore, treatment of 
trophoblasts in vitro with IL-10 decreases MMP-9 mRNA levels. This has lead to the 
hypothesis that IL-10 is an autocrine regulator of trophoblast invasion. IL-10 likely plays 
a role in regulating the MMP/TIMP balance in order to affect trophoblast invasion (Roth 
and Fisher, 1999). It has been proposed that IL-10 suppresses invasion through MMP-9 
inhibition without affecting TIMP-3 expression and this regulation appears to occur at the 
transcriptional level (Roth and Fisher, 1999).  
 
 
 
 8	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1.1.7  Integrins 
 
The ability of trophoblasts to invade may be related to their temporal and spatial 
regulation of integrin expression (Damsky et al., 1994; Zhou et al., 1997). Late gestation 
cytotrophoblasts show a decreased ability to invade and are unable to up-UHJXODWHĮȕ
integrin complexes, suggesting a role for these integrins in invasion (Damsky et al., 
([WUDYLOORXVĮintegrin immunopositive cytotrophoblasts are invasive, secrete 
large amounts of gelatinase, and appear to switch integrin expression thus changing their 
phenotype (Bischof et al., 1995). Furthermore, blocking expression of ĮRUȕLQWHJULQ
subunits almost completely inhibits migration of the trophoblast in vitro, supporting the 
notion that these subunits are important for trophoblast migration (Irving and Lala, 1995).  
SSDWLDOUHJXODWLRQRIĮ9ȕLQWHJULQKDVEHHQUHSRUWHGRQGLIIHUHQWLDWLQJKXPDQ
cytotrophoblasts suggesting involvement with invasion of first trimester trophoblasts 
(Zhou et al., 1997) through localization with MMP-2 at the cell surface (Brooks et al., 
1996([SUHVVLRQRIĮ9ȕLQWHJULQLVLQFUHDVHGLQF\WRWURSKREODVWVWKDWKDYHLQYDGHGWKH
uterine wall in vivo. In addition, anti-Į9ȕDQWLERG\reduces in vitro invasion in a 
matrigel by 75% (Zhou et al., 1997).   
 
1.1.8  Urokinase-type Plasminogen Activator and Plasminogen 
 
Plasminogen activators (PAs) and their inhibitors (PAIs) have been proposed to 
contribute to the balance of proteolytic activities during matrix turnover (Vassalli et al., 
1991). As reviewed by Vassalli and colleagues (1991) plasminogen activators are serine 
proteases whose preferred substrate is plasminogen (Vassalli et al., 1991). The urokinase-
type plasminogen activator (uPA) and plasminogen system has been proposed to be 
involved with trophoblast migration and invasion in the rhesus monkey (Feng et al., 
2000) and human (Liu et al., 2003). It has been proposed that plasminogen activators and 
their inhibitors regulate ECM degradation, while modifying migration and invasion of 
extravillous trophoblasts during early pregnancy in the rhesus monkey (Feng et al., 9	 ﾠ
2000). This idea is supported by the observation that in vitro migration of human 
trophoblast cell lines is stimulated through interaction of uPA with its receptor, uPAR 
(Liu et al., 2003).   
Further support comes from the expression of the uPA gene in invasive 
trophoblasts (Feng et al., 2000) and their ability to secrete PAI-1 and PAI-2 (Zini et al., 
1992). In addition, PAI-1 mRNA is only expressed in extravillous trophoblasts attached 
or close to cells at the maternal-fetal interface, suggesting the expression of PAI-1 is 
related to invasion and regulation of invasion depth (Feng et al., 2000). Term trophoblasts 
express fewer urokinase receptors compared to first trimester trophoblasts, further 
supporting a role for these receptors in placentation (Zini et al., 1992). 
 
1.1.9  Other Important Factors 
 
There are many other factors that may play a role in trophoblast invasion. 
Endothelin-1 stimulates proliferation and invasion of first trimester trophoblasts in vitro 
and may act in an autocrine or paracrine manner (Cervar et al., 1996). Insulin-like growth 
factor- II (IGF-II) and IGF binding protein-1 (IGFBP-1) have been localized to the 
decidual-trophoblast interface (Irwin et al., 1999). IGF-II (Hamilton et al., 1998; 
McKinnon et al., 2001) and IGFBP-1 (Irving and Lala, 1995) enhance migration of 
extravillous trophoblasts in vitro. IGF-II presumably stimulates migration through the 
activation of the IGF type 2 receptor and the mitogen-activated protein kinase (MAPK) 
pathway (McKinnon et al., 2001). It has also been suggested that IGF-II is trophoblast-
derived and acts in an autocrine manner while IGFBP-1 originates in the decidua, acts in 
a paracrine manner to stimulate trophoblast migration (Hamilton et al., 1998). Studies 
also demonstrate that the stimulatory effect of IGFBP-1 on migration depends on integrin 
expression (Irving and Lala, 1995), VSHFLILFDOO\Į5 integrin expression (Hamilton et al., 
1998). 
Cadherins may also be important in the development of an invasive phenotype in 
trophoblasts. E-cadherin immunopositive staining is reduced in areas where invasion is 10	 ﾠ
occurring in human first trimester placental tissue (Zhou et al., 1997). Trophoblasts 
treated with an anti-E-cadherin antibody in vitro demonstrated increased invasion, while 
anti-VE-cadherin antibody reduced invasion. This suggests VE-cadherin plays a role in 
facilitating trophoblast invasion (Zhou et al., 1997). 
Leptin and its receptor have been identified in the human placenta and are thought 
to be involved with invasion by regulating MMP activity and secretion. Using an ELISA, 
leptin treatment increases the secretion of immunoreactive MMP-2 in cultured 
trophoblasts, but not MMP-9 (Castellucci et al., 2000). Using zymography, treatment of 
trophoblasts with leptin increases MMP-9 activity, but not MMP-2 (Castellucci et al., 
2000). This study suggests that leptin can regulate factors identified to be crucial for 
trophoblast invasion. Leptin is secreted by cytotrophoblasts (Masuzaki et al., 1997), 
which is stimulated by interleukin-6 (IL-6) (Meisser et al., 1999a).  
Angiotensin II treatment of trophoblasts induces plasminogen inhibitor type 1 
(PAI-1) mRNA expression and appears to decrease invasion through activation of the 
PAI-1 gene (Xia et al., 2002). Transforming growth factor (TGF)-ȕGRZQ-regulates 
mRNA levels of MMP-9, MT1-MMP, MT2-MMP and urokinase-type plasminogen 
activator (uPA) while inducing the expression of TIMP-1 and TIMP-2 in first trimester 
trophoblasts (Karmakar and Das, 2002).  Together, this suggests that TGF- ȕ has an 
inhibitory effect on trophoblast migration. Transforming growth factor-ȕLVRIRUPV
and 3 inhibit trophoblast invasion in vitro presumably by lowering protease activity.  This 
is supported by evidence that trophoblast secretion of MMP-9 and uPA is significantly 
reduced following treatment (Lash et al., 2005). The isoform TGF-ȕKDValso been 
shown to increase integrin expression and reduce trophoblast migration (Irving and Lala, 
1995).  
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a serine protease 
inhibitor that is essential for maintaining the integrity of the basement membrane, 
apparently by regulating protease activities during placental development (Fan et al., 
2007). Mice lacking HAI-1 tend to have a smaller than normal trophoblast layer and die 
in utero due to placental labyrinth defects. The reportedly compact morphology seen in 11	 ﾠ
HAI-1 knock-out mice suggests that trophoblasts with this genotype fail to migrate 
properly (Fan et al., 2007). 
Tumor necrosis factor-alpha (TNFĮ) significantly increases total gelatinase 
activity, specifically MMP-DFWLYLW\0HLVVHUHWDOE71)ĮLVDOVRWKRXJKWWR
inhibit invasion through up-regulation of PAI-1 in vitro (Bauer et al., 2004). Peroxisome 
proliferator-DFWLYDWHGUHFHSWRUJDPPD33$5ȖLVH[SUHVVHGLQLQYDGLQJWURSKREODVWs and 
has been proposed to be involved with trophoblast invasion in the mink (Desmarais et al., 
2007) and human (Fournier et al., 2007). CXCL10 has been shown to act as a 
chemoattractant for trophoblasts in vitro and may influence invasion in vivo (Dominguez 
et al., 2008).  Leukemia inhibitory factor (LIF) has been immunolocalized to implantation 
sites in the rhesus monkey endometrium and conceptus (Sengupta et al., 2003). In the 
immortalized human trophoblast cell line HTR-8/SVneo, LIF is thought to stimulate 
trophoblast invasion through PGE2 production and PGE2 receptor expression (Horita et 
al., 2007). Leukemia inhibitory factor (LIF) and epidermal growth factor (EGF) stimulate 
production of uPA and MMP-9 activity in murine blastocyst outgrowths in culture 
(Harvey et al., 1995). 
 
1.1.10 Conclusion 
 
Trophoblast invasion is a process that is regulated both spatially and temporally in 
transcription and translation. The regulation of trophoblast invasion is likely due to the 
integrated actions of multiple factors. Discovering the link between these factors and 
more clearly defining their role may finally elucidate the regulatory mechanism of this 
process. 
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1.2    GENETIC REGULATION OF TROPHOBLAST REGRESSION AND         
PLACENTAL RELEASE AT PARTURITION 
 
 
 
1.2.1  Significance 
 
A better understanding of the factors that regulate trophoblast regression, 
placental release, and tissue remodeling in normal parturition is crucial for the study of 
placental abnormalities in the peripartum period. Retention of placental membranes in 
cows is thought to be due to a failure of collagen breakdown following parturition (Eiler 
and Hopkins, 1992). Changes in protease activity such as matrix metalloproteinases 
(MMPs) may be related to pathologic conditions like retention of placental membranes in 
cattle (Maj and Kankofer, 1997). The balance of MMPs and tissue inhibitors of matrix 
metalloproteinases (TIMPs) may also be associated with pre-term rupture of fetal 
membranes in humans (Athayde et al., 1998; Parry and Strauss III, 1998). However, 
before the mechanisms behind these conditions can be determined a clear understanding 
of the molecular factors in placental release needs to be achieved.  
 
1.2.2  Summary 
 
The initiation of placental release is likely controlled by a variety of endocrine, 
inflammatory, and mechanical factors. Multiple factors have been proposed to regulate 
the expression of genes involved in placental release (Gibb et al., 2006) and these factors 
vary from species to species (Smith, 2007). Despite years of research however, the exact 
genetic regulation of placental release and trophoblast regression remains elusive. 
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1.2.3  Matrix Metalloproteases and their Tissue Inhibitors 
 
Several species rely on the degradation of the extracellular matrix for the 
detachment and separation of placental membranes at parturition, including the cow 
(Eiler and Hopkins, 1993; Walter and Boos, 2001), rat (Lei et al., 1996) and human (Xu 
et al., 2002). A balance between MMPs and TIMPs are thought to help modulate the 
release of the placenta following labor (Parry and Strauss III, 1998).  Degradation of 
collagen when fetal membranes rupture in normal term parturition is also thought to rely 
on the balance of MMPs and TIMPs (Parry and Strauss III, 1998).  
  In humans, separation of the placenta from the endometrium and loss of placental 
mass may rely upon MMP-1 (collagenase-1) and MMP-3 expression (Vettraino et al., 
1996). In addition, a rise in MMP-9 mRNA expression (Xu et al., 2002) and enzymatic 
activity (Tsatas et al., 1999) in the human placenta is associated with the onset of labor 
suggesting MMP-9 facilitates the separation of placental membranes during human 
parturition (Tsatas et al., 1999; Xu et al., 2002). MMP-9 activity may be triggered by 
tumor necrosis factor (TNF)-ĮRULQWHUOHXNLQ,/-1 (Vadillo-Ortega et al., 1995). 
Evidence suggests MMP-1 activation may rely on increased expression of both MMP-3 
and MMP-9 in order to degrade ECM components during placental release (Bryant-
Greenwood and Yamamoto, 1995).   
MMP-9 mRNA and protein increase in the human placenta with the onset of labor 
(Vadillo-Ortega et al., 1995); whereas MMP-9, MMP-3, and MMP-2 gene expression is 
increased in tissues collected following natural delivery compared to Cesarean section. 
ProMMP-9 and proMMP-2 activity also significantly increases in the human placenta 
following spontaneous delivery (Bryant-Greenwood and Yamamoto, 1995).    
Reports are contradictory in regard to the expression of TIMPs during labor. 
Goldman and colleagues (2003) describe a decrease in TIMP-1 expression in the human 
placenta during labor (Goldman et al., 2003); whereas Bryant-Greenwood and Yamamoto 
(1995) found an increase in TIMP-1 mRNA (Bryant-Greenwood and Yamamoto, 1995). 
Secretion of TIMPs into the human amniotic fluid decreases with the onset of labor 14	 ﾠ
(Riley et al., 1999), while MMP-9 (Vadillo-Ortega et al., 1996; Athayde et al., 1998) and 
MMP-3 (Park et al., 2003) concentrations in amniotic fluid increase. Conversely, serum 
levels of TIMP-1 increase at labor and significantly higher levels of TIMP-1 through the 
post-partum period suggest that it may play a role in uterine involution and remodeling 
(Clark et al., 1994).  
Matrix metalloproteinases and TIMPs are also thought to play a role in placental 
separation at parturition in cattle (Maj and Kankofer, 1997; Walter and Boos, 2001; 
Takagi et al., 2007; Dilly et al., 2011), goats (Uekita et al., 2004) and sheep (Vagnoni et 
al., 1998). Specifically, MMP-14 (MT1-MMP) (Dilly et al., 2011), MMP-2 and TIMP-2 
(Takagi et al., 2007; Dilly et al., 2011) expression are involved with placental release 
during bovine parturition. In the cow (Walter and Boos, 2001) and goat (Uekita et al., 
2004), a decrease in TIMP-2 expression near the end of gestation may be essential for 
placental release. Furthermore, MMP-2, MMP-9 and TIMP-1 protein expression in the 
ovine placenta during the last third of gestation suggest these factors may be also 
involved in sheep placental release (Vagnoni et al., 1998). 
 
1.2.4  KiSS-1 and its Receptor KiSS-1R 
 
The exact role of KiSS-1 and its receptor KiSS-1R at the end of gestation remains 
unclear and contradictory results have been reported. Placental KiSS-1 mRNA expression 
reportedly increases in placentas collected after term vaginal delivery compared to those 
following term Cesearean sections (Torricelli et al., 2008). However, others suggest the 
anti-invasive effect of KiSS-1 and KiSS-1R is only present in the first trimester (Bilban et 
al., 2004). 
 
1.2.5  Other Important Factors 
 
  Toll-like receptor 8 (TLR8), nuclear factor of kappa light polypeptide gene 
enhancer in B-cell 1 (NFKB1), inhibin, VEGF-A, Flt-1 and sFlt-1 are up-regulated in 15	 ﾠ
human placentas collected following spontaneous vaginal delivery compared to those 
collected following elective c-section (Cindrova-Davies et al., 2007; Lee et al., 2010). 
Leptin and COX-2 protein have also been shown to increase in human placentas collected 
following spontaneous vaginal delivery compared to those collected following elective c-
section (Cindrova-Davies et al., 2007). Furthermore COX-2 is primarily seen in the 
trophoblasts and the increase in placental COX-2 is associated with NF-ț%DFWLYDWLRQ, 
suggesting a role for this pathway in placental release (Cindrova-Davies et al., 2007). 
 CD44 (hyaluronan receptor) is expressed at the end of gestation in basal plate 
cytotrophoblasts and decidual cells, which may be important in human placental release 
(Marzioni et al., 2009). Major histocompatibility antigen expression in bovine 
trophoblasts peaks just prior to parturition (Davies et al., 2000). This suggests MHC 
Class I antigen may play a role in placental separation, possibly through maternal 
immunological recognition (Davies et al., 2004). Tissue plasminogen activator is also 
reported to increase in human placenta collected following spontaneous natural delivery 
compared to elective Cesarean section (Bryant-Greenwood and Yamamoto, 1995).  At 
the end of gestation in humans, endometrial relaxin acts on trophoblasts to increase tPA, 
MMP-1, and MMP-3 at the transcriptional and translational level (Qin et al., 1997a; Qin 
et al., 1997b). 
 
1.2.6  Conclusion 
 
A number of molecular factors are involved in the regulation of trophoblast 
regression, placental release, and tissue remodeling in the peripartum period. Most of 
these systems include proteases (e.g. metalloproteinases). Dysregulation of these 
pathways can result in abnormal trophoblast regression and/or placental retention 
following parturition.  
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1.3 GENES INVOLVED IN CARNIVORE IMPLANTATION, PLACENTAL 
DEVELOPMENT AND PARTURITION 
 
 
 
1.3.1  Summary 
 
Placentation in most carnivores like the dog is endotheliochorial (Sandoval et al., 
2001; Johnston et al., 2001). This placental type is invasive, but the degree of 
invasiveness is relatively shallow compared to other invasive placental type species. 
Canine syncytiotrophoblasts and cytotrophoblasts invade the maternal endothelium and 
endometrial glands early in gestation.  These cells form “cuffs” around the maternal 
blood vessels and form the placental labyrinth (Barrau et al., 1975; Sandoval et al., 2001. 
Little is known regarding the regulation of trophoblast invasion in carnivores. Molecular 
studies have identified factors in the canine uterus recognized as important for 
implantation in other species, but few have looked specifically at placental gene 
expression and none have examined the placental transcriptome. 
 
1.3.2  Canine Uterine and Placental Gene Expression 
 
Matrix metalloproteinase (MMP)-2 expression has been detected in canine 
trophoblasts and myometrium (Beceriklisoy et al., 2007); whereas MMP-9 expression has 
been detected in endometrial crypts and glands (Beceriklisoy et al., 2007). In addition, 
both MMP-2 and MMP-9 have been detected in the pre-implantation embryo 10-12 days 
after mating (Schäfer-Somi et al., 2008). Furthermore, the highest expression of MMP-2 
and MMP-9 previously reported is around the time of implantation (Beceriklisoy et al., 
2007), suggesting that these proteases may be involved in this process. Peroxisome 
proliferator-DFWLYDWHGUHFHSWRUJDPPD33$5ȖP51$LVH[SUHVVHGLQWKHFDQLQH
placenta and localized to trophoblasts (Kowalewski et al., 2011). The up-regulation of 
33$5ȖP51$DIWHULPSODQWDWLRQDQGWKURXJKPLG-gestation (Kowalewski et al., 2011), 
suggests it too may play a role in trophoblast invasion.  17	 ﾠ
As previously reported by Kowalewski and coworkers (2010), components of the 
prostaglandin system are temporally expressed in the canine uteroplacental unit (Table 
1.1). 7URSKREODVWVPD\EHWKHSULPDU\WDUJHWIRU3*)ĮDQG3*(.RZDOHZVNLHWDO
2010).  Cycloooxygenase (COX-2, also known as PTGS2) expression is localized to 
trophoblasts surrounding maternal vessels (Kowalewski et al., 2010). These factors may 
contribute to canine placental maturation and release at parturition. 18	 ﾠ
 
Table 1.1. A summary of previously reported prostaglandin components genetically expressed in the canine uteroplacental unit 
through the first half of gestation (Kowalewski et al., 2010) PGR: Prostaglandin receptor, PTGS2: Cycloooxygenase (COX-2), 
PGFS: ProstaglandiQ)ĮV\QWKDVH, PTGFR: Prostaglandin F Receptor, PTGES: Prostaglandin E2 synthase, PTGER2: 
Prostaglandin E Receptor 2, PTGER4: Prostaglandin E Receptor 4  
 
  
 
 
 
 
 
Prostaglandin  Pre-implantation  Post-implantation  Mid-gestation  Prepartal luteolysis 
PGR  High  Moderate  Moderate  Moderate 
PTGS2  Low  Low  Low  High 
PGFS  Low  Moderate  High  Moderate 
PTGFR  High  Low  Low  High 
PTGES  Low  Moderate  High  High 
PTGER2  High  Moderate  Moderate  High 
PTGER4  High  Moderate  Low  Low 19	 ﾠ
  The placenta has been identified as the main (if not sole) source of relaxin in the 
dog (Tsutsui and Stewart, 1991). Canine cytotrophoblasts also express relaxin-like factor 
mRNA during early and mid-gestation (Klonisch et al., 2001). The expression of relaxin-
like factor at the end of gestation has not been studied. The canine endometrium does not 
express relaxin mRNA (Klonisch et al., 1999a). However, canine mammary tumors can 
produce relaxin, whose expression correlates with MMP-2 mRNA expression and cell 
invasion (Lamp et al., 2009) suggesting a role for relaxin in trophoblast cell invasion. 
This suggests a possible correlation between relaxin, MMP-2 and trophoblast invasion in 
dogs.   
The expression of other factors has been identified in canine pre-implantation 
embryos. Pre-implantation embryos express mRNA for interleukin (IL)-ȕLQWHUOHXNLQ 
(IL)-8, hepatocyte growth factor (HGF), leukemia inhibitory factor (LIF), COX-2 and 
tumor necrosis factor (TNF)-Į6FKlIHU-Somi et al., 2008). Interleukin-ȕ/LEUDFKHWDO
1994), interleukin--RYDQRYLüHWDOOHXNHPLDLQKLELWRUy factor (Sengupta et al., 
2003DQG71)Į0HLVVHUHWDOEKDYHDOOEHHQSURSRVHGWRLQIOXHQFHWURSKREODVW
invasion in other species. A strong expression of COX-2 is thought to indicate activation 
of prostaglandin synthesis, which may be important in the regulation of embryonic and 
HQGRPHWULDOF\WRNLQHV7KHH[SUHVVLRQRI71)ĮDQG,/-6 is thought to be important in 
regulating the balance of tissue remodeling during canine implantation (Schäfer-Somi et 
al., 2008). 
Expression of CD-8, COX-1, transforming growth factor (TGF)-ȕ+*)LQVXOLQ-
like growth factor (IGF)-1, IL-4, IL-10 and LIF have been reported in canine 
endometrium at placental sites (Beceriklisoy et al., 2009). IL-10 expression decreases at 
implantation in placental sites, which may facilitate trophoblast invasion (Beceriklisoy et 
al., 2009). Furthermore, IGF-1 is only expressed at placental sites and may also be 
important for implantation (Beceriklisoy et al., 2009). 
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1.3.3  Placental Gene and Protein Expression in Other Carnivores 
 
The feline placenta is also endotheliochorial (Miglino et al., 2006) and similar to 
the dog, it is the main source of relaxin during pregnancy (Addiego et al., 1987; Klonisch 
et al., 1999b). Matrix metalloproteinase activity (specifically MMP-1 and MMP-13) has 
also been identified in feline trophoblasts (Walter and Schönkypl, 2006). 
Immunohistochemistry experiments have shown that MMP-2 is expressed in maternal 
connective tissue surrounding endometrial glands, decidual cells in the junctional zone 
and giant cells of the placental labyrinth (Walter and Schönkypl, 2006), while MMP-9 
was not detected. The latent forms of MMP-2 and MMP-9 are the most common, with 
very low levels of active enzymes present in the feline placenta during late gestation 
(Walter and Schönkypl, 2006). Furthermore, collagen types I and III in the feline placenta 
decrease throughout gestation suggesting a role for matrix degrading enzymes in this 
species (Walter and Schönkypl, 2006). 
In the mink (Mustela vison), peroxisome proliferator-activated receptor gamma 
33$5ȖP51$LVH[SUHVVHGLQWKHSODFHQWDIROORZLQJLPSODQWDWLRQ and its expression is 
specific to the trophoblasts in contact with the endometrium (Desmarais et al., 2007). 
33$5ȖOigands may also be involved with the regulation of implantation and 
PDLQWHQDQFHRIWKHSODFHQWD'HVPDUDLVHWDO,QDQLQYLWURVWXG\33$5ȖP51$
expression was significantly up-regulated following treatment of 15-deoxy-delta 12, 14 
prostaglandin (15-d-PGJ2) (Desmarais et al., 2007). This suggests that 15-d-PGJ2 acts 
WKURXJKWKH33$5ȖSDWKZD\0LQNHPEU\RVDOVRVHFUHWH3*(EXWHPEU\RVLQGLDSDXVH
do not (Lopes et al., 2006). COX-2 protein expression has been localized to the sites of 
embryo attachment and invasion in the mink (Song et al., 1998) and there is a 
corresponding increase in PGE synthase in the same location. It has been proposed that 
this regulates VEGF expression at this location (Lopes et al., 2006). Vascular endothelial 
growth factor protein expression has also been localized to invasive mink trophoblasts. In 
addition, Flt-1 expression has been noted to increase in the uterus around implantation 
along with other VEGF isoforms (Lopes et al., 2003).  21	 ﾠ
1.3.4  Conclusion 
 
Although relatively shallow compared to primates and rodents, canine trophoblast 
invasion is significantly more extensive and complex as compared to other domestic 
animals. Limited information is available regarding the ontogenic molecular changes that 
occur in the carnivore placenta, particularly at the end of gestation. Detailed 
investigations are needed in order to better understand differences and similarities 
between carnivore trophoblast invasion and that of other domestic animals. 
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CHAPTER II 
 
 
 
GENE EXPRESSION IN PRE-TERM, PRE-LABOR, AND PARTURIENT CANINE 
PLACENTA 
 
 
 
2.1 INTRODUCTION 
 
The completion of parturition involves the delivery of the placenta. Complications 
arise when the placenta is not properly delivered within a defined time following delivery 
of the fetus. Two common placental abnormalities in the dog are placental retention and 
subinvolution of placental sites (SIPs), which involve pathologic trophoblast invasion.  
Placental retention increases the risk of the bitch developing postpartum uterine 
infections and metritis (Wallace, 1994).  In addition, placental retention can be life 
threatening if the bitch becomes very ill (e.g. fever, anorexia, depression).  The 
mechanisms behind placental retention remain unknown. 
Subinvolution of placental sites (SIPS) is characterized by abnormally deep 
invasion of the trophoblasts into the myometrium following delivery of the placenta (Al-
Bassam et al., 1981), resulting in a failure or delay in uterine involution (Beck and 
McEntee, 1966). Instead of degenerating after parturition, trophoblasts persist within the 
endometrium, preventing endometrial blood vessels from developing thromboses, 
resulting in persistent bleeding (Al-Bassam et al., 1981).  In addition, trophoblasts may 
on rare occasions erode through the serosa resulting in peritonitis (Beck and McEntee, 
1966).  The factors involved with SIPs are unknown.  
Many molecular factors are involved in trophoblast invasion as well as placental 
release during parturition. Some of these factors include matrix metalloproteinases 
(MMPs), their tissue inhibitors (TIMPs), vascular endothelial growth factor (VEGF)-A, 
VEGF-A receptor (Flt-1) and the KiSS-1 receptor (KiSS-1R) (Lei et al., 1996; Maj and 34	 ﾠ
Kankofer, 1997; Lash et al., 1999; Xu et al., 2002; Zhang et al., 2011). MMPs and TIMPs 
regulate normal trophoblast invasion and migration in humans (Librach et al., 1999). 
MMP-2 and MMP-9 are likely responsible for conditions of abnormal placentation in 
humans (Zhang et al., 2011). KiSS-1 and KiSS-1R may also play a role in the regulation 
of human trophoblast invasion (Zhang et al., 2011), while VEGF-A may be important in 
the initiation of trophoblast invasion (Lash et al., 1999).  
Detachment and release of the placenta at parturition in the human (Xu et al., 
2002), cow (Walter and Boos, 2001) and rat (Lei et al., 1996) relies on enzymatic 
degradation of the extracellular matrix likely by MMP activity. Disorders affecting the 
regulation of MMPs have been proposed to contribute to placental retention in the cow 
(Maj and Kankofer, 1997; Walter and Boos, 2001). Knowledge of the factors involved in 
normal placental release during parturition and pathologic placental conditions during the 
postpartum period in the dog is lacking. To the authors’ knowledge, gene expression of 
VEGF-A, Flt-1, KiSS-1R, MMP-2, MMP-9 and TIMP-2 in the canine placenta have not 
been previously published. The aim of this study was to determine whether MMP-2, 
MMP-9, TIMP-2, VEGF-A, Flt-1 and KiSS-1R are expressed in the canine placenta. 
Once established, the objective was to compare expression patterns during late gestation 
in the bitch (pre-term), around the initiation of labor (pre-labor) and after delivery 
(parturient).  
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Tissue Collection 
 
Canine chorioallantoic tissue was collected from various breeds following 
elective pregnancy termination by ovariohysterectomy at 61 ± 1 day past the LH surge 
(late gestation; n=4), elective C-section at 64 ± 1 day past the LH surge prior to first stage 
labor (pre-labor; n=4), and natural delivery (parturient; n=3). Prior to being flash frozen 35	 ﾠ
in liquid nitrogen, the marginal hematoma was dissected away and any excess tissue and 
blood were removed. Tissue was then stored at -80°C until analyzed. 
 
2.2.2 RNA Isolation 
 
Total RNA was isolated using the TRIzol Plus RNA Purification Kit (Invitrogen, 
Carlsbad, CA) following the manufacturer’s instructions. RNA concentration and purity 
was determined using a spectrophotometer (NanoPhotometer, IMPLEN, Munich, 
Germany). Total RNA samples were submitted to the Center for Genome Research and 
Biocomputing (CGRB) at Oregon State University to measure RNA quality. RNA 
integrity numbers (RIN) were obtained for each sample using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).  
 
2.2.3 TaqMan Real-Time RT-PCR 
 
RNA was reverse transcribed to cDNA using oligo dT as a primer with the 
SuperScript III First-Strand Synthesis System according to the manufacturer’s 
instructions (Invitrogen). Concentrations of the cDNA samples were measured using the 
DNA setting on a spectrophotometer (NanoPhotometer, IMPLEN) and then diluted 10-
fold for RT-PCR. TaqMan primers and probes of proprietary sequences developed for 
canine MMP-2, MMP-9, TIMP-2, VEGF-A, Flt-1 and KiSS-1R (Table 2.1) by the 
company were used for real-time RT-PCR on the ABI 7300 RT-PCR machine (Applied 
Biosystems, Carlsbad, CA). Default cycling conditions were used (Table 2.2). Gene 
expression was normalized to mRNA expression of hypoxanthine-phosphoribosyl 
transferase 1 (HPRT-1) based upon its success in other canine studies (Brinkhof et al., 
2006; Etschmann et al., 2006; Schlotter et al., 2009) and its stable expression in this study 
(Ct mean ± SEM; 32.7 ± 0.52). The first parturient sample collected was used as a 
calibrator sample. All RT-PCR reactions were performed in triplicate with a final 36	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UHDFWLRQYROXPHRIȝOHDFK5HODWLYHH[SUHVVLRQZDVFDOFXODWHGXVLQJWKH
-
ǻǻ&Wmethod. 
 
2.2.4 Statistical Analysis 
 
Statistical analysis was performed using a one-way ANOVA with Bonferroni 
corrections to make comparisons between the three groups. Statistical significance was 
calculated using the Stata 12.0 software (StataCorp LP, College Station, TX). Data were 
expressed as mean ± standard deviation (SD). Significance was defined as p<0.05.37	 ﾠ
Table 2.1. TaqMan Primers and Probes used for real-time RT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Name  Assay ID  RefSeq 
Exon 
Boundary 
Assay 
Location 
Amplicon 
Length 
MMP-2  Cf02623423_m1  XM_535300.2  3 to 4  520  58 
MMP-9  Cf02621845_m1  NM_001003219.1  12 to 13  2015  59 
TIMP-2  Cf02623335_m1  NM_001003082.1  1 to 2  234  81 
VEGF-A  Cf02623453_m1  NM_001003175.1  7 to 8  906  62 
Flt-1  Cf02696454_g1  XM_534520.2  26 to 27  3489  116 
KiSS-1R  Cf02715933_u1  XM_850105.1  3 to 3  635  141 
HPRT-1  Cf026262558_m1  NM_001003357.1  8 to 9  605  129 38	 ﾠ
 
Table 2.2. Real-time RT-PCR cycling conditions 
 
 
 
 
 
 
 
 
   
Stage  Temperature (°C) and Time (Mins)  Replications 
Stage 1  50.0°C for 2:00  1 
Stage 2  95.0°C for 10:00  1 
Stage 3  95.0°C for 0:15 then 60.0°C for 1:00  40 39	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2.3 RESULTS 
 
All RNA samples used in the synthesis of cDNA for real-time RT-PCR studies 
were determined to be of good quality based on a RIN > 7.0. MMP-9 mRNA expression 
was significantly higher in pre-term samples compared to pre-labor and parturient 
samples (Table 2.3). Although not statistically significant (p=0.21), there is a similar 
apparent decrease in expression of VEGF-A prior to parturition (Table 2.3). There was no 
significant difference in mRNA expression between the samples for MMP-2, TIMP-2 or 
Flt-1 (Table 2.3). Based on Ct values of greater than 38 following a protocol with 10 ng 
of starting cDNA, KiSS-1R was not expressed in any of the placentas in this study (data 
not shown).  
   40	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Table 2.3. Relative quantitation (mean ± SD) of placental gene expression at three time 
points prior to parturition. *p<0.05 
 
  Pre-term (n=4)  Pre-labor (n=4)  Parturient (n=3) 
MMP-9  15.2 ± 4.30*  2.16 ± 1.23  4.27 ± 2.32 
MMP-2  0.62 ± 0.19  1.57 ± 0.89  1.34 ± 1.0 
TIMP-2  0.08 ± 0.04  0.37 ± 0.26  9.31 ± 14.4 
VEGF-A  0.98 ± 0.54  0.40 ± 0.30  0.71 ± 0.26 
Flt-1  0.99 ± 0.25  0.64 ± 0.30  0.77 ± 0.26 
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2.4 DISCUSSION 
 
Molecular changes in the canine placenta in the periparturient period have not 
been previously described in the literature. Therefore the aim of this study was to 
characterize changes in the expression of genes known in other species to regulate 
trophoblast invasion from late gestation to immediately following parturition. In the 
current study, MMP-9 mRNA expression was significantly higher in pre-term tissues 
compared to pre-labor and parturient tissues. MMPs have been shown to play an essential 
role in the regulation of trophoblast invasion in humans (Librach et al., 1991), so these 
factors may also be important in the abnormal regulation of trophoblast invasion in SIPs.   
Previous research has also described the involvement of MMPs in placental 
release at parturition in cattle and humans.  Walter and Boos (2001) suggested that MMP-
2 and MMP-9 are important in the detachment of placental membranes at parturition in 
the cow. A similar role at the end of pregnancy for MMP-9 has been proposed in the 
human placenta by Xu and coworkers, who demonstrated an increase in MMP-9 at labor, 
but no change in MMP-2 (Xu et al., 2002).  MMP-9 has been proposed to be crucial in 
the degradation of the extracellular matrix at the end of gestation for successful 
detachment of placental membranes in the human (Xu et al., 2002). In the present study, 
MMP-9 mRNA expression was significantly increased during late gestation and then 
decreased around the initiation of labor suggesting that while it may play a role during 
this period in the dog, this role may be different than that reported in humans and cows.  
The relationship of these factors in canine placental retention remains unknown. 
Maj and Kankofer (1997) suggested that a lack of active MMP-2 in maternal and fetal 
parts of retained placenta could contribute to the improper release of fetal membranes at 
the time of parturition. Lack of MMP inhibition has been demonstrated to be important in 
placental release. Walter and Boos (2001) reported a decrease in TIMP-2 expression at 
parturition in cows and suggested this decrease was required for normal placental release. 
The decrease in TIMP-2 in their study differs from what was found in the current study as 
TIMP-2 mRNA expression was not significantly different between the three study 42	 ﾠ
groups. This suggests the role of TIMP-2 in the dog may differ slightly from that in the 
cow. However, the relationship of all these factors to canine placental retention will 
require further study. 
  VEGF-A and associated receptor, Flt-1, are important in initiating trophoblast 
invasion in humans (Lash et al., 1999). In addition, Flt-1 placental mRNA increased in 
women who experienced labor compared to those that did not go through labor (Lee et 
al., 2010). Based on these studies, we expected to see a change in VEGF-A and Flt-1 
mRNA expression at the end of gestation in dogs, but this was not the case. In the current 
study, VEGF-A and Flt-1 were not significantly different between the periparturient 
groups. One possibility for the different expression patterns in the dog compared to the 
human at the end of gestation may be the difference in placental types. The human 
placenta is more invasive than the canine placenta, which may necessitate a lesser role of 
VEGF-A and Flt-1 in the dog at the time of parturition. 
Previous studies in humans suggest the primary role of KiSS-1 and its receptor 
KiSS-1R occurs during the first trimester of pregnancy where it acts to suppress 
trophoblast invasion by inhibiting protease activity of factors such as MMP-2 (Bilban et 
al., 2004). In addition, KiSS-1 placental mRNA increased in women who experienced 
labor compared to those that did not go through labor (Torricelli et al., 2008). Studies in 
vitro have shown that KiSS-1 transfection of human trophoblast cells decreases cell 
invasion (Zhang et al., 2011) and an up-regulation has been reported in women with 
abnormal placentation such as preeclampsia (Zhang et al., 2011). The results of this study 
led to the conclusion that there was no expression of KiSS-1R mRNA in any of the 
canine tissues based upon a cut-off for relevant expression that was chosen according to 
the upper limit of the possible detection range (40 cycles) following a starting cDNA 
amount of 10 ng (Goni et al., 2009). The receptor does not appear to play a role or be 
present in these tissues at this time in the dog. Further studies are needed to investigate 
the KiSS-1 gene itself as well as expression of KiSS-1R earlier in canine gestation.  
In summary, MMP-9 mRNA expression was significantly different in the pre-
term groups compared to pre-labor and parturient groups. While the increase in MMP-2 43	 ﾠ
mRNA expression prior to labor was not statistically significant it warrants recognition 
due to the relevance to previous studies in other species.  The results of this study suggest 
that parturition influences the expression of MMP-9 in the dog, which is similar to what 
has been reported in humans and cattle. However, further studies are needed to determine 
whether changes in mRNA expression of MMP-2, MMP-9, TIMP-2, VEGF-A, Flt-1 and 
KiSS-1R play a role in canine placental abnormalities such as retained placental 
membranes and excessive trophoblast invasion (SIPs) in dogs.  
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CHAPTER III 
 
 
 
INVESTIGATING THE CANINE PLACENTAL TRANSCRIPTOME IN THE 
PERIPARTUM PERIOD 
 
 
 
3.1 INTRODUCTION 
 
  In the dog, physical interactions between maternal and fetal tissues are restricted 
to an equatorial belt surrounding the fetus in the canine zonary endotheliochorial placenta 
(Anderson, 1969; Barrau et al., 1975; Sandoval et al., 2001; Burton et al., 2006). Normal 
canine trophoblast invasion during implantation is relatively shallow compared to other 
deciduate placental species (e.g. primates, rodents) (Carter et al., 2006). Canine 
syncytiotrophoblasts and cytotrophoblasts invade the maternal endothelium and 
endometrial glands early in gestation. These cells form “cuffs” around the maternal blood 
vessels and form the labyrinth (Barrau et al., 1975; Sandoval et al., 2001). With the 
exception of the marginal hematoma that forms by mid-gestation (Barrau et al., 1975; 
Sandoval et al., 2001), canine trophoblasts do not come into direct contact with maternal 
blood (Carter et al., 2006).  
  Despite years of research using a variety of species, the regulatory mechanisms 
behind trophoblast invasion at implantation and placental release at parturition remain 
largely unknown. Many studies have identified different factors involved within these 
critical periods of pregnancy including matrix metalloproteinases, interleukins, and 
growth factors. Aberrent trophoblast invasion and retained placental membranes are seen 
in many species (Al-Bassam et al., 1981; Brosens et al., 1972; Fernández et al., 1998; 
Maj and Kankofer, 1997; Pijnenborg et al., 1991). In humans, pathologically shallow 
trophoblast invasion results in preeclampsia (Brosens et al., 1972; Pijnenborg et al., 
1991), while uninhibited trophoblast invasion results in placenta accreta (Davidson, 1944; 
Khong and Robertson, 1987). Uninhibited trophoblast invasion and failure of trophoblast 47	 ﾠ
regression at parturition (subinvolution of placental sites (SIPs)) also occur in dogs (Al-
Bassam et al., 1981; Fernández et al., 1998).  Before conditions of pathologic trophoblast 
invasion and retention can be properly investigated, the mechanisms involved in normal 
trophoblast invasion and release must be studied. Therefore, the objective of this research 
was to characterize global gene expression changes in the peripartum period, using a 
canine model. 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Tissue Collection 
 
Canine chorioallantoic tissue was collected following elective pregnancy 
termination by ovariohysterectomy at 61 ± 1 day past the LH surge (pre-term; n=4), 
following elective C-section at 64 ± 1 day past the LH surge prior to first stage labor 
(pre-labor; n=4), and natural delivery (parturient; n=4). Upon tissue collection, the 
marginal hematoma was dissected away and any blood or excess tissue (nonvillous 
chorioallantois, amnion and umbilical cord) were removed. Tissues were flash frozen in 
liquid nitrogen and stored at -80°C until RNA was isolated. 
 
3.2.2 RNA Isolation 
 
Total RNA was isolated using the TRIzol Plus RNA Purification Kit (Invitrogen, 
Carlsbad, CA) following the manufacturer’s instructions. RNA concentration and purity 
was determined using a spectrophotometer (NanoPhotometer, IMPLEN, Munich, 
Germany). RNA integrity numbers (RIN) were obtained for each sample using the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only RNA samples 
with a RIN >7.0 were used for microarray analysis. 
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3.2.3 Microarray Analysis 
 
Microarray was performed at the Center for Genome Research and Biocomputing 
Core Laboratory (CGRB) at Oregon State University using the standard protocol for the 
facility. Briefly, labeled target amplified antisense RNA (aRNA) was prepared from 200 
ng of total RNA using the MessageAMP Premier Amplification Kit (Life Technologies, 
Grand Island, NY). Samples were in vitro transcribed (IVT) and incubated for 16 hours. 
)ROORZLQJLQFXEDWLRQȝJRID51$IURPHDFKVDPSOHZDVKybridized to an Affymetrix 
Canine Genome 2.0 Array (Affymetrix, Santa Clara, CA) for 18 hours. All samples were 
hybridized in one day in two sets. Washing, staining and scanning was performed using 
the GeneChip Expression Wash, Stain and Scan Manual for Cartridge Arrays 
(Affymetrix) using the GeneChip Command Console Software (AGCC) software with a 
Fluidics Station 450 (Affymetrix) and a GeneChip Scanner 3000 with an autoloader 
(Affymetrix). Image processing and data extraction was performed using AGCC 
Software Version 3.0 (Affymetrix). 
 
3.2.4 Statistical Analysis 
 
Overall gene expression changes between groups were averaged and plotted in 
scatterplots using ArrayStar (DNASTAR, Madison, WI). In order to graph these 
comparisons the average expression levels of the sample groups were plotted on the x- 
and y-axes. Linear correlation coefficients were calculated within the ArrayStar program. 
Pre-processing, normalization of the microarray data as well as differential 
expression statistics was carried out in the open-source statistical program known as R 
(www.R-project.org) using the Bioconductor software package. Quantile normalization 
was carried out using robust multichip average (RMA) (Irizarry et al., 2003). Linear 
modeling and differential gene expression using an empirical Bayes analysis was 
calculated using the Bioconductor software along with the limma and affy software 
packages (Smyth, 2004) in R. This involves calculating a moderated t-statistic, which 49	 ﾠ
draws inferences from all genes in the set to shrink the standard errors toward a common 
value. This provides more degrees of freedom and more stable standard error estimates 
(Smyth, 2004). A false discovery rate adjusted (FDR) p value was used to adjust for 
multiple testing and false positives (Benjamini and Yekutieli, 1995). Differential 
expression was defined by a p-YDOXH)'5DGMXVWHGSYDOXHDQGDORJIROG
FKDQJHEDVHGRQSDUDPHWHUVXVHGLQSUHYLRXVVWXGLHV6LWUDVHWDO+RHJKHW
al., 2010; Lian et al., 2010). Gene ontology was explored using ArrayStar (DNASTAR, 
Madison, WI).  
 
3.3 RESULTS 
 
  Global gene expression profiles between pre-term, pre-labor and parturient canine 
chorioallantois tissue were compared. Initially for microarray analysis the parturient 
group had a sample size of four. One sample from the parturient group was eliminated 
based on the knowledge that the litter died from Canine Herpes Virus resulting in a 
sample size of three parturient dogs for microarray analysis. High correlation coefficients 
within and between sample groups indicated good concordance within the study groups, 
but minimal overall variation between groups (mean correlation coefficient = 0.985). 
This suggests there is little overall variation in global gene expression between the three 
sample groups (Figure 3.1). 
Microarray analysis demonstrated 18 genes that were differentially expressed 
between pre-term and pre-labor sample groups (Table 3.1) and 38 genes that were 
differentially expressed between pre-term and parturient samples (Table 3.2). There were 
no differentially expressed genes between pre-labor and parturient sample groups (Table 
3.3). There were 12 genes that were up-regulated and 20 down-regulated genes between 
pre-term samples compared to parturient samples (Figure 3.2). Between pre-term and 
pre-labor groups, there were 8 up-regulated genes and 4 down-regulated genes. In 
addition there were 6 differentially expressed genes whose expression changed in the 
same direction between pre-term and pre-labor as well as pre-term to parturient (Figure 50	 ﾠ
3.2). The most represented biological processes included proteolysis, maintenance of 
location, cell adhesion, stem cell division, hormone catabolic processing, peptide 
hormone processing, protein metabolic process, morphogenesis of a branching structure 
and collagen catabolic process (Table 3.4). 51	 ﾠ
     
 
 
 
 
Figure 3.1. Correlation of overall gene expression profiles between sample groups (r=0.985).52	 ﾠ
Table 3.1. Top differentially expressed genes between pre-term and pre-labor sample groups (p )'5DGMXVWHGS
ORJ)&FRQWLQXHGRQQH[WSDJH 
Gene   Gene Name  logFC  P.Value  FDR adj.P.Val 
MXD1  MAX dimerization protein 1  -1.45  2.95E-05  0.08 
SERINC5  serine incorporator 5  -1.33  6.40E-05  0.08 
LOC607225  hypothetical protein  1.40  9.12E-05  0.08 
HBD  hemoglobin, delta  1.40  9.13E-05  0.08 
PI3  peptidase inhibitor 3, skin-derived  -1.81  0.0001  0.10 
LOC475901  hypothetical protein  1.50  0.0002  0.10 
SLC26A11  solute carrier family 26, member 11  -1.20  0.0002  0.10 
FTSJD2  FtsJ methyltransferase domain containing 2  -1.65  0.0003  0.10 
ASPM 
asp (abnormal spindle) homolog, microcephaly associated 
(Drosophila)  1.23  0.0003  0.10 
RBP7  retinol binding protein 7, cellular  1.90  0.0004  0.10 53	 ﾠ
Table 3.1. Top differentially expressed genes between pre-term and pre-labor sample groups (p )'5DGMXVWHGS
ORJ)&FRQWLQXHGIURPSUHYLRXVSDJH 
 
 
   
Gene   Gene Name  logFC  P.Value  FDR adj.P.Val 
EPHX2  epoxide hydrolase 2, cytoplasmic  1.28  0.001  0.10 
CD44  CD44 molecule (Indian blood group)  -1.20  0.001  0.10 
POU1F1  POU class 1 homeobox 1  1.50  0.001  0.10 
NR4A1  nuclear receptor subfamily 4, group A, member 1  1.75  0.001  0.10 
ULK4  unc-51-like kinase 4 (C. elegans)  1.20  0.001  0.10 
ERRFI1  ERBB receptor feedback inhibitor 1  -1.30  0.001  0.10 
SLC37A2  solute carrier family 37 (glycerol-3-phosphate transporter), 
member 2 
-1.40  0.002  0.10 
MFI2  antigen p97 (melanoma associated) identified by 
monoclonal antibodies 133.2 and 96.5 
-1.27  0.002  0.10 54	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Table 3.2. Top differentially expressed genes between pre-term and parturient sample groups (p )'5DGMXVWHGS
ORJ)&FRQWLQXHGRQQH[WSDJH 
 
   
Gene   Gene Name  logFC  P.Value  FDR adj.P.Val 
BDH2  3-hydroxybutyrate dehydrogenase, type 2  1.20  1.06E-06  0.02 
CIRBP  cold inducible RNA binding protein  1.55  3.32E-06  0.02 
DAG1  dystroglycan 1 (dystrophin-associated glycoprotein 1)  1.47  5.58E-06  0.02 
EGLN3  egl nine homolog 3 (C. elegans)  -1.31  1.78E-05  0.02 
CXCL10  chemokine (C-X-C motif) ligand 10  1.84  1.89E-05  0.02 
NDC80  NDC80 homolog, kinetochore complex component (S. cerevisiae)  1.25  1.93E-05  0.02 
RBP7  retinol binding protein 7, cellular  2.62  5.30E-05  0.03 
CELA1  chymotrypsin-like elastase family, member 1  1.35  0.0001  0.04 
HSP70  heat shock protein 70  -1.92  0.0002  0.05 55	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Table 3.2. Top differentially expressed genes between pre-term and parturient sample groups (p )'5DGMXVWHGS
ORJ)&FRQWLQXHGRQQH[WSDJH 
   
Gene   Gene Name  logFC  P.Value  FDR adj.P.Val 
BPHL  biphenyl hydrolase-like (serine hydrolase)  1.50  0.0002  0.05 
MXD1  MAX dimerization protein 1  -1.21  0.0002  0.05 
SERINC5  serine incorporator 5  -1.21  0.0002  0.05 
ERRFI1  ERBB receptor feedback inhibitor 1  -1.53  0.0005  0.06 
ART3  ADP-ribosyltransferase 3  -1.33  0.0005  0.06 
FTSJD2  FtsJ methyltransferase domain containing 2  -1.60  0.001  0.06 
DNAJB1  DnaJ (Hsp40) homolog, subfamily B, member 1  -1.28  0.001  0.07 
LIPG  lipase, endothelial  -1.62  0.001  0.07 
TEX10  testis expressed 10  1.30  0.002  0.09 
DEPDC1  DEP domain containing 1  1.20  0.002  0.09 56	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Table 3.2. Top differentially expressed genes between pre-term and parturient sample groups (p )'5DGMXVWHGS
ORJ)&FRQWLQXHGRQQH[WSDJH   
Gene   Gene Name  logFC  P.Value  FDR 
adj.P.Val 
SPAM1  sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida 
binding) 
1.80  0.002  0.09 
SORT1  sortilin 1  -1.20  0.002  0.09 
MFI2  antigen p97 (melanoma associated) identified by monoclonal 
antibodies 133.2 and 96.5 
-1.36  0.002  0.09 
DEGS2  degenerative spermatocyte homolog 2, lipid desaturase (Drosophila)  -1.20  0.002  0.10 
MMP1  matrix metallopeptidase 1 (interstitial collagenase)  -2.99  0.003  0.10 
SERPINE1  serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
-1.50  0.003  0.10 
DIO3  deiodinase, iodothyronine, type III  -1.26  0.004  0.10 
SOCS1  suppressor of cytokine signaling 1  -1.21  0.004  0.10 
FBN2  fibrillin 2  1.85  0.004  0.10 57	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Table 3.2. Top differentially expressed genes between pre-term and parturient sample groups (p )'5DGMXVWHGS
ORJ)&FRQWLQXHGIURPSUHYLRXVSDJHV
Gene   Gene Name  logFC  P.Value  FDR adj.P.Val 
NRN1  neuritin 1  2.10  0.004  0.10 
LYVE1  lymphatic vessel endothelial hyaluronan receptor 1  -1.20  0.004  0.10 
HRH3  histamine receptor H3  -1.22  0.005  0.10 
ALDH4A1  aldehyde dehydrogenase 4 family, member A1  -1.28  0.005  0.10 
TUFT1  tuftelin 1  -1.20  0.005  0.10 
SSTR2  somatostatin receptor 2  -1.30  0.005  0.10 
COCH  coagulation factor C homolog, cochlin (Limulus polyphemus)  -1.82  0.005  0.10 
MARK2  MAP/microtubule affinity-regulating kinase 2  -1.30  0.005  0.10 
PHLDA1  pleckstrin homology-like domain, family A, member 1  -1.20  0.005  0.10 
IL6  interleukin 6 (interferon, beta 2)  -1.72  0.006  0.10 58	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Table 3.3. Top genes reported from pre-labor to parturient samples (continued on next page)  
 
   
Gene   Gene Name  logFC  P.Value  FDR adj.P.Val 
CIRBP  cold inducible RNA-binding protein  1.03  1.37E-05  0.15 
ARRDC3  arrestin domain containing 3  -0.82  2.38E-05  0.19 
BDH2  3-hydroxybutyrate dehydrogenase, type 2  0.85  2.82E-05  0.19 
RCOR3  REST corepressor 3  -0.55  9.46E-05  0.45 
ALKBH3  alkB, alkylation repair homolog 3 (E. coli)  0.40  0.0001  0.47 
LYRM5  LYR motif containing 5  0.75  0.0001  0.47 
LOC609334  similar to leiomodin-2-like  -0.78  0.0001  0.47 
NFIL3  nuclear factor, interleukin 3 regulated  -0.87  0.0002  0.47 
ZBTB38  zinc finger and BTB domain containing 38  0.50  0.0002  0.47 
PUS7L  pseudouridylate synthase 7 homolog (S. 
cerevisiae)-like 
-1.14  0.0002  0.47 59	 ﾠ
Table 3.3. Top genes reported from pre-labor to parturient samples (continued from previous page)  
 
 
 
 
   
Gene   Gene Name  logFC  P.Value  FDR 
adj.P.Val 
GADD45B  growth arrest and DNA-damage-inducible, 
beta 
-1.38  0.0002  0.47 
NFIL3  nuclear factor, interleukin 3 regulated  -0.81  0.0002  0.47 
DHX9  DEAH (Asp-Glu-Ala-His) box polypeptide 9  0.41  0.0002  0.50 
IFI44L  interferon-induced protein 44-like  0.94  0.0002  0.50 
LOC612530  hypothetical protein LOC612530  0.61  0.0003  0.56 
HSP70  heat shock protein 70  -1.93  0.0003  0.56 
HABP4  hyaluronan binding protein 4  -0.39  0.0003  0.56 
XRCC6BP1  XRCC6 binding protein 1  0.48  0.0004  0.60 60	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Figure 3.2. Venn Diagram demonstrating down-regulation and up-regulation of genes among sample groups compared to pre-
term.61	 ﾠ
 
Table 3.4. Most over-represented biological processes with the most differentially 
expressed genes based on 95% significance according to an ANOVA test 
 
Biological Process  P-value 
Proteolysis  0.004 
Maintenance of Location  0.006 
Stem Cell Division  0.019 
Cell Adhesion  0.02 
Hormone Catabolic Process  0.031 
Peptide Hormone Processing  0.031 
Protein Metabolic Process  0.044 
Morphogenesis of a Branching Structure  0.047 
Collagen Catabolic Process  0.048 
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3.4 DISCUSSION 
 
  Overall, knowledge is lacking regarding molecular changes in the canine placenta 
around the time of parturition. To the authors’ knowledge, this is the first report of gene 
expression in the canine placenta using microarray analysis at any gestational age. While 
previous studies have looked at gene expression in the canine uterus and uteroplacental 
tissues (Klonisch et al., 2001; Beceriklisoy et al., 2007; Schäfer-Somi et al., 2008; 
Schäfer-Somi et al., 2009; Kowalewski et al., 2010; Kanca et al., 2011; Kowalewski et 
al., 2011), no studies have focused on the chorioallantois tissue of the placenta at the end 
of gestation.  
The current study of the canine placental transcriptome demonstrates little global 
variation between sample groups in the peripartum period.  Nevertheless, there were 
many genes involved in trophoblast invasion and placental release that were differentially 
expressed between peripartal groups. This is consistent with what has been found in a 
similar microarray study of the human placenta (Vu et al., 2008; Lee et al., 2010).  
  The most represented biological processes included proteolysis, cell adhesion, 
hormone catabolism, collagen catabolic process and protein metabolic processes. The 
overrepresentation of these processes in the differential gene expression studies may be 
evidence for late gestation tissue remodeling in the dog. Degradation of extracellular 
matrix proteins and breakdown of collagen is considered important for the rupture of fetal 
membranes in humans (Parry and Strauss III, 1998) and placental release in cattle (Eiler 
and Hopkins, 1993; Walter and Boos, 2001). Therefore, the overrepresentation of these 
processes in the current study supports a role for the differentially expressed genes in 
both tissue remodeling at the time of labor and possibly rupture of fetal membranes at 
canine parturition.  This placental transcriptome analysis has lead to the identification of 
several candidate genes for future study including IL-6, MMP-1, DAG-1, CXCL10 and 
CD44. 
  The receptor for hyaluronan, CD44 (Aruffo et al., 1990; Goshen et al., 1996) may 
be important in trophoblast invasion as well as tissue remodeling in late gestation in the 63	 ﾠ
human (Marzioni et al., 2009). The migration of human melanoma cells has been 
correlated to a high expression of CD44 protein (Thomas et al., 1993) suggesting a role in 
migration of other cell types. Hyaluronan is internalized upon binding to CD44 and 
degraded within the cell. This receptor-mediated degradation of hyaluronan is thought to 
be important in the process of macrophage cell migration (Culty et al., 1992).  
CD44 protein expression has been identified on human trophoblast cells. In 
addition, invasive extravillous trophoblast cells express an alternatively spliced form of 
CD44 known as CD44v7-8. It has been proposed that invading trophoblasts use 
alternative splicing to become invasive. Furthermore, CD44 isoform CD44v7-8 
expression may be involved in placenta accreta (Goshen et al., 1996) a condition of 
aberrant trophoblast invasion in the human (Davidson, 1944; Khong and Robertson, 
1987). Others suggest expression of CD44 during the second half of pregnancy plays a 
role during late gestation tissue remodeling (Marzioni et al., 2009). In microarray 
analysis, CD44 was down-regulated from pre-term to pre-labor. The expression of CD44 
in late gestation in the dog supports a role for CD44 in late gestation tissue remodeling. 
The decline in expression around labor seen in this study may suggest that CD44 is 
needed during late gestation (61 days of gestation), but not at the initiation of labor. 
The expression of DAG-1 was up-regulated between pre-term and parturient 
samples in microarray analysis. The mammalian DAG-1 JHQHHQFRGHVIRUĮDQGȕ
subunits of the dystrophin-glycoprotein complex. Human dystroglycan is a laminin 
receptor thought to function in the stabilization of the extracellular matrix in skeletal 
muscle, but it is thought to play a similar role in membrane stability in other cell-types as 
well (Ibraghimov-Beskrovnaya et al., 1993). Dystroglycan is required for the 
development of Reichert’s membrane during murine development. Furthermore, mice 
null for DAG-1 display fatal disruptions to this membrane (Williamson et al., 1997).  
5HFHQWO\ERWKĮ- DQGȕ-dystroglycan has been identified in human placental 
tissue and trophoblast cell lines. It has been proposed that dystroglycan may have an 
inhibitory effect on trophoblast invasion as the invasive first-trimester trophoblast cell 
OLQH+7569GRHVQRWH[SUHVVĮ-dystroglycan. In addition, first-trimester human 64	 ﾠ
placental samples express lower levels compared to term placental samples (Street et al., 
2012). The increase in DAG-1 observed in the current study around parturition leads to 
the speculation that an increase in DAG-1 mRNA expression at canine parturition may be 
important for maintaining membrane integrity during placental release. 
Interleukin-6 (IL-6) has been implicated in trophoblast invasion and its expression 
has been noted to change depending on the occurrence of labor. IL-6 stimulates invasion 
RIKXPDQF\WRWURSKREODVWFHOOVLQYLWUR-RYDQRLüDQG9LüRYDFDQGPD\EH
involved with the regulation of trophoblast invasion by stimulating MMP-2 and MMP-9 
activation (Meisser et al., 1999). An increased production of IL-6 by placental cell 
cultures is associated with normal term labor in humans (Steinborn et al., 1999). 
)XUWKHUPRUHWKHH[SUHVVLRQRI71)ĮDQG,/-6 in the pre-implantation canine embryo is 
thought to be important in regulating the balance of tissue remodeling during 
implantation (Schäfer-Somi et al., 2008). Based on previous studies we expected to see a 
distinct expression pattern around the time of canine parturition. Interleukin-6 (IL-6) was 
down-regulated from pre-term to parturient in microarray analysis. This difference in the 
present study compared to what has been previously been reported in humans may 
suggest IL-6 plays a different role in the canine placenta.  
Degradation of the extracellular matrix (ECM) by matrix metalloproteinases is 
thought to be essential not only for trophoblast invasion, but also the separation of 
placental membranes at parturition in a number of species (Walter and Boos, 2001; Xu et 
al., 2002). Matrix metalloproteinase (MMP)-1 or collagenase-1 is a member of the MMP 
family (Matrisan, 1990). Separation of the placenta from the uterine wall and loss of 
placental mass may rely on expression of MMPs such as MMP-1 and MMP-3 in the 
human (Vettraino et al., 1996). In addition, an increased expression of MMP-9 and 
MMP-3 mRNA in the human choriondecidua is proposed to activate MMP-1 in order to 
degrade ECM components during labor (Bryant-Greenwood and Yamamoto, 1995). 
MMP-1 was significantly expressed between pre-term and parturient samples suggesting 
that tissue remodeling in the canine placenta may be occurring around the time of 
parturition in the dog. MMP activity has also been noted in the feline placenta suggesting 65	 ﾠ
MMP expression may play an important role in the endotheliochorial placental type 
(Walter and Schönkypl, 2006).  
Chemokines play an important role during implantation. CXCL10 acts as a 
chemoattractant for the trophoblast cell line JEG-3 (Dominguez et al., 2008). CXCL10 
has been identified in the caprine endometrium while its receptor CXCR3 mRNA and 
protein is expressed by caprine trophoblast cells (Nagaoka et al., 2003; Imakawa et al., 
2006). It has been proposed that CXCL10 produced by the endometrium in the goat may 
stimulate adhesion and invasion of the trophoblast to the uterus by interacting with its 
receptor CXCR3 found on the trophoblast (Nagaoka et al., 2003; Imakawa et al., 2006). 
  Chemokines such as CXCL10 are considered important molecules in the 
regulation of normal and pathological parturition (Gomez-Lopez et al., 2010). CXCL10 is 
a chemokine that was once known as interferon-Ȗ-inducible protein 10 (IP-10) and is 
induced by factors such as interleukin-1 and tumor necrosis factor-ĮLQPXOWLSOHFHOOW\SHV
(Dominguez et al., 2008). It is thought that in humans, specific chemokines, including 
CXCL10 are primarily produced by the choriodecidua and amnion early in labor resulting 
in the recruitment of various leukocyte populations who along with local cells secrete 
cytokines and MMPs. This results in the cascade of events that lead to parturition 
(Gomez-Lopez et al., 2010). The up-regulation of CXCL10 in the current study between 
pre-term and parturient samples suggests the chemokine CXCL10 in the dog may play a 
role in the initiation of parturition, similar to that reported in humans. 
  In conclusion, this is the first published report of a canine placental gene 
expression profile during the peripartum period. This placental transcriptome analysis 
presents a number of candidate genes that warrant further study to better understand the 
molecular changes that occur at the end of gestation in the bitch. Characterizing gene 
expression changes at the end of gestation is the first step in better understanding the 
regulation of trophoblast invasion and regression. Further study is needed to investigate 
global gene expression earlier in canine gestation as well as compare gene expression of 
normal placentas to pathologic placental tissue 
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CHAPTER IV 
 
 
 
CONCLUSION AND FUTURE STUDIES 
 
 
 
We have demonstrated that canine chorioallantois tissue expresses CD-44, 
CXCL10, DAG-1, Flt-1, HPRT-1, IL-6, MMP-1, MMP-2, MMP-9, TIMP-2, and VEGF-
A during the peripartum period using technologies such as real-time RT-PCR and 
microarray analysis. These genes are of interest in human studies related to abnormal 
trophoblast invasion (Nishizawa et al., 2007; Sitras et al., 2009; Winn et al., 2009; Lian et 
al., 2010; Centlow et al., 2011; Mayor-Lynn et al., 2011; Zhang et al., 2011) and 
placental release  (Vettraino et al., 1996; Xu et al., 2002; Torricelli et al., 2008; Street et 
al., 2012). This is the first report on global gene expression in the canine placenta using 
microarray analysis. 
Throughout pregnancy, the placenta is vital in the transport of nutrients to and 
removal of waste from the developing fetus, as well as synthesizing substances necessary 
for pregnancy maintenance (Johnston et al., 2001). The tissues studied in this research 
represent a time period when the placenta transitions from this vital role to the expulsion 
during parturition. Despite the significant physiological changes that are occurring within 
the peripartum canine placenta, overall gene expression changes were minimal.  Results 
on peripartum placental gene expression in human studies vary. Similar to our findings, 
several report minimal overall global gene expression variation (Sitras et al., 2008; Vu et 
al., 2008); while others report significantly different gene expression profiles (Cindrova-
Davies et al., 2007; Lee et al., 2010) in tissues from normal term spontaneous labor 
compared to those obtained by term elective Cesearean section. Although the overall 
gene expression changes in the canine placenta were much smaller than those reported in 
human placental transriptome studies (Cindrova-Davies et al., 2007; Lee et al., 2010), the 
differential expression reported was between similar genes such as Flt-1 (Cindrova-71	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Davies et al., 2007; Lee et al., 2010), SERPINE1 (Lee et al. 2010), CIRBP (Cindrova-
Davies et al., 2007) and MMP-1 (Vu et al., 2008).  
It is possible the difference between this research and other human microarray 
studies that showed greater global gene expression variability may represent the 
uniqueness of the modified deciduate and endotheliochorial placenta of the dog. Future 
studies may focus on determining if this lack of variability is characteristic to other 
carnivores (similar kind of placenta) or other domestic species (having a non-deciduate, 
epitheliochorial placenta). In addition, future studies should focus on other canine 
reproductive tissues at this time period (e.g., endometrium) to better capture gene 
expression changes that mirror the physiologic changes known to occur at parturition. 
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APPENDIX A: TOTAL RNA ISOLATION FROM CANINE CHORIOALLANTOIS 
TISSUE AND ISOLATED CANINE TROPHOBLASTS 
 
Cleaning and Preparatory Steps 
  Prior to RNA isolation, the work space was cleaned meticulously to prevent RNA 
degradation from RNases present in the environment. The day before the isolation was to 
take place fresh blotter paper was laid down in the fume hood and the surrounding area. 
On the day of the isolation, further cleaning and preparation took place. The first step was 
to turn on the microcentrifuge and set it to 4°C to insure that this temperature was 
reached at the appropriate time in the protocol. The fume hood and any surfaces that 
tubes containing RNA sample may come into contact with were cleaned using a kim-
wipe sprayed with RNase Zap (BIOHIT, Inc., Cat. No. 724000, Neptune, NJ), In 
addition, the hand-held homogenizer handle was wiped with RNase Zap (BIOHIT, Inc). 
A 2% Absolve solution (PerkinElmer Inc. Waltham MA) was prepared in a labeled 50 ml 
conical tube. Another labeled 50 ml conical tube was filled with NanoPure water and the 
homogenizer blades were cleaned using 2% Absolve (PerkinElmer Inc.) followed by a 
wash in NanoPure water. 
 
RNA Isolation  
Total RNA was isolated from frozen chorioallantois tissue using the TRIzol Plus 
RNA Purification Kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. Approximately 100 mg of frozen canine chorioallantois tissue was sliced off 
previously flash frozen specimens using a razor blade, placed in a labeled 50 ml conical 
tube, and then stored at -80°C if not used immediately. One reagent within the RNA 
Purification Kit (Wash Buffer II) was prepared prior to the first isolation using the kit. In 
the vial provided by the kit, 60 ml of 100% ethanol was added to Wash Buffer II and the 
buffer was stored at room temperature. 
   The following procedure was carried out under the fume hood due to the use of 
TRIzol Reagent provided with the kit, which contains phenol and guanidine 
isothiocyanate. In the 50 ml conical tube containing the tissue sample, 1 ml of TRIzol 76	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Reagent (Invitrogen, Carlsbad, CA) was added, and then the sample was homogenized. 
Following a 5 minute incubation at room temperature, 0.2 ml of chloroform was added to 
the lysate. The tube was shaken vigorously by hand for 15 seconds, but not vortexed 
based on the manufacturers instructions. The sample was then transferred to a 
microcentrifuge tube where it was incubated at room temperature for 3 minutes.  
Total RNA was isolated from isolated trophoblasts using the same TRIzol Plus 
RNA Purification Kit. Cells that had previously been isolated and frozen were removed 
from the liquid nitrogen tank and thawed on ice. Once thawed, the vials were centrifuged, 
the supernatant was pipetted off and 1 ml of TRIzol was added to the vial. The cells were 
then lysed in the TRIzol by pipetting up and down. The cells and TRIzol reagent were 
then pipetted into a fresh 1.5 ml RNase-free microcentrifuge tube.  The lysates were 
incubated in the TRIzol at room temperature for 5 minutes.  Following the incubation, 0.2 
ml of chloroform was added to the tube. The tube was shaken vigorously by hand for 15 
seconds and then incubated at room temperature for 3 minutes.  
Irrespective of sample type (chorioallantois tissue or isolated trophoblasts), the 
sample was then centrifuged at 12,000 x g for 15 minutes at 4°C. After centrifugation, the 
mixture separated into an organic phase (lower, red phenol-chloroform portion), a white 
interphase (containing DNA) and an upper, clear phase (containing RNA). After 
FHQWULIXJLQJȝORIWKHFOHDU51$FRQWDLQLQJSKDVHZDVWUDQVIHUUHGWRDQHZ5Nase-
free microcentrifuge tube.  
$ILQDOHWKDQROFRQFHQWUDWLRQRIZDVDFKLHYHGE\DGGLQJȝORI
ethanol to the tube. The tube was then mixed by vortexing and inverted to disperse any 
visible precipitate that may form after the addition of the ethanol. After the tube was 
LQYHUWHGȝORIWKHVDPSOHZDVWUDQVIHUUHGWRDVSLQFDUWULGJHZLWKDFROOHFWLRQWXEH
provided by the kit. The spin cartridge was then centrifuged at 12,000 x g for 15 seconds 
at room temperature. The effluent located in the collection tube after centrifuging was 
discarded and the spin cartridge was reinserted into the collection tube. This step was 
repeated until the entire sample was processed through the spin cartridge.  77	 ﾠ
After the last processing step, the effluent was discaUGHGDQGȝORI:DVK
Buffer I (provided by the kit) was added to the spin cartridge. The spin cartridge was then 
centrifuged at 12,000 x g for 15 seconds at room temperature. The effluent in the 
collection tube was then discarded as previously described and the spin cartridge was 
UHLQVHUWHGLQWRDQHZFROOHFWLRQWXEH:DVK%XIIHU,,SURYLGHGZLWKWKHNLWȝOZDV
then added to the spin cartridge. The sample was centrifuged at 12,000 x g for 15 seconds 
at room temperature and the effluent was discarded as described previously. The step 
requiring the addition of the Wash Buffer II was repeated once. The sample was then 
centrifuged at 12,000 x g for 15 seconds at room temperature and the spin cartridge was 
placed in the same collection tube. The sample was then centrifuged again at 12,000 x g 
for 1 minute at room temperature to dry the membrane with the attached RNA. After this 
centrifugation step, the collection tube was discarded and the spin cartridge was inserted 
into a recovery tube provided by the kit.  
2QFHLQWKHUHFRYHU\WXEHȝORI51DVH-free water was added to the spin 
cartridge and the sample was incubated at room temperature for 1 minute. The spin 
cartridge was then centrifuged with the recovery tube at 12,000 x g for 2 minutes at room 
temSHUDWXUH$IWHUWKHFHQWULIXJDWLRQȝORI51DVH-free water was added again, the 
sample was incubated and centrifuged as just described. This was repeated until the final 
YROXPHRIWKHHOXDWHZDVȝO 
 
Determination of RNA Concentration and Purity 
Following RNA isolation, the RNA concentration and purity of the sample was 
determined using a NanoPhotometer, Version 2.1 (IMPLEN, Munich, Germany).  
Concentration was determined using the concentration measurement through the RNA 
setting on the NanoPhotometer (IMPLEN). Purity was determined using the A260/280 ratio 
where a ratio of 1.8-2.0 indicated a pure RNA sample (IMPLEN, 2012).  
Briefly, the clear cover was removed from the machine and the black cuvette was 
removed from its location. The NanoPhotometer was powered on and allowed to heat up 
and self-calibrate. Once it was calibrated the black cuvette was returned to its holder. A 78	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kim-wipe was used to gently wipe the surface of the cuvette. On the menu screen “Option 
1” or “LabelGuard Applications” was selected. On the next screen, “RNA” was selected. 
On the third screen, “Lid Factor: 10” was highlighted and the button labeled “OK” was 
pushed to select the lid factor. RNase-free water was used to blank the NanoPhotometer. 
$SSUR[LPDWHO\ȝORI51DVHIUHe water was pipetted on the well of the cuvette. The lid 
labeled “Factor 10” was placed over the water on the cuvette. The NanoPhotometer was 
“blanked” for further measurements by pressing the blue button on the keypad labeled 
“Blank”. A kimwipe was used to gently wipe the surface of the cuvette. In order to 
PHDVXUHDEVRUEDQFHȝORIWKHVDPSOHWREHPHDVXUHGZDVFDUHIXOO\SLSHWWHGRQWRWKH
well on the cuvette surface. The lid labeled “Factor 10” was again placed on the cuvette, 
covering the sample. To run the sample, the button on the keypad labeled “Sample” was 
pressed. Sample concentration as well as absorbance was measured and appeared on the 
screen. If the sample was too concentrated for Lid Factor 10 an image appeared in the 
upper left hand corner of the NanoPhotometer screen with a 10Æ50 image indicating the 
sample should be rerun with the lid labeled “Factor 50”. Once the measurement was 
satisfactory the button on the keypad labeled “Options” was pressed and “2” or “Print” 
was clicked in order to print the results. A kim-wipe was then used to wipe the cuvette 
before the machine was powered off. The RNA concentrations determined for placental 
tissue and isolated trophoblasts are provided in Tables A.1 and A.2, respectively. 
 
Determination of RNA Integrity 
)ROORZLQJGHWHUPLQDWLRQRI51$FRQFHQWUDWLRQDȝODOLTXRWRIVDPSOHZDV
pipetted into a 0.5 ml microcentrifuge tube to determine RNA integrity on the Agilent 
2100 Bioanalyzer (Agilent Techonolgies, Santa Clara, CA).  The samples were stored at -
80°C until twelve samples had been prepared and they were submitted as a batch to the 
Center for Genome Research and Biocomputing (CGRB) at Oregon State University.  
During the RNA isolation procedure, samples were eluted in water so they were 
submitted to the CGRB suspended in water. Concentrations of samples to be submitted 79	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needed to be between 25-QJȝO6RPHVDPSOHVZHUHWRRFRQFHQWUDWHGVRWKH\ZHUH
GLOXWHGDQGVXEPLWWHGDVȝODOLTXRWV 
 Prior to submitting samples to the CGRB, an online account was set up through 
the staff at the CGRB core lab. Samples were submitted to the CGRB through the online 
submission form at http://www.cgrb.oregonstate.edu.  Once the samples were submitted 
using the online submission form, the samples were taken to the CGRB core lab located 
in Room 3012 of the Agricultural Life Sciences Building for analysis. A labeled test tube 
rack was placed in the -80°C freezer. Staff from the CGRB ran the samples on the 
Agilent 2100 and emailed the results when they were complete. The software produces an 
electropherogram that displays the size distribution of fragments of each RNA sample 
and allows a visual inspection of the RNA quality as well as a RNA integrity number 
(RIN) (Figure A.1). 
 
 
Appendix A. References 
 
IMPLEN, 2012. Nucleic Acids Estimation of Purity. [WWW Document]. URL 
http://implen.com/nanophotometer/applications.php.  
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Table A.1.  RNA Concentration, A260/280 ratio and RNA integrity number (RIN) for 
chorioallantois samples. R1-R3: first-third placenta in right uterine horn from uterine 
body, respectively, #1-3: tissue replicates used in Appendix F 
 
    Sample  RNA concentration  A260/280  RIN 
681 R1   QJȝO  1.969  9.60 
405 R1 #1  QJȝO  1.970  9.60 
405 R1 #2  345 QJȝO  1.986  9.50 
405  R1 #3  QJȝO  1.988  10 
638 R3 #1  QJȝO  1.973  9.60 
638 R3 #2  QJȝO  1.986  10 
638 R3 #3  QJȝO  1.989  10 
311 R2 #1  QJȝO  1.932  9.5 
311 R2 #2  QJȝO  2.004  9.9 
311 R2 #3  QJȝO  2.004  9.7 
Twix   QJȝO  1.971  9.70 
Gracie   QJȝO  2.016  9.30 
Piper   QJȝO  2.003  8.90 
Samba   QJȝO  2.007  9.70 
Gemima   QJȝO  1.983  9.80 
Gidget   QJȝO  1.990  9.50 
Cher   QJȝO  1.997  9.60 
Amber   QJȝO  2.010  9.8 81	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Table A.2.  RNA Concentration, A260/280 ratio and RNA integrity number (RIN) for 
isolated trophoblasts 
   
Sample  RNA 
concentration 
A260/280  RIN 
BS1118  QJȝO  2.014  9.9 
S123  QJȝO  2.012  8.8 
Abb315  QJȝO  1.943  9.8 
Cleo624  QJȝO  1.940  9.3 
Fan624  QJȝO  1.966  9.2 82	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Figure A.1.  Agilent 2100 Bioanalyzer results.  
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Figure A.1.  Agilent 2100 Bioanalyzer results (continued). 84	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Figure A.1.  Agilent 2100 Bioanalyzer Results (continued). 
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APPENDIX B: CDNA SYNTHESIS USING THE SUPERSCRIPT III SYSTEM 
 
Synthesis of cDNA was performed using the SuperScript III First-Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, Cat No. 18080-051) according 
to the manufacturer’s instructions. Prior to starting the cDNA synthesis, the thermal 
cycler was set up to the protocol; 65°C for 5 minutes, 50°C for 50 minutes, then 85°C for 
5 minutes followed by 37° C for 20 minutes. This protocol was saved in the thermal 
cycler in Withycombe 315 under the username “ejfellows”; protocol “cdnalf”. First, 0.2 
ml microcentrifuge tubes were labeled to correspond to the appropriate RNA sample to 
EHUHYHUVHWUDQVFULEHG7KHDPRXQWRI51$VDPSOHQHHGHGWREHXSWRȝJRI51$IRU
successful reverse transcription. The amount of RNA was calculated by multiplying the 
concentratioQȝJPOE\EHFDXVHȝORIVDPSOHZDVUHPRYHGWRIXOILOOWKHNLWSURWRFRO 
  The RNA samples and kit reagents were thawed on ice. Once thawed, the samples 
and reagents were briefly mixed by flicking. The samples were then briefly centrifuged 
DQGȝORI51$VDPSOHZDVSLSHWWHGLQWKHDSSURSULDWHO\ODEHOHGWXEH1H[WȝORI
ȝ0ROLJRG7SULPHUDQGȝORIP0G173PL[ERWKSURYLGHGE\WKHNLWZHUHDGGHG
to the sample tube. The tube was then placed into the thermal cycler for the first step of 
the “cdnalf” protocol (65°C for 5 minutes). After the 5 minutes were up, the thermal 
cycler was paused and the tube was removed from the thermal cycler. The sample was 
placed on ice for 3 minutes. During this time, a cDNA synthesis mix was prepared in a 
sepaUDWHWXEHFRQWDLQLQJȝORI;57%XIIHUȝORIP00J&O2ȝORI0
'77ȝORI51DVH287DQGȝORI6XSHU6FULSW,,,57WRJHWDILQDOYROXPHRIȝO
per reaction. This tube was mixed by flicking and centrifuged briefly. After the sample 
VDWRQLFHIRUPLQXWHVȝORIWKHF'1$V\QWKHVLVPL[ZDVDGGHG to the RNA/primer 
mixture tube. The tube was then mixed gently by flicking and the reaction was collected 
by brief centrifugation. The sample was returned to the thermal cycler to resume the 
“cdnalf” protocol by incubating at 50°C for 50 minutes and then 85°C for 5 minutes. 
After the 5 minutes, the protocol was again paused and the sample was removed from the 
thermal cycler. The sample was chilled on ice for 1 minute and after the 1 minute was up 
ȝORI51DVH+SURYLGHGE\WKHNLWZDVSLSHWWHGLQWRWKHWube. RNase H is an 86	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endoribonuclease that specifically degrades the RNA strand of the RNA:DNA hybrid in 
order to create 5' phosphate- terminated oligoribonucleotides and single-stranded DNA 
(Invitrogen, 2012). The sample was then returned to the thermal cycler where the 
protocol was resumed and the sample incubated for 20 minutes at 37°C. The cDNA 
concentration was measured using the DNA setting on the NanoPhotometer (IMPLEN, 
Munich, Germany), as previously described in Appendix A. Once concentration had been 
GHWHUPLQHGDȝOVDPSOHZDVSLSHWWHGLQWRDWXEHRIȝORI51DVH-free water for future 
real-time RT-PCR experiments. The cDNA sample was then stored at -20°C until further 
analysis. 
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APPENDIX C: SELECTION OF A REFERENCE GENE  
 
  Reference genes or housekeeping genes are an important part of measuring 
relative gene expression using real-time RT-PCR. An effective reference gene should be 
one whose expression levels do not significantly differ between different conditions or 
gestation age. Initially, glyceraldhyde-3-phosphate dehydrogenase (GAPDH) and 18S 
rRNA were selected based on previous studies that identified these two genes as effective 
housekeeping genes in other canine tissues. GAPDH was identified as a good reference 
gene in tissues that included the canine corpus luteum, uteroplacental samples 
(Kowalewski et al., 2011), kidney (Rao et al., 2003) and endometrium (Kida et al., 2010). 
Several canine studies have used 18S rRNA as a reference gene in other canine tissues 
including canine hemangiosarcoma (Tamburini et al., 2010), corpus luteum and 
uteroplacental tissues (Kowalewski et al., 2011).  
  Following the first experiment, 18S rRNA expression appeared to be stable, 
however GAPDH did not amplify. After consultation with technical support at Applied 
Biosystems (Vivian Cullen, personal communication), GAPDH was eliminated from 
further study. Additional review of the literature identified a problem with the use of 18S 
rRNA.  The cDNA synthesis protocol used relies on oligo dT as a primer, which binds to 
the poly-A tail of mRNA to synthesize cDNA. Since 18S rRNA does not have a poly-A 
tail, its use in this protocol could result in unreliable synthesis of the gene (Vivian Cullen, 
personal communication). Therefore, this gene was eliminated from the studies as a 
reference gene.  
  Hypoxanthine-phosphoribosyl transferase 1 (HPRT-1) was then selected for 
investigation based upon its success in other canine studies (Brinkhof et al., 2006; 
Etschmann et al., 2006; Schlotter et al., 2009). HPRT-1 was stably expressed in all 
chorioallantois tissues within sample groups and between sample groups as determined 
by Ct values (Ct mean ± SEM; 32.02 ± 0.24) as well as an inter-assay and intra-assay 
coefficient of variation of 3.86% and 3.60% respectively. Coefficients of variation of 88	 ﾠ
<5% indicate little variation between a normalized measure of distribution (Gerd Bobe, 
personal communication).  
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APPENDIX D: PROTOCOL FOR REAL-TIME RT-PCR FOR RELATIVE 
QUANTITATION OF GENE EXPRESSION IN CANINE CHORIOALLANTOIS 
TISSUE 
 
Setting up the Plate and Calculations 
  In order to visualize the 96-well plate, the wells were diagrammed and color- 
coded indicating which samples would be placed in what wells. The cDNA samples and 
reagents were thawed on ice. Once thawed, the cDNA samples and reagents were mixed 
by flicking and collected by brief centrifugation. The concentration of each cDNA 
sample was measured using the NanoPhotometer (Appendix A). The amount of cDNA 
sample needed in each well to provide 10 ng of cDNA per well was calculated by 
dividing 10 by the concentration of cDNA. Then the amount of water needed in each well 
was calculated by subtracting the amount of sample needed from 9 (Table D.1). For each 
sample run in triplicate, a corresponding “no template control (NTC)” was also run in 
triplicate (Table D.2). The NTC samples contained the master mix, TaqMan primer 
assays and water, but no cDNA sample. The purpose of NTC wells was to control for 
contamination in the wells containing sample and act as negative controls. 
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Table D.1. Examples of how to determine the volume of cDNA template needed for each 
reaction 
 
Samples  Concentration  Volume of Sample for  
10 ng cDNA 
Water needed 
ȝO 
Example 1  QJȝO  ȝO  8.32 
Example 2  QJȝO  ȝO  8.49 
Example 3  QJȝO  ȝO  8.43 
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Table D.2. Sample table of no template control (NTC) and corresponding sample 
calculations. The total volume per well was always 20 ȝO 
 
Sample  Master Mix 
Volume 
 Water   cDNA 
 NTC4052MMP9  ȝOSHUZHOO  ȝOSHUZHOO  0 ȝOSHUZHOO 
405-2 MMP9  ȝOSHUwell   ȝOSHUZHOO  ȝOSHUZHOO 
NTC464053 MMP9  ȝOSHUZHOO  ȝOSHUZHOO  ȝOSHUZHOO 
 405-3 MMP9  ȝOSHUZHOO   ȝOSHUZHOO  ȝOSHUZHOO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92	 ﾠ
Preparing the Master Mix and Triplicates 
  Each reaction contained 10 ȝORIWKH7DT0DQ8QLYHUVLDO3&50DVWHU0L[
$SSOLHG%LRV\VWHPV&DUOVEDG&$DQGȝORIWKH7DT0DQ*HQH$VVD\$SSOLHG
Biosystems). The TaqMan gene assays used were primer and probes that were pre-made 
and pre-optimized for canine tissues (Table D.3). A “master” master mix was prepared 
for each gene assay and endogenous control in a 1.5 ml microcentrifuge tube according to 
how many reactions were to be run (Table D.4).  Each 1.5 ml microcentrifuge tube 
containing master mix stock was vortexed and centrifuged briefly. The reagent stocks for 
each cDNA and NTC sample to be run in triplicate were calculated (Table D.5) and 
combined in labeled 1.5 ml microcentrifuge tubes. Each tube was then mixed by 
inversion and flicking. The tubes were centrifuged briefly and kept on ice. Once all 
VDPSOHVZHUHUHDG\ȝORIHDFKWULSOLFDWHZDVSLSHWWHGLQWRWKHDSSURSULDWHZHOOVRQD
96-ZHOOSODWH2QFHDOOWKHZHOOVFRQWDLQHGȝORIWKHUHDFWLRQDQRSWLFDOFRYHUVOLSZDV
placed over the top. The cover slip was sealed to the plate by running a fingernail and a 
pen along the edges to prevent evaporation during the experiment. The plate was then 
placed on ice until it was ready to be run in the RT-PCR machine. Prior to placing the 
plate into the machine the plate was carried on ice to Dr. Gerd Bobe’s Laboratory in the 
Linus Pauling Building to be run on a centrifuge that could hold plates. The plate was 
centrifuged as maximum speed for about 20 seconds and then the plate was observed to 
make sure all samples were in the bottom of the wells. The plate was then placed back on 
ice.93	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Table D.3. TaqMan Primer and Probe Assays (continued on the next page) 
 
    Gene  Assay ID  RefSeq  Exon 
Boundary 
Assay 
Location 
Amplicon 
Length 
MMP-2  Cf02623423_m1  XM_535300.2  3 to 4  520  58 
MMP-9  Cf02621845_m1  NM_001003219.1  12 to 13  2015  59 
TIMP-2  Cf02623335_m1  NM_001003082.1  1 to 2  234  81 
VEGF-A  Cf02623453_m1  NM_001003175.1  7 to 8  906  62 
Flt-1  Cf02696454_g1  XM_534520.2  26 to 27  3489  116 
KiSS-1R  Cf02715933_u1  XM_850105.1  3 to 3  635  141 
CD44  Cf02628940_m1  XM_533152.2  3-4  552  76 
CXCL10  Cf-26225529_m1  NM_001010949.1  2-3  187  69 94	 ﾠ
Table D.3. TaqMan Primer and Probe Assays (continued from previous page) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene  Assay ID  RefSeq  Exon 
Boundary 
Assay 
Location 
Amplicon 
Length 
DAG-1  Cf03023355_m1  NM_001033992.1  2-3  505  93 
IL-6  Cf02624153_m1  NM_001003301.1  4-5  516  66 
MMP-1  Cf02651000_g1  XM_546546.2  2-3  383  63 
HPRT-1  Cf026262558_m1  NM_001003357.1  8 to 9  605  129 
18S 
rRNA  Hs99999901_s1  X03205.1  1 to 1  609  187 
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Table D.4. Example of a gene specific “master” master mix preparation where n is the 
number of reactions. N +4 was found to be an appropriate amount to allot for pipetting 
error  
 
Reagent  Volume per Reaction  n+4 
TaqMan Universal PCR Master Mix  10 ȝO  ȝl 
MMP9 TaqMan Assay  1 ȝO  ȝO 
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Table D.5. Example of Triplicate Stocks. An n+0.25 was found to be effective at allotting 
for pipetting error 
 
Sample  Master Mix (n+0.25)  Water (n+0.25)  cDNA Sample (n+0.25) 
NTC4052MMP9  ȝO  ȝO  ȝO 
405-2 MMP9  ȝO  ȝO  ȝO 
NTC4053MMP9  ȝO  ȝO  ȝO 
405-3 MMP9  ȝO  ȝO  ȝO 
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Creating A Relative Quantification (RQ) Plate Document 
  The computer program SDS Software 1.3.1 (Applied Biosystems, Carlsbad, CA) 
was used to perform relative quantification using the 7300 RT-PCR Machine (Applied 
Biosystems). The computer program was started by selecting Start>Programs>Applied 
Biosystems 7300>Applied Biosystems SDS software on the computer hooked up to the 
7300 RT-PCR machine (Applied Biosystems). To create a new document, “File” on the 
tool bar was selected and “New” was selected from the drop down menu in order to start 
a new document. In the assay drop-down list of the “New Document Wizard”, “Relative 
Quantification (ddCt) Plate” was selected. The default settings for container and template 
(96-Well Clear and Blank Document) were accepted. A name was then entered in the 
Default Plate Name Field and “Next” was clicked. Detectors including MMP-9, MMP-2, 
TIMP-2, Flt-1, VEGF-A, KiSS-1R, CD44, IL-6, CXCL10, MMP-1 and DAG-1 were 
selected to be added to the plate document when needed. These detectors were assigned 
as the targets. This was repeated for HPRT-1, which was designated as the endogenous 
control (ENDO) (see Appendix C). The detectors were added to the plate document by 
clicking “Add” and then clicking “Next”. Detectors and tasks for each well were then 
specified by clicking a well or group of wells. Once a well was selected a detector was 
clicked on to add it to the well and a task (target or endo) was assigned to the well by 
clicking the drop down menu “Task Column”. To finalize the detectors and tasks, “Use” 
was clicked followed by “Finish”. Sample names were added by opening the “Well 
Inspector”. The wells were clicked to select the replicate wells and the sample name was 
then typed in. This was repeated until all sample names and passive reference dyes for 
each well were specified. The information was then verified in each well using the “Setup 
Tab” located at the top of the screen. 
 
Specifying Thermal Cycling Conditions and Starting the Run 
  The “Instrument Tab” was then selected to verify the thermal cycling conditions. 
The default PCR thHUPDOF\FOLQJFRQGLWLRQVZHUHXVHG7DEOH'DQGȝOVDPSOH
volume was entered. Once this was verified, “File” was selected at the tool bar and the 98	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RQ Plate Document was saved by clicking “Save As”. The plate was then loaded into the 
instrument and “Start” was selected to begin the run. Each run took about 1 hour and 41 
minutes. If the run was successful a message popped up that said “Run Successful” at the 
end of the 1 hour and 41 minute time period. At this time the plate was removed and 
discarded. 
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Table D.6. Real-time RT-PCR default cycling conditions 
 
   
Stage  Temperature and Time   Replications 
Stage 1  50.0°C for 2 min  1 
Stage 2  95.0°C for 10 min  1 
Stage 3  95.0°C for 15 sec then 60.0°C for 1 min  40 100	 ﾠ
Analyzing Data in an RQ Study 
  A new RQ study document was created by selecting “File” and “New”. In the 
assay drop-down list of the New Document Wizard, Relative Quantification (ddCt) study 
was selected. The default settings for container and template (96-Well Clear and Blank 
Document) were accepted. The name of the plate was then entered into the Plate Name 
field and “Next” was selected. RQ plates to be analyzed were then added to the study by 
clicking “Add Plates”. The plates to be added were selected and opened by clicking 
“open” followed by “finish”. The file was then saved under the name of the samples on 
the plate. The RQ detector grid allowed detectors to be selected that were associated with 
the study. Each detector, color, detector name, threshold value, auto Ct and baseline are 
shown in the RQ detector grid. In the RQ Sample Grid, the samples associated with the 
selected detectors are displayed. This grid has two subtabs called Sample Summary and 
Well Information that provide numerical results of the RQ calculations. The RQ Results 
Panel contains three results-based tabs Plate, Amplification Plot and Gene Expression to 
allow more visualization of the results. 
 
Configuring Analysis Settings 
  To configure analysis settings, “Analysis” was selected from the tool bar and 
“Analysis Settings” was selected from the drop-down menu. In the detector drop-down 
menu “All” was selected. The SDS software automatically generated baseline and 
threshold values for each well when “Auto Ct” was selected.  The Calibrator sample was 
selected (usually this was the first sample collected of the group run on the plate, but 
overall during the analysis the calibrator was the first parturient sample collected known 
as “Piper”). The endogenous control detector was selected as HPRT-1 and RQ Min/Max 
Confidence Level was selected at 95%. To finish the analysis “OK & Reanalyze” was 
selected. After the analysis, the RQ Manual that came with the 7300 Machine (Applied 
Biosystems) was used to verify visually that the baseline and threshold were called 
correctly for each detector. 
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Exporting RQ Study Data 
  The data was exported into a .csv file for analysis in Microsoft Excel (Microsoft, 
Redmond, WA) and Stata 12.0 (StataCorp LP, College Station, TX). To export the data 
“File” was selected from the tool bar, “Export” was selected from the drop-down menu 
and “Results” was then selected. Both Sample Summary data and Well Information data 
was selected for export. The .csv file was then saved for further analysis.  
 
Analyzing RT-PCR Data 
  Following exportation from the SDS Software 1.3.1, the .csv files containing 
exported results were saved into Microsoft Excel (Microsoft, Redmond, WA) 
spreadsheets for analysis.  First, Ct values from NTC samples were observed to ensure 
they were not less than 37.  The Ct value negatively correlates to the amount of gene 
present.  All NTC samples on plates used for analysis were listed as “undetermined”, 
which indicates no amplification was measured during the run in the RT-PCR machine. 
Any NTC triplicates that were consistently less than 35 were suspect of contamination or 
faulty Master Mix. Average Ct values for the genes of interest and endogenous controls 
were calculated for the three triplicates of each sample using Microsoft Excel (Microsoft, 
Redmond, WA). The Ct values of the genes of interest were normalized to the controls by 
FDOFXODWLQJWKHǻ&W7KHǻ&WZDVFDOFXODWHGE\VXEWUDFWLQJWKH$YHUDJH+RXVHNHHSLQJ
Gene Ct (HPRT-1) from the Average Gene Ct. The first parturient sample (Piper) 
collected was selected as the control and calibrator for the sake of the relative expression 
FDOFXODWLRQ7KHǻǻ&WZDVFDOFXODWHGE\VXEWUDFWLQJWKHǻ&WRIWKHILUVWSDUWXULHQWVDPSOH
FROOHFWHG3LSHUIURPHDFKVDPSOHǻ&W5HODWLYHH[SUHVVLRQRIWKHJHQHVRILQWHUHVWZas 
calculated using the standard 2 
– ǻǻ&Wmethod. This was achieved by setting the sample 
“Piper” to one by calculating RQ = 2 
– ǻǻ&W for each sample including “Piper”. 
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APPENDIX E: RT VERSUS NO-RT CONTROL EXPERIMENT 
 
  All assays used for RT-PCR studies were pre-made, pre-optimized TaqMan 
Primer and Probe Gene Assays (Applied Biosystems, Santa Clara, CA). However, two of 
the assays (Flt-1 and MMP-1) might detect genomic DNA or one assay (KiSS-1R) might 
detect unspliced transcripts based on where the primers annealed to the gene (Cullen, 
2009). In order to confirm that amplification achieved with these assays was not due to 
the presence of genomic DNA, an RT (+RT) versus no RT (–RT) experiment was 
performed (Cullen 2009). In this experiment, several representative RNA samples were 
run on a plate after being reverse transcribed to cDNA (Table E.1) alongside samples that 
had not been reverse transcribed (Figure E.1). MMP-9 was used as the tester gene 
because we had previously shown that it was expressed in the tissues. 
After running the samples in the standard two-step protocol described in 
Appendix D, +RT samples and –RT samples should have Ct values that are at least 6-7 
Ct values apart. Any difference in Ct value between +RT and –RT samples less than 6 
corresponds to contribution from genomic DNA of greater than 1% (Cullen 2009). The –
RT samples run in this experiment did not amplify at all as indicated by an 
“undetermined” Ct value (Table D.2.) indicating there was no contribution from genomic 
DNA. 
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Figure E.1. Flow chart for RT (+RT) versus no RT (–RT) experiment. 
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Table E.1. 96-well plate set up for RT (+RT) versus no RT (–RT) experiment 
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Table E.2. Results from RT versus no RT experiments using MMP9 as a detector. All no RT reactions had undetermined Ct 
values 
 
Sample  Ct  Ct std err  Avg Ct  Sample  Ct  Ct std err  Avg Ct 
681 MMP9 RT  32.138  0.039  32.18  Gemima MMP9 RT  31.884  0.163  32.067 
681 MMP9 RT  32.257  0.039  32.18  Gemima MMP9 RT  32.391  0.163  32.067 
681 MMP9 RT  32.143  0.039  32.18  Gemima MMP9 RT  31.925  0.163  32.067 
405 MMP9 RT  32.598  0.126  32.83  Gidget MMP9 RT  35.258  0.19  35.066 
405 MMP9 RT  33.03  0.126  32.83  Gidget MMP9 RT  35.255  0.19  35.066 
405 MMP9 RT  32.861  0.126  32.83  Gidget MMP9 RT  34.686  0.19  35.066 
311 MMP9 RT  35.45  0.16  35.746  Piper MMP9 RT  32.521  0.224  32.966 
311 MMP9 RT  35.788  0.16  35.746  Piper MMP9 RT  33.147  0.224  32.966 
311 MMP9 RT  36  0.16  35.746  Piper MMP9 RT  33.229  0.224  32.966 
638 MMP9 RT  33.141  0.224  32.936  Gracie MMP9 RT  30.156  0.169  29.978 
638 MMP9 RT  33.178  0.224  32.936  Gracie MMP9 RT  30.138  0.169  29.978 
638 MMP9 RT  32.489  0.224  32.936  Gracie MMP9 RT  29.639  0.169  29.978 106	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APPENDIX F: REAL-TIME RT-PCR REPLICATES OF CANINE 
CHORIOALLANTOIS SAMPLES  
 
To the author’s knowledge, no other studies have been published on gene 
expression in the canine chorioallantois. Due to the lack of knowledge of gene expression 
in this tissue, it was not known whether the location of the tissue used for RNA isolation 
within a single chorioallantois tissue sample would have an affect on gene expression. 
Therefore, an experiment was performed to determine if there were any differences in 
gene expression between tissue samples collected from different locations within the 
same chorioallantois tissue sample. Chorioallantois tissue was used from three pre-term 
samples (311, 405 and 638). Total RNA was isolated, RNA concentrations were 
determined, RNA integrity was verified, total RNA was reverse transcribed to cDNA, 
and real-time RT-PCR was performed as described in the previous appendices. The gene 
used for this experiment was MMP-9 because it had previously been shown to be 
expressed in all of these samples. A one-way ANOVA with bonferroni corrections was 
performed to determine if there were any differences in Ct values between the replicates 
using the Stata 12.0 software (StataCorp LP, College Stations, TX). Significance was set 
at p < 0.05. There was no significant difference (p> 0.05) between Ct values of the 
replicates of the same sample (Table F.1.). 
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Table F.1. Results for Replicates 
 
 
Sample  Replicate #1  
Ct Value 
 (Mean ± SD) 
Replicate #2  
Ct Value 
 (Mean ± SD) 
Replicate #3  
Ct Value  
(Mean ± SD) 
405 R1  33.36 ± 0.16 
 
 
34.01  ± 0.16 
 
 
34.45 ± 0.19 
638 R3  31.89 ± 0.16 
 
 
34.21  ± 0.26 
 
31.91 ± 0.26 
 
 
311 R2  35.319 ± 0.09 
 
 
29.74 ± 0.08 
 
 
32.03 ± 0.08 
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APPENDIX G: MICROARRAY ANALYSIS PROTOCOL 
 
Sample Preparation 
  Total RNA was isolated and RNA concentration, purity and integrity were 
measured as previously described in Appendix A. All samples submitted for microarray 
analysis had an A260/280 ratio of between 1.8-2.0 and a RNA integrity number (RIN) of 
>7.0. Total RNA samples were submitted to the Center for Genome Research and 
%LRFRPSXWLQJ&*5%DW2UHJRQ6WDWH8QLYHUVLW\LQȝODOLTXRWVWRHQVXUHDPLQLPXP
of 200 ng of RNA.  
 
Microarray Protocol 
All total RNA samples were run on microarray at the CGRB using their standard 
protocol for Affymetrix chips. Briefly, labeled target aRNA was prepared from 200 ng of 
total RNA using the MessageAMP Premier Amplification Kit (Life Technologies, Grand 
,VODQG1<6DPSOHVZHUH,97LQFXEDWHGIRUKRXUVDQGȝJRID51$IURPHDFK
sample was hybridized for 18 hours to an Affymetrix Canine 2.0 Array (Affymetrix, 
Santa Clara, CA). Samples were hybridized in one day in two sets. Washing, staining and 
scanning was performed using the GeneChip Expression Wash, Stain and Scan Manual 
for Cartridge Arrays (Affymetrix) using the AGCC software with a Fluidics Station 450 
(Affymetrix) along with a GeneChip Scanner 3000 with autoloader (Affymetrix). Image 
processing and data extraction was performed using AGCC Software version 3.0 
(Affymetrix). 
 
 
Microarray Analysis Protocol 
Differential gene expression was calculated using the Bioconductor software with 
the limma and affy packages (Smyth, 2004) in the open-source statistical program known 
as R. In order to perform statistical analysis on microarray data the R statistical program 
was downloaded from www.R-project.org. Microarray data was received from the CGRB 
core lab on a CD and data files were then downloaded on to the computer. All .CEL files 109	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were then saved in a separate folder on the desktop titled “CASCEL”. To perform 
analysis the program R was then opened and the limma and affy packages were 
downloaded from www.bioconductor.org using the R commands: 
>source(http://bioconductor.org/biocLite.R)  
>biocLite(limma) and >biocLite(“affy”) 
The limma library and affy software packages were then loaded into R using the 
commands: 
 >library(limma) and >library(affy)  
The directory the R program read the data from was then changed by selecting 
File>Change dir… The directory was changed to the file that contained the .CEL files 
(C:/Users/fellowel/Desktop/CASCEL). The R program was directed to read the raw data 
using the command: 
 >myrawdata<-ReadAffy().  
Pre-processing and normalization of the microarray data was carried out using robust 
multichip average (RMA) for quantile normalization (Irizarry et al., 2003) within R. The 
normalization using RMA was achieved with the command:  
>eset<-rma(myrawdata).  
Limma works by fitting a linear regression model to all of the genes and treating the data 
as a linear model. This way an analysis can be performed similar to an ANOVA. In order 
to perform this analysis a matrix was created within R using the following command: 
>design<-model.matrix(~-1+factor(c(1,1,1,1,2,2,2,2,3,3,3,3,4,4,4,4))) 
Column names and sample group names were assigned using the command: 
  >colnames(design)<-c(“parturient”, “prelabor”, “preterm”) 
A linear model was fit to the data using the command:  
  >fit<-lmFit(eset, design)  
Pairwise comparisons were made between sample groups using a contrast matrix created 
by the following commands: 
>contrast.matrix<-makeContrasts(prelabor-parturient, preterm-prelabor, preterm-
parturient, levels=design) 110	 ﾠ
  >fit2<-contrasts.fit(fit, contrast.matrix) 
  >fit2<-eBayes(fit2) 
The top differentially expressed genes were exported into Microsoft Excel (Microsoft, 
Redmond, WA) for the comparison using the commands: 
>write.table(topTable(fit2, coef=1, adjust=”fdr”, sort.by=”B”, number=50000), 
file”limma_complete.xls”, row.names=F, sep=”\t”) 
>write.table(topTable(fit2, coef=1, adjust=”fdr”, sort.by=”B”, number=50000), 
file”limma_complete2.xls”, row.names=F, sep=”\t”) 
>write.table(topTable(fit2, coef=1, adjust=”fdr”, sort.by=”B”, number=50000), 
file”limma_complete3.xls”, row.names=F, sep=”\t”) 
A p-value, log fold change and a p value adjusted for a false discovery rate (FDR) was 
calculated for each gene. Linear modeling and differential gene expression using an 
empirical Bayes analysis used in this microarray study involves calculating a moderated 
t-statistic, which draws inferences from all genes in the set to shrink the standard errors 
toward a common value. This provides more degrees of freedom and more stable 
standard error estimates (Smyth, 2004). A false discovery rate (FDR) is a commonly used 
p value that is adjusted for studies such as microarray that involve multiple testing. The 
FDR is the proportion of incorrect rejections among all rejections of a tested hypothesis 
(Benjamini and Yekutieli, 1995). 
  Following exportation into Excel, the spreadsheet only contained probe IDs and 
no gene names or symbols. A “Master Key” Excel spreadsheet that was exported from 
ArrayStar (DNASTAR, Madison, WI) contained all information on each gene probe and 
was copied into each Excel spreadsheet. Probe IDs for each gene were then matched with 
the appropriate gene name and symbol by entering the formula: =VLOOKUP(A2, 
‘Master Key’!A:C,2,FALSE) into the top cell of the “Gene Symbol” column of the 
exported spreadsheet. Then all gene symbols and probe IDs were matched for their 
appropriate gene name in the “Master Key” excel spreadsheet with the following 
formula: =VLOOKUP(A2,’Master Key”!A:C,3 FALSE). There are a certain number of 
probes that are present on the Canine 2.0 Chip (Affymetrix) that do not have a gene name 111	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or symbol associated with them. For the purposes of this study, these were deleted from 
WKH([FHOVSUHDGVKHHW6LJQLILFDQFHZDVGHILQHGDVS)'5DGMXVWHGSYDOXH
DQGDORJIROGFKDQJHJUHDWHUEDVHGRQSDUDPHWHUVXVHGLQSUHYLRXVVWXGLHV6LWUDV
et al., 2009; Hoegh et al., 2010; Lian et al., 2010). Genes were first sorted based on p 
value and any that did not meet criteria were deleted. Genes that were statistically 
significant and had a log fold change of less than 1.2 were then eliminated to further 
condense the gene table. A Venn diagram was also created to visualize the genes that 
were up-regulated and down-regulated between sample groups using Microsoft 
Powerpoint (Microsoft, Redmond, WA). 
  Gene ontology was explored using ArrayStar (DNASTAR). ArrayStar was 
accessed through the CGRB website at timeslots reserved prior to analysis. Once 
ArrayStar was opened, the files to be analyzed were loaded by selecting File>Open 
Project and selecting the project file. To look at differentially expressed genes 
Data>Show Gene Table was selected from the toolbar. In order to identify differentially 
expressed genes Filter>Filter All was selected from the toolbar to open the filter dialog 
box. The (-) button was clicked in the dialog box on the second filter row so that only one 
filter row remained. Statistics was then selected from the first drop down menu in the 
dialog box’s filter row. To compare between the three sample groups, all three groups 
were selected for analysis and an ANOVA was then selected for analysis with 95% 
significance. The search button was then clicked to search for genes that were significant. 
Next, Gene Set in All Views was selected from the tool bar and genes were sorted by 
selecting the column header Gene Ontology Biological Process. Next, the toolbar option 
Data>Show Gene Ontology was selected. Clicking the p-value column header after 
opening the Gene Ontology View sorted the Gene Ontology Tree by p-value. 
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APPENDIX H EXPRESSION OF SELECTED CANDIDATE GENES IN CANINE 
CHORIOALLANTOIS TISSUE USING REAL-TIME RT-PCR 
 
Canine chorioallantoic tissue was collected following ovariohysterectomy at 61 ± 
1 day past the LH surge (pre-term; n=4), elective C-section at 64 ± 1 day past the LH 
surge prior to first stage labor (pre-labor; n=4), and natural delivery (parturient; n=4). 
Following collection, the marginal hematoma was dissected away and any blood or 
excess tissue (nonvillous chorioallantois, amnion and umbilical cord) were removed. 
Tissues were flash frozen in liquid nitrogen and stored at -80°C until RNA was isolated. 
Total RNA was isolated and RNA concentration, purity and integrity were 
measured as previously described in Appendix A. Microarray analysis was performed as 
described in Appendix G. Real-time RT-PCR was carried out to validate microarray 
results as described in Appendix D following cDNA synthesis (Appendix B). Of 
particular interest were genes previously shown to be involved in trophoblast invasion or 
parturition in other species. Five genes were chosen for real-time RT-PCR validation 
including DAG-1, CD44, CXCL10, MMP-1 and IL-6 based on their differential 
H[SUHVVLRQSYDOXH)'5DGMXVWHGSYDOXHDQGDORJIROGFKDQJH 
Statistical analysis was performed using a one-way ANOVA with Bonferroni 
corrections to make comparisons between the three groups. Statistical significance was 
calculated using the Stata 12.0 software (StataCorp LP, College Station, TX). Data was 
expressed as mean ± standard deviation (SD). Significance was defined as p<0.05. There 
was no significant difference in expression of any of the five candidate genes between the 
three samples (Table H.1). 114	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Table H.1. Relative quantitation (mean ± SD) of placental gene expression at three time 
points prior to parturition  
 
 
Gene  Pre-term (n=4)  Pre-labor (n=4)  Parturient (n=4) 
CD44  5.19 ± 3.66  1.92 ± 0.16  1.31 ± 0.34 
IL-6  2.87 ± 1.28  2.47 ± 0.44  2.84 ± 3.03 
CXCL10  6.51 ± 4.72  3.93 ± 1.54  1.12 ± 14.4 
MMP-1  1.00 ± 1.04  20.44 ± 39.8  0.71 ± 0.34 
DAG-1  0.91 ± 0.63  4.86 ± 8.21  1.95 ± 2.10 
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APPENDIX I: GENE EXPRESSION PROFILES OF CANINE CHORIOALLANTOIS 
TISSUE COMPARED TO ISOLATED CANINE TROPHOBLASTS 
 
Tissue Collection and RNA Isolation 
  Chorioallantois tissue was collected as previously described for the pre-labor 
sample group (n=4) and isolated trophoblast cells from four dogs were used according to 
a protocol used in the lab. Total RNA was isolated and quality of RNA was determined 
as described in Appendix A. Total RNA samples containing a minimum of 200 ng were 
submitted to the Center for Genome Research and Biocomputing (CGRB) at Oregon 
State University for microarray (Appendix G).  
 
Microarray Analysis 
Microarray analysis was carried out as previously described (Appendix G). All R 
commands were the same as described in Appendix G except for the commands for 
setting up the comparisons. A comparison was made between the pre-labor 
chorioallantois tissue samples and the isolated trophoblast samples using the command to 
specify column names: 
  >colnames(design)<-c( “prelabor”, “cells”) 
A linear model was then fit to the data using the command:  
  >fit<-lmFit(eset, design)  
Pairwise comparisons were made between the two sample groups using a contrast matrix 
created by the following commands: 
>contrast.matrix<-makeContrasts(prelabor-cells, levels=design) 
  >fit2<-contrasts.fit(fit, contrast.matrix) 
  >fit2<-eBayes(fit2) 
All subsequent exportation of results, preprocessing and analysis was performed as 
described in Appendix G. 
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Results 
  Overall global variation of gene expression between the isolated trophoblast cells 
and pre-labor chorioallantois tissue was larger than that seen between the different 
chorioallantois tissue samples (Figure H.1). There were 1150 genes that were 
differentially expressed between isolated canine trophoblast cells compared to pre-labor 
FKRULRDOODQWRLVWLVVXHEDVHGRQDSYDOXHDQ)'5DGMXVWHGSYDOXHDQGD
log-fold change of  >1.2 (Table H.1). In addition, there were 576 genes that were down-
regulated in the chorioallantois tissue compared to isolated trophoblast cells and 574 up-
regulated genes in the tissue samples compared to the isolated cell samples. Interestingly, 
several genes already examined in this thesis including, MMP-2, MMP-1, TIMP-2, FLT-
1, CD44, IL-6 and CXCL10 were differentially expressed between isolated trophoblast 
cells and chorioallantois tissue. 
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Figure I.1. Correlation coefficients of gene expression profiles from each pre-labor 
placental tissue and pre-labor isolated trophoblasts. Red indicates 1.0, whereas blue 
indicates 0.950. 118	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Table H.1. Top differentially expressed genes between trophoblasts and chorioallantois tissue   
 
Gene   Name  logFC  P.Value  adj.P.Val 
HSD3B1  hydroxy-'-5-VWHURLGGHK\GURJHQDVHȕ- and steroid '-isomerase 1  3.80  1.25E-16  5.36E-12 
CD320  CD320 molecule  4.35  1.16E-15  1.66E-11 
TMEM45A  transmembrane protein 45A  4.18  3.64E-15  3.13E-11 
CP  ceruloplasmin (ferroxidase)  2.86  5.67E-15  3.231E-11 
BMP4  bone morphogenetic protein 4  2.52  1.19E-14  4.66E-11 
TSPAN5  tetraspanin 5  3.35  1.58E-14  5.68E-11 
TMEM108  transmembrane protein 108  3.71  1.79E-14  5.94E-11 
FST  follistatin  4.46  1.94E-14  5.95E-11 
MMP2  matrix metallopeptidase 2  
(gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 
4.54  2.18E-14  6.10E-11 
SLC35F2  solute carrier family 35, member F2  5.22  2.37E-14  6.10E-11 
SCD  stearoyl-CoA desaturase ('-9-desaturase)  4.64  3.59E-14  8.59E-11 
SLC5A6  solute carrier family 5 (Na
+-dependent vitamin transporter) member 6  4.05  3.80E-14  8.61E-11 
NAPEPLD  N-acyl phosphatidylethanolamine phospholipase D  3.24  4.24E-14  9.13E-11 
BMP10  bone morphogenetic protein 10  5.26  5.87E-14  1.10E-10 
LPGAT1  lysophosphatidylglycerol acyltransferase 1  4.30  1.02E-13  1.75E-10 
CSNK2A2  FDVHLQNLQDVHĮSULPHSRO\SHSWLGH  2.48  1.40E-13  2.13E-10 
SMPD1  sphingomyelin phosphodiesterase 1, acid lysosomal  4.97  1.44E-13  2.13E-10 
BACE1  ȕ-site APP-cleaving enzyme 1  4.69  1.55E-13  2.15E-10 119	 ﾠ
TFRC  transferrin receptor (p90, CD71)  4.05  1.72E-13  2.24E-10 
CADM1  cell adhesion molecule 1  2.53  1.85E-13  2.34E-10 
BBOX1  EXW\UREHWDLQHȖ-R[RJOXWDUDWHGLR[\JHQDVHȖ-butyrobetaine hydroxylase) 1  4.58  2.12E-13  2.55E-10 
PGF  placental growth factor  3.83  2.38E-13  2.63E-10 
EDNRB  endothelin receptor type B  2.43  2.39E-13  2.63E-10 
UBE2A  ubiquitin-conjugating enzyme E2A (RAD6 homolog)  1.64  2.44E-13  2.63E-10 
TIMP2  TIMP metallopeptidase inhibitor 2  2.58  3.16E-13  3.17E-10 
WIPI1  WD repeat domain, phosphoinositide interacting 1  2.85  3.18E-13  3.17E-10 
LASS5  LAG1 homolog, ceramide synthase 5  3.25  4.92E-13  4.41E-10 
AZGP1  Į-2-glycoprotein 1, Zn
++-binding  5.19  5.31E-13  4.66E-10 
CYB5R1  NAD(P)H:quinone oxidoreductase type 3, polypeptide A2  2.29  6.08E-13  5.03E-10 
FZD7  frizzled homolog 7 (Drosophila)  2.96  6.79E-13  5.41E-10 
SLC16A7  solute carrier family 16, member 7 (monocarboxylic acid transporter 2)  3.61  7.54E-13  5.90E-10 
MAN1C1  PDQQRVLGDVHĮFODVV&PHPEHU  4.04  8.10E-13  6.00E-10 
NFE2L3  nuclear factor (erythroid-derived 2)-like 3  4.36  8.31E-13  6.00E-10 
OSBPL2  oxysterol binding protein-like 2  2.74  1.47E-12  9.30E-10 
AACS  acetoacetyl-CoA synthetase  2.74  1.54E-12  9.62E-10 
SLC4A10  solute carrier family 4, sodium bicarbonate transporter, member 10  4.80  1.68E-12  1.02E-09 
CAPNS2  calpain, small subunit 2  3.78  1.77E-12  1.06E-09 
SEC14L2  SEC14-like 2 (S. cerevisiae)  3.78  1.97E-12  1.14E-09 
ADRB2  DGUHQHUJLFȕ-2-, receptor, surface  3.51  2.29E-12  1.27E-09 
PLA2G16  phospholipase A2, group XVI  3.20  2.33E-12  1.27E-09 
MSI2  musashi homolog 2 (Drosophila)  2.05  2.79E-12  1.46E-09 
LDOC1  leucine zipper, down-regulated in cancer 1  2.92  2.82E-12  1.46E-09 120	 ﾠ
EGFLAM  EGF-like, fibronectin type III and laminin G domains  2.29  3.02E-12  1.55E-09 
ELOVL4  elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 4  3.50  3.12E-12  1.58E-09 
PRDX6  peroxiredoxin 6  1.92  3.71E-12  1.83E-09 
LIFR  OHXNHPLDLQKLELWRU\IDFWRUUHFHSWRUĮ  3.63  3.74E-12  1.83E-09 
SLC31A1  solute carrier family 31 (Cu
++ transporters), member 1  2.87  4.02E-12  1.92E-09 
REPS2  RALBP1 associated Eps domain containing 2  1.99  4.06E-12  1.92E-09 
RHPN2  rhophilin, Rho GTPase binding protein 2  3.33  4.47E-12  2.09E-09 
ABHD2  abhydrolase domain containing 2  2.95  5.18E-12  2.35E-09 
HPSE  heparanase  4.15  5.67E-12  2.54E-09 
ATXN2  ataxin 2  1.94  6.43E-12  2.80E-09 
MFSD2A  major facilitator superfamily domain containing 2A  4.84  7.34E-12  3.15E-09 
KATNA1  katanin p60 (ATPase-containing) subunit A 1  2.80  8.37E-12  3.44E-09 
SPATS2  spermatogenesis associated, serine-rich 2  -1.38  9.46E-12  3.77E-09 
GXYLT2  glucoside xylosyltransferase 2  2.69  1.03E-11  4.01E-09 
TFAP2A  transcription factor AP-ĮDFWLYDWLQJHQKDQFHUELQGLQJSURWHLQĮ  3.00  1.36E-11  5.00E-09 
SQLE  squalene epoxidase  2.08  1.36E-11  5.00E-09 
HMGCS1  3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble)  1.82  1.39E-11  5.06E-09 
GNA12  JXDQLQHQXFOHRWLGHELQGLQJSURWHLQ*SURWHLQĮ  3.72  1.40E-11  5.07E-09 
HHIPL2  HHIP-like 2  5.60  1.48E-11  5.19E-09 
SERINC5  serine incorporator 5  4.11  1.49E-11  5.19E-09 
TMEM164  transmembrane protein 164  2.46  1.96E-11  6.60E-09 
DQX1  DEAQ box RNA-dependent ATPase 1  1.92  2.24E-11  7.30E-09 
RNF180  ring finger protein 180  3.50  2.32E-11  7.46E-09 
DUSP4  dual specificity phosphatase 4  2.62  2.39E-11  7.55E-09 121	 ﾠ
TGFBR3  WUDQVIRUPLQJJURZWKIDFWRUȕUHFHSWRU,,,  2.33  2.51E-11  7.76E-09 
SLC7A2  solute carrier family 7 (cationic amino acid transporter, y+ system), member 2  4.84  2.53E-11  7.76E-09 
FAR2  fatty acyl CoA reductase 2  2.04  2.58E-11  7.83E-09 
BPGM  2,3-bisphosphoglycerate mutase  2.62  2.64E-11  7.89E-09 
STAU2  staufen, RNA binding protein, homolog 2 (Drosophila)  2.54  2.73E-11  8.10E-09 
SLC37A2  solute carrier family 37 (glycerol-3-phosphate transporter), member 2  5.34  2.82E-11  8.32E-09 
RAPGEF5  Rap guanine nucleotide exchange factor (GEF) 5  2.98  2.94E-11  8.56E-09 
MCFD2  multiple coagulation factor deficiency 2  1.62  2.94E-11  8.56E-09 
WIPI2  WD repeat domain, phosphoinositide interacting 2  1.30  3.28E-11  9.23E-09 
ALPL  alkaline phosphatase, liver/bone/kidney  4.31  3.47E-11  9.62E-09 
MSX2  msh homeobox 2  3.02  3.51E-11  9.62E-09 
GCNT4  glucosaminyl (N-acetyl) transferase 4, core 2  3.62  3.59E-11  9.71E-09 
DCLK3  doublecortin-like kinase 3  2.43  3.63E-11  9.75E-09 
LRP2  low density lipoprotein receptor-related protein 2  5.39  3.65E-11  9.76E-09 
FANCE  Fanconi anemia, complementation group E  3.23  3.90E-11  1.04E-08 
CASR  Ca
++ -sensing receptor  5.54  4.43E-11  1.17E-08 
ADIPOR2  adiponectin receptor 2  1.92  4.45E-11  1.17E-08 
SEMA5A  sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A 
2.17  4.47E-11  1.17E-08 
PRCP  prolylcarboxypeptidase (angiotensinase C)  2.75  4.50E-11  1.17E-08 
GOLGA2  golgin A2  1.78  4.59E-11  1.18E-08 
ST8SIA1  67Į-N-acetyl-QHXUDPLQLGHĮ-2,8-sialyltransferase 1  3.51  4.84E-11  1.22E-08 
PPM1A  protein phosphatase, Mg2+/Mn2+ dependent, 1A  3.25  4.96E-11  1.22E-08 
GPR87  G protein-coupled receptor 87  2.72  4.98E-11  1.22E-08 122	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SEMA6D  sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6D 
2.20  5.06E-11  1.23E-08 
HMGCR  3-hydroxy-3-methylglutaryl-CoA reductase  2.90  5.19E-11  1.25E-08 
PTHLH  parathyroid hormone-like hormone  3.74  5.19E-11  1.25E-08 
GPRC5B  G protein-coupled receptor, family C, group 5, member B  3.18  5.33E-11  1.26E-08 
PRKCD  protein kinase C, '  2.42  5.34E-11  1.26E-08 
CD164  CD164 molecule, sialomucin  2.00  5.72E-11  1.34E-08 
CCDC6  coiled-coil domain containing 6  1.43  5.83E-11  1.36E-08 
PPAP2B  phosphatidic acid phosphatase type 2B  2.45  6.01E-11  1.39E-08 
IL4I1  interleukin 4 induced 1  4.03  6.09E-11  1.40E-08 
GRB14  growth factor receptor-bound protein 14  2.37  6.15E-11  1.40E-08 
TNFRSF11B  tumor necrosis factor receptor superfamily, member 11b  3.52  6.41E-11  1.44E-08 
CTSA  cathepsin A  3.29  6.65E-11  1.49E-08 
FGF20  fibroblast growth factor 20  4.04  7.28E-11  1.59E-08 
GAS2  growth arrest-specific 2  3.80  7.86E-11  1.69E-08 
NPPC  natriuretic peptide precursor C  5.14  7.90E-11  1.69E-08 
FGFBP1  fibroblast growth factor binding protein 1  4.93  8.31E-11  1.76E-08 
MPP6  membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6)  2.66  8.67E-11  1.81E-08 
SLC19A2  solute carrier family 19 (thiamine transporter), member 2  3.20  8.78E-11  1.83E-08 
XIAP  X-linked inhibitor of apoptosis  1.93  9.33E-11  1.93E-08 
SC4MOL  sterol-C4-methyl oxidase-like  1.93  1.06E-10  2.11E-08 
TIMP3  TIMP metallopeptidase inhibitor 3  3.37  1.09E-10  2.15E-08 
SFRP2  secreted frizzled-related protein 2  5.11  1.12E-10  2.20E-08 
SLC7A5  solute carrier family 7 (cationic amino acid transporter, y+ system), member 5  2.43  1.17E-10  2.28E-08 123	 ﾠ
PPARD  peroxisome proliferator-activated receptor '  2.40  1.19E-10  2.29E-08 
YPEL1  yippee-like 1 (Drosophila)  2.05  1.20E-10  2.30E-08 
PLA2G7  phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)  3.71  1.27E-10  2.40E-08 
LBH  limb bud and heart development homolog (mouse)  3.03  1.35E-10  2.52E-08 
DNAJC1  DnaJ (Hsp40) homolog, subfamily C, member 1  1.91  1.42E-10  2.63E-08 
MANBA  PDQQRVLGDVHȕ$O\VRVRPDO  2.64  1.45E-10  2.66E-08 
TP53INP1  tumor protein p53 inducible nuclear protein 1  2.09  1.49E-10  2.72E-08 
KREMEN1  kringle containing transmembrane protein 1  3.12  1.51E-10  2.75E-08 
EXT1  exostosin 1  1.64  1.54E-10  2.77E-08 
cOR2AV3  olfactory receptor family 2 subfamily AV-like  1.58  1.57E-10  2.80E-08 
CMAS  cytidine monophosphate N-acetylneuraminic acid synthetase  2.01  1.81E-10  3.12E-08 
BPGM, 
LOC610322 
2,3-bisphosphoglycerate mutase; hypothetical protein LOC610322  2.48  1.87E-10  3.21E-08 
STXBP2  syntaxin binding protein 2  2.17  1.93E-10  3.25E-08 
NCOR1  nuclear receptor corepressor 1  2.31  2.02E-10  3.36E-08 
NRP1  neuropilin 1  -1.68  2.11E-10  3.47E-08 
SLC38A2  solute carrier family 38, member 2  2.32  2.11E-10  3.47E-08 
CDH5  cadherin 5, type 2 (vascular endothelium)  -1.33  2.13E-10  3.49E-08 
SERAC1  serine active site containing 1  2.02  2.18E-10  3.55E-08 
HVCN1  H
+ voltage-gated channel 1  1.99  2.40E-10  3.87E-08 
SLC45A4  solute carrier family 45, member 4  2.66  2.41E-10  3.88E-08 
DHRS13  dehydrogenase/reductase (SDR family) member 13  2.87  2.48E-10  3.94E-08 
ZNF281  Zn
++ finger protein 281  1.44  2.51E-10  3.96E-08 
FERMT2  fermitin family member 2  1.44  2.52E-10  3.96E-08 124	 ﾠ
H2AFY2  H2A histone family, member Y2  4.30  2.55E-10  3.97E-08 
GCOM1  GRINL1A complex locus  -1.76  2.58E-10  3.99E-08 
KHK  ketohexokinase (fructokinase)  1.93  2.59E-10  4.00E-08 
MFI2  antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 
and 96.5 
4.35  2.71E-10  4.16E-08 
MXD1  MAX dimerization protein 1  2.79  2.78E-10  4.25E-08 
SH3BGRL3  SH3 domain binding glutamic acid-rich protein like 3  2.16  2.80E-10  4.26E-08 
DLX5  distal-less homeobox 5  3.42  3.02E-10  4.54E-08 
JUNB  jun B proto-oncogene  -2.48  3.10E-10  4.63E-08 
CHCHD6  coiled-coil-helix-coiled-coil-helix domain containing 6  1.50  3.10E-10  4.63E-08 
ECSCR  endothelial cell-specific chemotaxis regulator  -1.90  3.23E-10  4.79E-08 
PIP5K1B  phosphatidylinositol-4-phosphate 5-NLQDVHW\SH,ȕ  2.95  3.25E-10  4.79E-08 
MDM2  Mdm2 p53 binding protein homolog (mouse)  -2.13  3.36E-10  4.91E-08 
EBPL  emopamil binding protein-like  -1.40  3.36E-10  4.91E-08 
SLC6A6  solute carrier family 6 (neurotransmitter transporter, taurine), member 6  3.02  3.67E-10  5.26E-08 
SDC2  syndecan 2  2.71  3.98E-10  5.61E-08 
TRIM36  tripartite motif-containing 36  3.28  4.19E-10  5.87E-08 
NTRK3  neurotrophic tyrosine kinase, receptor, type 3  3.30  4.20E-10  5.87E-08 
KLHDC5  kelch domain containing 5  2.71  4.34E-10  6.03E-08 
GM2A  GM2 ganglioside activator  1.89  4.37E-10  6.03E-08 
MAP7  microtubule-associated protein 7  1.97  4.40E-10  6.05E-08 
GALNT11  UDP-N-acetyl-Į-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 11 (GalNAc-T11) 
3.07  4.51E-10  6.18E-08 
FGD4  FYVE, RhoGEF and PH domain containing 4  1.66  4.55E-10  6.22E-08 125	 ﾠ
STIM1  stromal interaction molecule 1  3.23  4.69E-10  6.35E-08 
PIGN  phosphatidylinositol glycan anchor biosynthesis, class N  -1.24  4.70E-10  6.35E-08 
CCDC34  coiled-coil domain containing 34  2.04  4.72E-10  6.35E-08 
NSDHL  NAD(P) dependent steroid dehydrogenase-like  1.81  4.74E-10  6.35E-08 
CHORDC1, 
LOC609430 
cysteine and histidine-rich domain (CHORD)-containing 1; similar to 3-ȕ-
hydroxysteroid-'(8),'(7)-isomerase (Cholestenol '-isomerase) ('8-'7 sterol 
isomerase) (D8-D7 sterol isomerase) (Emopamil-binding protein) 
2.13  4.84E-10  6.45E-08 
TMEM47  transmembrane protein 47  -1.88  4.99E-10  6.59E-08 
ZNF532  Zn
++ finger protein 532  2.09  4.99E-10  6.59E-08 
ZC3H12C  Zn
++ finger CCCH-type containing 12C  1.98  5.11E-10  6.70E-08 
UXS1  UDP-glucuronate decarboxylase 1  2.66  5.20E-10  6.80E-08 
CES1  carboxylesterase 1  4.41  5.27E-10  6.86E-08 
SLC3A2  solute carrier family 3 (activators of dibasic and neutral amino acid transport), 
member 2 
2.06  5.36E-10  6.94E-08 
PECAM1  platelet/endothelial cell adhesion molecule  -1.96  5.40E-10  6.98E-08 
GRN  granulin  1.56  5.57E-10  7.18E-08 
FDPS  farnesyl diphosphate synthase  1.18  5.61E-10  7.20E-08 
SLC22A23  solute carrier family 22, member 23  3.03  5.68E-10  7.28E-08 
GPC4  glypican 4  2.39  5.83E-10  7.43E-08 
NAA11  1Į-acetyltransferase 11, NatA catalytic subunit  1.27  5.85E-10  7.43E-08 
STT3B  STT3, subunit of the oligosaccharyltransferase complex, homolog B (S. 
cerevisiae) 
2.17  6.13E-10  7.72E-08 
ANGPT2  angiopoietin 2  3.35  6.15E-10  7.72E-08 
NOS1  nitric oxide synthase 1 (neuronal)  3.05  6.26E-10  7.81E-08 126	 ﾠ
MITF  microphthalmia-associated transcription factor  2.30  6.61E-10  8.18E-08 
AK3L1  adenylate kinase 3-like 1  -1.40  6.64E-10  8.19E-08 
NDRG3  NDRG family member 3  1.39  6.81E-10  8.38E-08 
MANF  mesencephalic astrocyte-derived neurotrophic factor  1.69  6.93E-10  8.47E-08 
GPR155  G protein-coupled receptor 155  2.42  7.02E-10  8.53E-08 
RBBP6  retinoblastoma binding protein 6  2.39  7.04E-10  8.53E-08 
UBXN11  UBX domain protein 11  2.24  7.19E-10  8.65E-08 
UTRN  utrophin  -1.62  7.40E-10  8.85E-08 
NEK7  NIMA (never in mitosis gene a)-related kinase 7  1.86  7.84E-10  9.22E-08 
PPM1K  protein phosphatase, Mg2+/Mn2+ dependent, 1K  1.76  7.94E-10  9.31E-08 
CD19  CD19 molecule  1.40  7.96E-10  9.31E-08 
SVIP  small VCP/p97-interacting protein  2.24  8.10E-10  9.45E-08 
GSK3B  JO\FRJHQV\QWKDVHNLQDVHȕ  1.74  8.22E-10  9.53E-08 
SLC26A6  solute carrier family 26, member 6  2.46  8.29E-10  9.56E-08 
CFI  complement factor I  -1.85  8.39E-10  9.65E-08 
ALDH1L2  aldehyde dehydrogenase 1 family, member L2  -1.25  8.51E-10  9.74E-08 
RECK  reversion-inducing-cysteine-rich protein with kazal motifs  2.46  8.89E-10  1.01E-07 
ASAH1  N-acylsphingosine amidohydrolase (acid ceramidase) 1  2.12  9.42E-10  1.05E-07 
IER2  immediate early response 2  -2.55  9.55E-10  1.07E-07 
COL4A3BP  FROODJHQW\SH,9Į*RRGSDVWXUHDQWLJHQELQGLQJSURWHLQ  1.41  9.80E-10  1.08E-07 
ERBB2IP  erbb2 interacting protein  1.57  1.01E-09  1.10E-07 
GGH  Ȗ-JOXWDP\OK\GURODVHFRQMXJDVHIRO\OSRO\ȖJOXWDP\OK\GURODVH  2.58  1.03E-09  1.12E-07 
JMY  junction mediating and regulatory protein, p53 cofactor  1.71  1.08E-09  1.18E-07 
RGS1  regulator of G-protein signaling 1  -2.92  1.09E-09  1.18E-07 127	 ﾠ
OSGIN2  oxidative stress induced growth inhibitor family member 2  2.59  1.15E-09  1.23E-07 
CANX  calnexin  1.29  1.17E-09  1.25E-07 
RALGPS2  Ral GEF with PH domain and SH3 binding motif 2  1.42  1.18E-09  1.25E-07 
TRAM2  translocation associated membrane protein 2  1.54  1.20E-09  1.27E-07 
TGFBR1  WUDQVIRUPLQJJURZWKIDFWRUȕUHFHSWRU  2.34  1.22E-09  1.28E-07 
FDFT1  farnesyl-diphosphate farnesyltransferase 1  2.23  1.25E-09  1.30E-07 
SAR1A  SAR1 homolog A (S. cerevisiae)  1.86  1.30E-09  1.35E-07 
ANK3  ankyrin 3, node of Ranvier (ankyrin G)  1.52  1.32E-09  1.35E-07 
IREB2  Fe
++-responsive element binding protein 2  1.23  1.33E-09  1.36E-07 
LPAR1  lysophosphatidic acid receptor 1  1.44  1.35E-09  1.37E-07 
GATA3  GATA binding protein 3  1.91  1.35E-09  1.37E-07 
SNTA1  V\QWURSKLQĮG\VWURSKLQ-associated protein A1, 59kDa, acidic component)  2.76  1.35E-09  1.37E-07 
PTPRF  protein tyrosine phosphatase, receptor type, F  2.00  1.39E-09  1.39E-07 
CRB3  crumbs homolog 3 (Drosophila)  1.60  1.39E-09  1.39E-07 
GPR157  G protein-coupled receptor 157  3.13  1.46E-09  1.45E-07 
PNPLA8  patatin-like phospholipase domain containing 8  1.25  1.46E-09  1.45E-07 
LGMN  legumain  1.32  1.48E-09  1.46E-07 
FLNB  ILODPLQ%ȕ  2.05  1.50E-09  1.48E-07 
SPP2  secreted phosphoprotein 2, 24kDa  3.98  1.60E-09  1.55E-07 
ZBTB10  Zn
++ finger and BTB domain containing 10  1.46  1.66E-09  1.60E-07 
S100P  S100 Ca
++  binding protein P  1.31  1.70E-09  1.62E-07 
SC5DL  sterol-C5-desaturase (ERG3 '-5-desaturase homolog, S. cerevisiae)-like  2.37  1.72E-09  1.63E-07 
OVOL2  ovo-like 2 (Drosophila)  1.34  1.77E-09  1.67E-07 
KLHL5  kelch-like 5 (Drosophila)  -1.55  1.80E-09  1.69E-07 128	 ﾠ
APIP  APAF1 interacting protein  1.31  1.85E-09  1.72E-07 
TJP1  tight junction protein 1 (zona occludens 1)  -1.16  1.95E-09  1.80E-07 
HSF2  heat shock transcription factor 2  -1.16  1.97E-09  1.82E-07 
MAP4K4  mitogen-activated protein kinase kinase kinase kinase 4  1.66  2.00E-09  1.84E-07 
PMM1  phosphomannomutase 1  1.44  2.04E-09  1.87E-07 
GUCY1A3  JXDQ\ODWHF\FODVHVROXEOHĮ  -1.67  2.12E-09  1.93E-07 
ABR  active BCR-related gene  1.78  2.17E-09  1.97E-07 
SGCG  VDUFRJO\FDQȖN'DG\VWURSKLQ-associated glycoprotein)  3.19  2.18E-09  1.97E-07 
MGST1  microsomal glutathione S-transferase 1  1.85  2.19E-09  1.98E-07 
SDAD1  SDA1 domain containing 1  1.59  2.27E-09  2.03E-07 
ICAM2  intercellular adhesion molecule 2  -1.68  2.36E-09  2.07E-07 
NNT  nicotinamide nucleotide transhydrogenase  -1.42  2.36E-09  2.07E-07 
NAT10  N-acetyltransferase 10 (GCN5-related)  1.59  2.54E-09  2.20E-07 
TGFBR2  WUDQVIRUPLQJJURZWKIDFWRUȕUHFHSWRU,,N'D  2.62  2.56E-09  2.21E-07 
CCDC113  coiled-coil domain containing 113  2.22  2.57E-09  2.22E-07 
GRHL2  grainyhead-like 2 (Drosophila)  1.89  2.60E-09  2.24E-07 
CDS1  CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1  1.59  2.62E-09  2.25E-07 
TACC1  transforming, acidic coiled-coil containing protein 1  -1.31  2.63E-09  2.25E-07 
IRF2  interferon regulatory factor 2  1.31  2.63E-09  2.25E-07 
AMIGO2  adhesion molecule with Ig-like domain 2  2.20  2.64E-09  2.25E-07 
EIF2AK2  eukaryotic translation initiation factor 2-ĮNLQDVH  1.60  2.65E-09  2.25E-07 
TF  transferrin  -1.49  2.66E-09  2.256E-07 
USHBP1  Usher syndrome 1C binding protein 1  -1.45  2.67E-09  2.26E-07 
CMTM7  CKLF-like MARVEL transmembrane domain containing 7  2.16  2.72E-09  2.30E-07 129	 ﾠ
CHSY1  chondroitin sulfate synthase 1  -1.94  2.76E-09  2.33E-07 
C1GALT1  core 1 synthase, glycoprotein-N-acetylgalactosamine 3-ȕ-galactosyltransferase, 1  2.48  2.78E-09  2.34E-07 
SPTLC3  serine palmitoyltransferase, long chain base subunit 3  2.60  2.79E-09  2.34E-07 
IRX3  iroquois homeobox 3  2.29  3.01E-09  2.49E-07 
SNTB2  V\QWURSKLQȕG\VWURSKLQ-associated protein A1, 59kDa, basic component 2)  -1.32  3.07E-09  2.51E-07 
PLBD1  phospholipase B domain containing 1  1.77  3.11E-09  2.53E-07 
PPIC  peptidylprolyl isomerase C (cyclophilin C)  -1.61  3.12E-09  2.53E-07 
CTSH  cathepsin H  1.92  3.13E-09  2.54E-07 
TMEM126A  transmembrane protein 126A  -1.24  3.18E-09  2.58E-07 
SASH1  SAM and SH3 domain containing 1  2.19  3.22E-09  2.60E-07 
ANO6  anoctamin 6  2.08  3.23E-09  2.61E-07 
TRAK1  trafficking protein, kinesin binding 1  1.35  3.36E-09  2.69E-07 
DDAH2  dimethylarginine dimethylaminohydrolase 2  -1.34  3.36E-09  2.69E-07 
ATP1B1  $73DVH1D.WUDQVSRUWLQJȕSRO\SHSWLGH  1.41  3.49E-09  2.76E-07 
RCN2  reticulocalbin 2, EF-hand Ca
++  binding domain  1.54  3.56E-09  2.81E-07 
CLIC2  chloride intracellular channel 2  -1.75  3.57E-09  2.81E-07 
FBLN2  fibulin 2  -1.55  3.61E-09  2.83E-07 
RABGAP1L  RAB GTPase activating protein 1-like  1.27  3.65E-09  2.86E-07 
SLC18A2  Solute carrier family 18 (vesicular monoamine), member 2  -1.38  3.68E-09  2.87E-07 
SSFA2  sperm specific antigen 2  1.87  3.72E-09  2.89E-07 
CD2AP  CD2-associated protein  2.20  3.73E-09  2.89E-07 
INSIG1  insulin induced gene 1  2.40  3.73E-09  2.89E-07 
CDCP1  CUB domain containing protein 1  2.17  3.90E-09  3.01E-07 
TUSC3  tumor suppressor candidate 3  1.50  4.02E-09  3.07E-07 130	 ﾠ
EMP1  epithelial membrane protein 1  -2.07  4.13E-09  3.12E-07 
LYZ  lysozyme  -2.02  4.19E-09  3.16E-07 
KANK3  KN motif and ankyrin repeat domains 3  -1.82  4.23E-09  3.18E-07 
GNPAT  glyceronephosphate O-acyltransferase  -1.46  4.24E-09  3.18E-07 
AP2A1  adaptor-UHODWHGSURWHLQFRPSOH[ĮVXEXQLW  2.75  4.28E-09  3.21E-07 
SNX27  sorting nexin family member 27  1.69  4.33E-09  3.24E-07 
HAGH  hydroxyacylglutathione hydrolase  1.63  4.37E-09  3.26E-07 
IGF2R  insulin-like growth factor 2 receptor  -1.28  4.43E-09  3.28E-07 
GRAMD1B  GRAM domain containing 1B  2.05  4.50E-09  3.31E-07 
ITGAV  LQWHJULQĮ9YLWURQHFWLQUHFHSWRUĮSRO\SHSWLGHDQWLJHQ&'  1.67  4.53E-09  3.33E-07 
LPCAT2  lysophosphatidylcholine acyltransferase 2  2.16  4.84E-09  3.51E-07 
IVNS1ABP  influenza virus NS1A binding protein  -1.35  4.86E-09  3.52E-07 
FGFR2  fibroblast growth factor receptor 2  1.63  5.00E-09  3.59E-07 
CCBL2  cysteine conjugate-ȕO\DVH  2.04  5.19E-09  3.70E-07 
CYP24A1  cytochrome P450, family 24, subfamily A, polypeptide 1  4.42  5.26E-09  3.74E-07 
NFIB  nuclear factor I/B  -1.47  5.33E-09  3.77E-07 
TEAD1  TEA domain family member 1 (SV40 transcriptional enhancer factor)  1.48  5.37E-09  3.79E-07 
SGPL1  sphingosine-1-phosphate lyase 1  1.75  5.49E-09  3.86E-07 
ASS1  argininosuccinate synthase 1  2.31  5.52E-09  3.87E-07 
ZNF185  Zn
++ finger protein 185 (LIM domain)  1.44  5.65E-09  3.95E-07 
C6  complement component 6  -1.69  5.82E-09  4.04E-07 
ITPK1  inositol 1,3,4-triphosphate 5/6 kinase  1.68  5.94E-09  4.09E-07 
WWC1  WW and C2 domain containing 1  1.59  5.97E-09  4.10E-07 
DAPK1  death-associated protein kinase 1  2.31  6.00E-09  4.12E-07 131	 ﾠ
BRP44L  brain protein 44-like  1.30  6.19E-09  4.22E-07 
GRIK4  glutamate receptor, ionotropic, kainate 4  1.67  6.81E-09  4.59E-07 
LMO1  LIM domain only 1 (rhombotin 1)  1.95  6.83E-09  4.60E-07 
ERO1LB  ERO1-OLNHȕS. cerevisiae)  1.92  7.23E-09  4.81E-07 
FBXO7  F-box protein 7  2.47  7.52E-09  4.96E-07 
MYST4  MYST histone acetyltransferase (monocytic leukemia) 4  1.96  7.66E-09  5.04E-07 
TUFT1  tuftelin 1  1.47  8.05E-09  5.22E-07 
ATP2B1  ATPase, Ca++ transporting, plasma membrane 1  -1.72  8.18E-09  5.28E-07 
FRMD3  FERM domain containing 3  1.40  8.26E-09  5.32E-07 
SLC6A8  solute carrier family 6 (neurotransmitter transporter, creatine), member 8  3.40  8.28E-09  5.32E-07 
SMAD2  SMAD family member 2  1.39  8.35E-09  5.35E-07 
LRRC70  leucine rich repeat containing 70  -1.90  8.74E-09  5.55E-07 
GPLD1  glycosylphosphatidylinositol specific phospholipase D1  4.11  8.92E-09  5.64E-07 
RASSF6  Ras association (RalGDS/AF-6) domain family member 6  2.53  9.09E-09  5.72E-07 
CASD1  CAS1 domain containing 1  -1.40  9.19E-09  5.75E-07 
SPECC1  sperm antigen with calponin homology and coiled-coil domains 1  1.60  9.26E-09  5.79E-07 
NOSTRIN  nitric oxide synthase trafficker  -1.62  9.33E-09  5.82E-07 
KRTCAP3  keratinocyte associated protein 3  1.50  9.42E-09  5.86E-07 
TSPAN12  tetraspanin 12  -1.55  9.79E-09  6.04E-07 
ERRFI1  ERBB receptor feedback inhibitor 1  3.17  9.81E-09  6.04E-07 
GRAMD3  GRAM domain containing 3  1.96  9.92E-09  6.09E-07 
KLHL20  kelch-like 20 (Drosophila)  1.62  1.01E-08  6.19E-07 
NMI  N-myc (and STAT) interactor  -1.41  1.03E-08  6.26E-07 
ORAI2  ORAI Ca
++  release-activated Ca
++ modulator 2  1.78  1.05E-08  6.38E-07 132	 ﾠ
COLEC12  collectin sub-family member 12  -1.75  1.06E-08  6.38E-07 
EIF4EBP2  eukaryotic translation initiation factor 4E binding protein 2  1.46  1.09E-08  6.57E-07 
GJA5  JDSMXQFWLRQSURWHLQĮN'D  -1.68  1.10E-08  6.60E-07 
ISM1  isthmin 1 homolog (zebrafish)  2.59  1.12E-08  6.70E-07 
BTBD3  BTB (POZ) domain containing 3  1.68  1.14E-08  6.76E-07 
VAMP8  vesicle-associated membrane protein 8 (endobrevin)  2.31  1.14E-08  6.77E-07 
ZNF564  Zn
++ finger protein 564  -1.35  1.14E-08  6.77E-07 
RNF138  ring finger protein 138  -1.77  1.20E-08  7.11E-07 
IL6ST  interleukin 6 signal transducer (gp130, oncostatin M receptor)  2.72  1.21E-08  7.16E-07 
CISD1  CDGSH Fe
++ sulfur domain 1  -1.37  1.23E-08  7.24E-07 
HIBADH  3-hydroxyisobutyrate dehydrogenase  -1.23  1.24E-08  7.27E-07 
SRGAP2  SLIT-ROBO Rho GTPase activating protein 2  1.63  1.29E-08  7.51E-07 
PNPLA3  patatin-like phospholipase domain containing 3  3.68  1.38E-08  7.96E-07 
CYTH1  cytohesin 1  1.66  1.40E-08  8.06E-07 
LIPA  lipase A, lysosomal acid, cholesterol esterase  3.74  1.43E-08  8.15E-07 
RILPL1  Rab interacting lysosomal protein-like 1  1.52  1.46E-08  8.27E-07 
NAP1L5  nucleosome assembly protein 1-like 5  1.55  1.46E-08  8.30E-07 
DCLK2  doublecortin-like kinase 2  3.09  1.49E-08  8.42E-07 
PSIP1  PC4 and SFRS1 interacting protein 1  -1.28  1.54E-08  8.66E-07 
ZSWIM1  Zn
++ finger, SWIM-type containing 1  1.65  1.58E-08  8.83E-07 
NAP1L1  nucleosome assembly protein 1-like 1  -1.30  1.61E-08  8.96E-07 
SF1  splicing factor 1  1.37  1.63E-08  9.3E-07 
DST  dystonin  -1.68  1.66E-08  9.15E-07 
EIF2B2  HXNDU\RWLFWUDQVODWLRQLQLWLDWLRQIDFWRU%VXEXQLWȕN'D  1.47  1.68E-08  9.23E-07 133	 ﾠ
LIMS1  LIM and senescent cell antigen-like domains 1  1.26  1.69E-08  9.25E-07 
LCLAT1  lysocardiolipin acyltransferase 1  1.72  1.71E-08  9.28E-07 
ABCA1  ATP-binding cassette, sub-family A (ABC1), member 1  1.73  1.75E-08  9.44E-07 
SOAT1  sterol O-acyltransferase 1  1.62  1.75E-08  9.44E-07 
PREB  prolactin regulatory element binding  1.53  1.77E-08  9.50E-07 
SHE  Src homology 2 domain containing E  -1.48  1.80E-08  9.63E-07 
PCYT2  phosphate cytidylyltransferase 2, ethanolamine  1.33  1.83E-08  9.77E-07 
SFXN1  sideroflexin 1  2.11  1.83E-08  9.77E-07 
PCP2  Purkinje cell protein 2  2.64  1.84E-08  9.81E-07 
SREBF2  sterol regulatory element binding transcription factor 2  2.36  1.85E-08  9.81E-07 
FOLH1  folate hydrolase (prostate-specific membrane antigen) 1  -2.10  1.86E-08  9.84E-07 
DENND4C  DENN/MADD domain containing 4C  2.75  1.86E-08  9.87E-07 
SH3TC2  SH3 domain and tetratricopeptide repeats 2  1.67  1.89E-08  9.93E-07 
TM7SF2  transmembrane 7 superfamily member 2  2.41  1.95E-08  1.02E-06 
TPCN1  two pore segment channel 1  1.81  1.95E-08  1.02E-06 
ARHGEF26  Rho guanine nucleotide exchange factor (GEF) 26  2.28  2.08E-08  1.07E-06 
PLEKHA6  pleckstrin homology domain containing, family A member 6  1.48  2.14E-08  1.09E-06 
ZDHHC2  Zn
++ finger, DHHC-type containing 2  2.08  2.14E-08  1.09E-06 
MYO1B  myosin IB  -1.83  2.21E-08  1.12E-06 
UBE2V1  ubiquitin-conjugating enzyme E2 variant 1  1.26  2.22E-08  1.12E-06 
PTPN14  protein tyrosine phosphatase, non-receptor type 14  2.23  2.27E-08  1.14E-06 
IDS  iduronate 2-sulfatase  1.82  2.28E-08  1.14E-06 
LRRC8D  leucine rich repeat containing 8 family, member D  1.35  2.29E-08  1.14E-06 
CSRP2BP  CSRP2 binding protein  1.58  2.30E-08  1.14E-06 134	 ﾠ
ELK3  ELK3, ETS-domain protein (SRF accessory protein 2)  -1.68  2.33E-08  1.15E-06 
CAMSAP1L1  calmodulin regulated spectrin-associated protein 1-like 1  1.44  2.36E-08  1.16E-06 
FNBP1L  formin binding protein 1-like  -1.45  2.45E-08  1.20E-06 
MYL6B  myosin, light chain 6B, alkali, smooth muscle and non-muscle  1.29  2.45E-08  1.20E-06 
LONRF1  LON peptidase N-terminal domain and ring finger 1  1.93  2.53E-08  1.23E-06 
MYH9  myosin, heavy chain 9, non-muscle  -2.05  2.60E-08  1.26E-06 
SCHIP1  schwannomin interacting protein 1  1.46  2.69E-08  1.30E-06 
KIF14  kinesin family member 14  2.51  2.70E-08  1.30E-06 
ARHGEF5  Rho guanine nucleotide exchange factor (GEF) 5  1.50  2.73E-08  1.31E-06 
AAK1  AP2 associated kinase 1  1.37  2.76E-08  1.32E-06 
ROBO1  roundabout, axon guidance receptor, homolog 1 (Drosophila)  -1.66  2.77E-08  1.32E-06 
DSE  dermatan sulfate epimerase  -1.37  2.77E-08  1.32E-06 
ANKRD55  ankyrin repeat domain 55  1.40  2.81E-08  1.33E-06 
PRDX4  peroxiredoxin 4  -1.36  2.82E-08  1.34E-06 
PAPOLG  SRO\$SRO\PHUDVHȖ  2.48  2.82E-08  1.34E-06 
LZTS2  leucine zipper, putative tumor suppressor 2  1.39  2.91E-08  1.36E-06 
ZNF608  Zn
++ finger protein 608  -1.80  2.94E-08  1.37E-06 
LUM  lumican  -1.93  2.94E-08  1.37E-06 
ZNF292  Zn
++ finger protein 292  -1.44  3.01E-08  1.40E-06 
USP53  ubiquitin specific peptidase 53  -1.52  3.06E-08  1.41E-06 
ERO1L  ERO1-like (S. cerevisiae)  1.47  3.12E-08  1.43E-06 
DNAJC3  DnaJ (Hsp40) homolog, subfamily C, member 3  1.50  3.14E-08  1.44E-06 
FLVCR1  feline leukemia virus subgroup C cellular receptor 1  1.22  3.17E-08  1.45E-06 
PON2  paraoxonase 2  1.24  3.17E-08  1.45E-06 135	 ﾠ
JAM2  junctional adhesion molecule 2  -1.64  3.21E-08  1.46E-06 
PMP22  peripheral myelin protein 22  -1.78  3.22E-08  1.46E-06 
LZTS1  leucine zipper, putative tumor suppressor 1  3.13  3.22E-08  1.46E-06 
BCL2  B-cell CLL/lymphoma 2  2.30  3.24E-08  1.46E-06 
PLOD2  procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2  1.68  3.31E-08  1.49E-06 
FGL1  fibrinogen-like 1  -1.90  3.34E-08  1.49E-06 
SLC25A40  Solute carrier family 25, member 40  -1.42  3.40E-08  1.52E-06 
NAALAD2  N-DFHW\ODWHGĮ-linked acidic dipeptidase 2  -1.64  3.49E-08  1.55E-06 
CEP120  centrosomal protein 120kDa  -1.31  3.54E-08  1.57E-06 
CMTM8  CKLF-like MARVEL transmembrane domain containing 8  2.36  3.57E-08  1.58E-06 
AZIN1  antizyme inhibitor 1  1.26  3.59E-08  1.59E-06 
GRINA  glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 
(glutamate binding) 
2.57  3.62E-08  1.60E-06 
MEF2C  myocyte enhancer factor 2C  -1.69  3.68E-08  1.61E-06 
SMARCD1  SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily d, member 1 
1.24  3.71E-08  1.62E-06 
SLC25A38  solute carrier family 25, member 38  1.26  3.80E-08  1.65E-06 
SYNE2  spectrin repeat containing, nuclear envelope 2  -1.88  3.93E-08  1.70E-06 
FXYD6  FXYD domain containing ion transport regulator 6  -1.65  3.95E-08  1.71E-06 
EPHA3  EPH receptor A3  1.67  3.98E-08  1.72E-06 
ARHGAP18  Rho GTPase activating protein 18  2.09  4.02E-08  1.73E-06 
KDELR3  KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3  -1.24  4.03E-08  1.73E-06 
TPST2  tyrosylprotein sulfotransferase 2  -1.25  4.06E-08  1.74E-06 
PROM1  prominin 1  -2.21  4.07E-08  1.74E-06 136	 ﾠ
ARMC2  armadillo repeat containing 2  2.24  4.20E-08  1.79E-06 
SPDEF  SAM pointed domain containing ets transcription factor  1.36  4.23E-08  1.81E-06 
DUSP6  dual specificity phosphatase 6  -1.40  4.27E-08  1.81E-06 
SLC9A2  solute carrier family 9 (sodium/hydrogen exchanger), member 2  2.76  4.28E-08  1.81E-06 
DPF3  D4, Zn
++ and double PHD fingers, family 3  1.51  4.28E-08  1.81E-06 
ROBO2  roundabout, axon guidance receptor, homolog 2 (Drosophila)  -1.63  4.32E-08  1.82E-06 
PRNP  prion protein  -1.38  4.40E-08  1.84E-06 
BCHE  butyrylcholinesterase  -2.50  4.40E-08  1.84E-06 
LETM2  Leucine zipper-EF-hand containing transmembrane protein 2  -1.61  4.47E-08  1.86E-06 
CD164L2  CD164 sialomucin-like 2  1.84  4.49E-08  1.87E-06 
SULF2  sulfatase 2  -1.69  4.53E-08  1.88E-06 
RALGAPA2  5DO*73DVHDFWLYDWLQJSURWHLQĮVXEXQLWFDWDO\WLF  1.41  4.55E-08  1.89E-06 
DCN  decorin  -1.26  4.57E-08  1.89E-06 
SPATS2L  spermatogenesis associated, serine-rich 2-like  1.35  4.73E-08  1.95E-06 
MECOM  MDS1 and EVI1 complex locus  -1.58  4.86E-08  1.99E-06 
USP6NL  USP6 N-terminal like  1.59  4.95E-08  2.02E-06 
NPTN  neuroplastin  -1.22  4.99E-08  2.03E-06 
KAT2B  K(lysine) acetyltransferase 2B  1.88  4.99E-08  2.03E-06 
ART3  ADP-ribosyltransferase 3  2.74  5.01E-08  2.03E-06 
TCF4  transcription factor 4  -1.36  5.02E-08  2.04E-06 
RSAD1  radical S-adenosyl methionine domain containing 1  -1.35  5.04E-08  2.04E-06 
CDR2  cerebellar degeneration-related protein 2, 62kDa  1.80  5.21E-08  2.09E-06 
HSF1  heat shock transcription factor 1  1.27  5.24E-08  2.10E-06 
ZBTB20  Zn
++ finger and BTB domain containing 20  -1.44  5.24E-08  2.10E-06 137	 ﾠ
ROD1  ROD1 regulator of differentiation 1 (S. pombe)  1.27  5.46E-08  2.18E-06 
BIRC2  baculoviral IAP repeat-containing 2  -1.29  5.61E-08  2.22E-06 
NFIL3  nuclear factor, interleukin 3 regulated  -2.07  5.74E-08  2.26E-06 
TCF7L2  transcription factor 7-like 2 (T-cell specific, HMG-box)  2.65  5.79E-08  2.28E-06 
SMC5  structural maintenance of chromosomes 5  -1.91  5.83E-08  2.29E-06 
GPR161  G protein-coupled receptor 161  2.38  5.96E-08  2.32E-06 
CTSK  cathepsin K  1.98  5.97E-08  2.33E-06 
UNC13D  unc-13 homolog D (C. elegans)  2.42  6.15E-08  2.38E-06 
LYPD6  LY6/PLAUR domain containing 6  1.90  6.26E-08  2.41E-06 
WBP2  WW domain binding protein 2  1.39  6.30E-08  2.43E-06 
PLA2G10  phospholipase A2, group X  2.11  6.30E-08  2.43E-06 
ABCC1  ATP-binding cassette, sub-family C (CFTR/MRP), member 1  2.29  6.32E-08  2.43E-06 
PTPRB, PTPRR  protein tyrosine phosphatase, receptor type, B; protein tyrosine phosphatase, 
receptor type, R 
-1.73  6.34E-08  2.44E-06 
LRRC8C  leucine rich repeat containing 8 family, member C  -1.91  6.37E-08  2.44E-06 
C1R  complement component 1, r subcomponent  -1.82  6.40E-08  2.44E-06 
TFPI2  tissue factor pathway inhibitor 2  1.56  6.41E-08  2.44E-06 
TMEM135  transmembrane protein 135  1.48  6.43E-08  2.45E-06 
ARAP3  ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3  -1.25  6.61E-08  2.51E-06 
RENBP  renin binding protein  1.67  6.71E-08  2.54E-06 
FAHD1  fumarylacetoacetate hydrolase domain containing 1  1.56  6.76E-08  2.56E-06 
PHLDB2  pleckstrin homology-like domain, family B, member 2  2.19  6.80E-08  2.56E-06 
LMBRD2  LMBR1 domain containing 2  1.34  6.86E-08  2.57E-06 
CAV1  caveolin 1, caveolae protein, 22kDa  -1.63  6.95E-08  2.60E-06 138	 ﾠ
ALAD  aminolevulinate dehydratase  2.05  7.14E-08  2.65E-06 
GJC1  JDSMXQFWLRQSURWHLQȖN'D  -1.66  7.17E-08  2.66E-06 
HORMAD1  HORMA domain containing 1  3.21  7.38E-08  2.72E-06 
ADD3  DGGXFLQȖ  -1.47  7.60E-08  2.79E-06 
SLC35A1  solute carrier family 35 (CMP-sialic acid transporter), member A1  -1.36  7.72E-08  2.82E-06 
APOA2  apolipoprotein A-II  1.42  7.92E-08  2.88E-06 
MAP3K1  mitogen-activated protein kinase kinase kinase 1  1.45  8.05E-08  2.92E-06 
DEGS2  degenerative spermatocyte homolog 2, lipid desaturase (Drosophila)  2.40  8.17E-08  2.95E-06 
EGLN3  egl nine homolog 3 (C. elegans)  1.90  8.29E-08  2.98E-06 
ANXA6  annexin A6  -1.62  8.33E-08  2.99E-06 
TTPA  WRFRSKHUROĮWUDQVIHUSURWHLQ  2.69  8.42E-08  3.01E-06 
SLC2A1  solute carrier family 2 (facilitated glucose transporter), member 1  1.48  8.54E-08  3.04E-06 
ROGDI  rogdi homolog (Drosophila)  1.36  8.82E-08  3.14E-06 
PCSK5  proprotein convertase subtilisin/kexin type 5  2.01  8.84E-08  3.14E-06 
TRIM13  tripartite motif-containing 13  1.37  8.98E-08  3.18E-06 
PTGS1  prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and 
cyclooxygenase) 
-1.40  9.10E-08  3.21E-06 
DHCR7  7-dehydrocholesterol reductase  2.15  9.20E-08  3.24E-06 
SIRPA  signal-UHJXODWRU\SURWHLQĮ  2.62  9.25E-08  3.25E-06 
FSD1L  fibronectin type III and SPRY domain containing 1-like  -1.46  9.29E-08  3.27E-06 
CARHSP1  Ca
++ regulated heat stable protein 1, 24kDa  1.70  9.44E-08  3.30E-06 
P2RY14  purinergic receptor P2Y, G-protein coupled, 14  1.64  9.78E-08  3.41E-06 
NHLRC1  NHL repeat containing 1  1.42  9.82E-08  3.42E-06 
CPE  carboxypeptidase E  -1.56  1.00E-07  3.47E-06 139	 ﾠ
CCL3  chemokine (C-C motif) ligand 3  -3.23  1.00E-07  3.48E-06 
F2RL2  coagulation factor II (thrombin) receptor-like 2  -1.64  1.01E-07  3.50E-06 
MNDA  myeloid cell nuclear differentiation antigen  -1.54  1.02E-07  3.52E-06 
F2R  coagulation factor II (thrombin) receptor  -1.21  1.03E-07  3.53E-06 
DEPDC6  DEP domain containing 6  1.70  1.04E-07  3.56E-06 
MAP3K4  mitogen-activated protein kinase kinase kinase 4  -1.33  1.04E-07  3.56E-06 
ADPRHL1  ADP-ribosylhydrolase like 1  2.27  1.04E-07  3.57E-06 
ILKAP  integrin-linked kinase-associated serine/threonine phosphatase  1.77  1.05E-07  3.57E-06 
RAP2A  RAP2A, member of RAS oncogene family  1.62  1.06E-07  3.60E-06 
EDEM1  (5GHJUDGDWLRQHQKDQFHUPDQQRVLGDVHĮ-like 1  1.56  1.08E-07  3.66E-06 
GNS  glucosamine (N-acetyl)-6-sulfatase  2.10  1.08E-07  3.68E-06 
CPEB2  cytoplasmic polyadenylation element binding protein 2  1.80  1.09E-07  3.70E-06 
TMC4  transmembrane channel-like 4  1.99  1.12E-07  3.77E-06 
TBX3  T-box 3  1.32  1.16E-07  3.87E-06 
NEURL2  neuralized homolog 2 (Drosophila)  1.62  1.19E-07  3.94E-06 
NR1H4  nuclear receptor subfamily 1, group H, member 4  -1.76  1.20E-07  3.96E-06 
NPR2  natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide 
receptor B) 
-1.27  1.22E-07  4.00E-06 
DNAJB4  DnaJ (Hsp40) homolog, subfamily B, member 4  -1.47  1.28E-07  4.18E-06 
STAT3  signal transducer and activator of transcription 3 (acute-phase response factor)  1.27  1.29E-07  4.20E-06 
CHRM4  cholinergic receptor, muscarinic 4  2.06  1.32E-07  4.28E-06 
YIPF6  Yip1 domain family, member 6  1.24  1.34E-07  4.34E-06 
PPAPDC3  phosphatidic acid phosphatase type 2 domain containing 3  -1.63  1.36E-07  4.39E-06 
GAB1  GRB2-associated binding protein 1  2.06  1.38E-07  4.41E-06 140	 ﾠ
P4HA2  prolyl 4-K\GUR[\ODVHĮSRO\SHSWLGH,,  -1.34  1.38E-07  4.41E-06 
GLT8D2  glycosyltransferase 8 domain containing 2  -1.62  1.38E-07  4.42E-06 
TWF1  twinfilin, actin-binding protein, homolog 1 (Drosophila)  1.31  1.43E-07  4.55E-06 
FADS1  fatty acid desaturase 1  2.52  1.44E-07  4.57E-06 
CLEC1A  C-type lectin domain family 1, member A  -1.70  1.46E-07  4.60E-06 
RLN  relaxin 1  1.36  1.46E-07  4.61E-06 
SEMA4D  sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 4D 
1.86  1.51E-07  4.72E-06 
TEC  tec protein tyrosine kinase  1.90  1.51E-07  4.72E-06 
CEP170  centrosomal protein 170kDa  -1.35  1.52E-07  4.76E-06 
EGR1  early growth response 1  -4.31  1.54E-07  4.79E-06 
MAP3K5  mitogen-activated protein kinase kinase kinase 5  1.55  1.54E-07  4.80E-06 
RFK  riboflavin kinase  1.66  1.55E-07  4.82E-06 
FKBP9  FK506 binding protein 9, 63 kDa  -1.33  1.59E-07  4.88E-06 
LAMC1  ODPLQLQȖIRUPHUO\/$0%  1.38  1.63E-07  4.99E-06 
ATF3  activating transcription factor 3  -3.85  1.63E-07  4.99E-06 
DUSP10  dual specificity phosphatase 10  2.31  1.67E-07  5.09E-06 
DUSP1  dual specificity phosphatase 1  -2.00  1.67E-07  5.10E-06 
HIGD1B  HIG1 hypoxia inducible domain family, member 1B  -1.51  1.67E-07  5.10E-06 
FARP2  FERM, RhoGEF and pleckstrin domain protein 2  1.74  1.68E-07  5.12E-06 
TBX4  T-box 4  -1.33  1.68E-07  5.12E-06 
ATP10A  ATPase, class V, type 10A  -1.36  1.70E-07  5.16E-06 
DISC1  disrupted in schizophrenia 1  2.67  1.71E-07  5.16E-06 
GLIPR1L2  GLI pathogenesis-related 1 like 2  1.42  1.71E-07  5.16E-06 141	 ﾠ
CDK16  cyclin-dependent kinase 16  1.22  1.73E-07  5.19E-06 
ALDH3A1  aldehyde dehydrogenase 3 family, member A1  2.64  1.73E-07  5.19E-06 
TLE1  transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)  -1.79  1.78E-07  5.33E-06 
RND3  Rho family GTPase 3  -2.05  1.78E-07  5.33E-06 
MPDZ  multiple PDZ domain protein  -1.93  1.84E-07  5.46E-06 
FOLR2  folate receptor 2 (fetal)  -1.66  1.84E-07  5.46E-06 
PIK3C2A  phosphoinositide-3-NLQDVHFODVVĮSRO\SHSWLGH  -1.36  1.86E-07  5.50E-06 
LCN2  lipocalin 2  1.21  1.86E-07  5.50E-06 
RASGRP3  RAS guanyl releasing protein 3 (Ca
++ and DAG-regulated)  -2.09  1.88E-07  5.53E-06 
ZEB1  Zn
++ finger E-box binding homeobox 1  -1.76  1.89E-07  5.54E-06 
RASSF8  Ras association (RalGDS/AF-6) domain family (N-terminal) member 8  -2.09  1.94E-07  5.68E-06 
PCDH9  protocadherin 9  1.35  1.95E-07  5.69E-06 
C3  complement component 3  -1.26  1.95E-07  5.70E-06 
PTPRG  protein tyrosine phosphatase, receptor type, G  -1.34  1.96E-07  5.70E-06 
LAMA4  ODPLQLQĮ  -1.59  1.96E-07  5.70E-06 
IRX2  iroquois homeobox 2  1.23  1.99E-07  5.76E-06 
CALU  calumenin  1.32  2.00E-07  5.78E-06 
LACTB2  ODFWDPDVHȕ  1.24  2.00E-07  5.80E-06 
TACC2  transforming, acidic coiled-coil containing protein 2  1.21  2.04E-07  5.86E-06 
41156  septin 4  -1.37  2.05E-07  5.88E-06 
PLEKHA3  pleckstrin homology domain containing, family A (phosphoinositide binding 
specific) member 3 
-1.38  2.05E-07  5.88E-06 
PLK2  polo-like kinase 2  -2.19  2.06E-07  5.90E-06 
SNX16  sorting nexin 16  -1.21  2.08E-07  5.94E-06 142	 ﾠ
BAZ1A  bromodomain adjacent to Zn
++ finger domain, 1A  -1.36  2.12E-07  6.06E-06 
MEGF9  multiple EGF-like-domains 9  1.90  2.13E-07  6.07E-06 
BAZ2B  bromodomain adjacent to Zn
++ finger domain, 2B  -1.40  2.16E-07  6.13E-06 
COL5A2  FROODJHQW\SH9Į  -1.79  2.20E-07  6.21E-06 
LIN7A  lin-7 homolog A (C. elegans)  1.27  2.23E-07  6.29E-06 
FBXL5  F-box and leucine-rich repeat protein 5  -1.26  2.25E-07  6.33E-06 
CD40  CD40 molecule, TNF receptor superfamily member 5  -1.26  2.25E-07  6.33E-06 
CUBN  cubilin (intrinsic factor-cobalamin receptor)  -1.68  2.30E-07  6.44E-06 
ACSF2  acyl-CoA synthetase family member 2  -1.29  2.31E-07  6.47E-06 
CTSS  cathepsin S  -1.61  2.36E-07  6.57E-06 
ZFP106  Zn
++ finger protein 106 homolog (mouse)  1.48  2.39E-07  6.64E-06 
SPRED1  sprouty-related, EVH1 domain containing 1  1.65  2.44E-07  6.73E-06 
IRS2  insulin receptor substrate 2  1.48  2.49E-07  6.84E-06 
SKAP2  src kinase associated phosphoprotein 2  -1.26  2.50E-07  6.84E-06 
FADS1, 
LOC612278 
fatty acid desaturase 1, similar to fatty acid desaturase 1  2.12  2.53E-07  6.93E-06 
SLC30A3  solute carrier family 30 (Zn
++ transporter), member 3  1.73  2.53E-07  6.93E-06 
IGF1  insulin-like growth factor 1 (somatomedin C)  3.11  2.56E-07  6.98E-06 
FBXO30  F-box protein 30  -1.68  2.58E-07  7.03E-06 
BCL2L1  BCL2-like 1  1.66  2.64E-07  7.17E-06 
PIBF1  progesterone immunomodulatory binding factor 1  -1.65  2.65E-07  7.18E-06 
ID1  inhibitor of DNA binding 1, dominant negative helix-loop-helix protein  -1.81  2.66E-07  7.21E-06 
DYSF  dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive)  -1.67  2.67E-07  7.22E-06 
SENP2  SUMO1/sentrin/SMT3 specific peptidase 2  1.64  2.70E-07  7.28E-06 143	 ﾠ
ABCC4  ATP-binding cassette, sub-family C (CFTR/MRP), member 4  2.24  2.73E-07  7.34E-06 
PITX2  paired-like homeodomain 2  -1.76  2.73E-07  7.34E-06 
RAB3IP  RAB3A interacting protein (rabin3)  -1.28  2.73E-07  7.34E-06 
NFAT5  nuclear factor of activated T-cells 5, tonicity-responsive  -1.30  2.77E-07  7.40E-06 
GTF2H5  general transcription factor IIH, polypeptide 5  1.27  2.79E-07  7.44E-06 
RGS2  regulator of G-protein signaling 2, 24kDa  -1.87  2.84E-07  7.55E-06 
OLFML2B  olfactomedin-like 2B  2.09  2.89E-07  7.62E-06 
ZNF521  Zn
++ finger protein 521  -1.34  2.89E-07  7.62E-06 
FGL2  fibrinogen-like 2  -3.19  2.91E-07  7.67E-06 
DENND5A  DENN/MADD domain containing 5A  -1.30  2.99E-07  7.84E-06 
SLC11A1  solute carrier family 11 (proton-coupled divalent metal ion transporters), member 
1 
-1.23  3.00E-07  7.86E-06 
PPP1R11  protein phosphatase 1, regulatory (inhibitor) subunit 11  1.66  3.06E-07  8.00E-06 
IER3  immediate early response 3  -1.50  3.08E-07  8.02E-06 
NR2F1  nuclear receptor subfamily 2, group F, member 1  -1.33  3.15E-07  8.14E-06 
NFKBIZ  QXFOHDUIDFWRURIțOLJKWSRO\SHSWLGHJHQHHQKDQFHULQ%-cells inhibitor, zeta  -2.09  3.17E-07  8.18E-06 
RAD21L1  RAD21-like 1 (S. pombe)  1.43  3.19E-07  8.21E-06 
XAB2  XPA binding protein 2  1.66  3.19E-07  8.21E-06 
EPHA6  EPH receptor A6  1.23  3.25E-07  8.34E-06 
FAP  ILEUREODVWDFWLYDWLRQSURWHLQĮ  -2.60  3.26E-07  8.34E-06 
PCTP  phosphatidylcholine transfer protein  -1.35  3.26E-07  8.34E-06 
HECTD2  HECT domain containing 2  -1.34  3.32E-07  8.45E-06 
HOMER1  homer homolog 1 (Drosophila)  1.75  3.35E-07  8.53E-06 
PROCR  protein C receptor, endothelial  -1.74  3.39E-07  8.59E-06 144	 ﾠ
ACACA  acetyl-&R$FDUER[\ODVHĮ  1.25  3.47E-07  8.77E-06 
ANAPC11  anaphase promoting complex subunit 11  1.62  3.6E-07  9.10E-06 
HLA-DQA1  major histocompatibility complex, class ,,'4Į  -2.30  3.78E-07  9.42E-06 
WIPF1  WAS/WASL interacting protein family, member 1  1.50  3.82E-07  9.50E-06 
ITCH  itchy E3 ubiquitin protein ligase homolog (mouse)  1.61  3.83E-07  9.52E-06 
HSD17B6  hydroxysteroid (17-ȕGHK\GURJHQDVHKRPRORJPRXVH  1.28  3.84E-07  9.52E-06 
PLEKHA1  pleckstrin homology domain containing, family A (phosphoinositide binding 
specific) member 1 
2.17  3.85E-07  9.54E-06 
ZNF609  Zn
++ finger protein 609  1.59  3.87E-07  9.58E-06 
STXBP5  syntaxin binding protein 5 (tomosyn)  1.32  3.98E-07  9.82E-06 
EPHB1  EPH receptor B1  1.75  4.07E-07  9.99E-06 
SULT1E1  sulfotransferase family 1E, estrogen-preferring, member 1  2.42  4.09E-07  1.00E-05 
PDE7A  phosphodiesterase 7A  1.48  4.09E-07  1.00E-05 
ESM1  endothelial cell-specific molecule 1  -1.95  4.16E-07  1.02E-05 
IL8  interleukin 8  -4.29  4.16E-07  1.02E-05 
SAMD9L  VWHULOHĮPRWLIGRPDLQFRQWDLQLQJ-like  -1.34  4.26E-07  1.03E-05 
B4GALT6  UDP-*DOȕ*OF1$Fȕ- galactosyltransferase, polypeptide 6  1.65  4.28E-07  1.04E-05 
HMCN1  hemicentin 1  -2.01  4.36E-07  1.05E-05 
TMPRSS11E  transmembrane protease, serine 11E  2.51  4.41E-07  1.06E-05 
FAT1  FAT tumor suppressor homolog 1 (Drosophila)  1.41  4.41E-07  1.06E-05 
TPD52  tumor protein D52  1.53  4.45E-07  1.07E-05 
STX5  syntaxin 5  1.22  4.49E-07  1.08E-05 
CBLB  Cas-Br-M (murine) ecotropic retroviral transforming sequence b  2.31  4.50E-07  1.08E-05 
PRR15  proline rich 15  1.53  4.50E-07  1.08E-05 145	 ﾠ
COL5A1  FROODJHQW\SH9Į  -1.66  4.59E-07  1.09E-05 
RASIP1  Ras interacting protein 1  -1.33  4.62E-07  1.10E-05 
TTLL12  Tubulin tyrosine ligase-like family, member 12  -1.41  4.64E-07  1.10E-05 
ALDH4A1  aldehyde dehydrogenase 4 family, member A1  2.93  4.65E-07  1.10E-05 
PGM2L1  phosphoglucomutase 2-like 1  -1.64  4.68E-07  1.11E-05 
TET1  tet oncogene 1  1.76  4.76E-07  1.12E-05 
EMCN  endomucin  -2.25  4.89E-07  1.15E-05 
PDGFRA  platelet-GHULYHGJURZWKIDFWRUUHFHSWRUĮSRO\SHSWLGH  1.39  4.93E-07  1.16E-05 
ATP11C  ATPase, class VI, type 11C  1.36  4.94E-07  1.16E-05 
ENTPD3  ectonucleoside triphosphate diphosphohydrolase 3  1.59  4.95E-07  1.16E-05 
A2M  Į-2-macroglobulin  -1.56  4.96E-07  1.16E-05 
HRH3  histamine receptor H3  2.80  5.01E-07  1.17E-05 
DDA1  DET1 and DDB1 associated 1  1.42  5.05E-07  1.18E-05 
RIC8B  resistance to inhibitors of cholinesterase 8 homolog B (C. elegans)  -1.26  5.08E-07  1.18E-05 
TSPAN13  tetraspanin 13  -1.85  5.12E-07  1.19E-05 
SENP6  SUMO1/sentrin specific peptidase 6  -1.37  5.12E-07  1.19E-05 
SIPA1L1  signal-induced proliferation-associated 1 like 1  1.56  5.12E-07  1.19E-05 
NUP153  nucleoporin 153kDa  1.53  5.25E-07  1.21E-05 
FSTL1  follistatin-like 1  -1.44  5.38E-07  1.23E-05 
SLC25A33  solute carrier family 25, member 33  -1.55  5.45E-07  1.24E-05 
HTR1A  5-hydroxytryptamine (serotonin) receptor 1A  1.52  5.61E-07  1.27E-05 
SERPINI1  serpin peptidase inhibitor, clade I (neuroserpin), member 1  -2.12  5.78E-07  1.30E-05 
LGR4  leucine-rich repeat-containing G protein-coupled receptor 4  1.51  6.11E-07  1.36E-05 
GPR146  G protein-coupled receptor 146  1.46  6.12E-07  1.36E-05 146	 ﾠ
PRKACB  protein kinase, cAMP-GHSHQGHQWFDWDO\WLFȕ  1.84  6.12E-07  1.36E-05 
ATP6V0D1  ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1  1.23  6.12E-07  1.36E-05 
CCL4  chemokine (C-C motif) ligand 4  -4.04  6.12E-07  1.36E-05 
UBXN4  UBX domain protein 4  1.21  6.17E-07  1.37E-05 
WDR44  WD repeat domain 44  -1.21  6.22E-07  1.37E-05 
SOX9  SRY (sex determining region Y)-box 9  2.87  6.22E-07  1.37E-05 
KIDINS220  kinase D-interacting substrate, 220kDa  1.44  6.23E-07  1.38E-05 
CHMP2B  chromatin modifying protein 2B  1.36  6.26E-07  1.38E-05 
TMEM49  transmembrane protein 49  -1.53  6.30E-07  1.39E-05 
MX1  myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 
(mouse) 
-1.41  6.55E-07  1.43E-05 
NRN1  neuritin 1  5.24  6.62E-07  1.44E-05 
ZNF704  Zn
++ finger protein 704  2.13  6.67E-07  1.45E-05 
MIPOL1  mirror-image polydactyly 1  -1.22  6.78E-07  1.48E-05 
HSD17B11  hydroxysteroid (17-ȕGHK\GURJHQDVH  -1.51  6.87E-07  1.49E-05 
PPP2R3A  SURWHLQSKRVSKDWDVHUHJXODWRU\VXEXQLW%Į  1.46  7.00E-07  1.51E-05 
MYCT1  myc target 1  -1.70  7.05E-07  1.52E-05 
SALL4  sal-like 4 (Drosophila)  1.31  7.08E-07  1.52E-05 
TPST1  tyrosylprotein sulfotransferase 1  -1.35  7.10E-07  1.53E-05 
PTGES  prostaglandin E synthase  1.57  7.18E-07  1.54E-05 
FAIM  Fas apoptotic inhibitory molecule  -1.26  7.40E-07  1.58E-05 
AVPI1  arginine vasopressin-induced 1  1.54  7.53E-07  1.59E-05 
PRKCDBP  protein kinase C, ' binding protein  1.83  7.62E-07  1.61E-05 
RND1  Rho family GTPase 1  -1.61  7.63E-07  1.61E-05 147	 ﾠ
ARHGAP12  Rho GTPase activating protein 12  1.26  7.69E-07  1.62E-05 
LIX1L  Lix1 homolog (mouse)-like  -1.26  7.71E-07  1.62E-05 
ZNF395  Zn
++ finger protein 395  1.52  8.02E-07  1.68E-05 
RGS12  regulator of G-protein signaling 12  1.36  8.10E-07  1.69E-05 
FOS  FBJ murine osteosarcoma viral oncogene homolog  -4.61  8.24E-07  1.71E-05 
IFT80  intraflagellar transport 80 homolog (Chlamydomonas)  -1.31  8.27E-07  1.71E-05 
COL4A5  FROODJHQW\SH,9Į  -2.13  8.42E-07  1.74E-05 
GUCY1B3  JXDQ\ODWHF\FODVHVROXEOHȕ  -1.34  8.44E-07  1.74E-05 
RBP1  retinol binding protein 1, cellular  1.57  8.45E-07  1.74E-05 
EBF1  early B-cell factor 1  -1.61  8.58E-07  1.76E-05 
ADA  adenosine deaminase  -1.27  8.69E-07  1.77E-05 
SLC2A13  solute carrier family 2 (facilitated glucose transporter), member 13  -1.58  8.83E-07  1.79E-05 
KLHL7  kelch-like 7 (Drosophila)  -1.44  9.29E-07  1.87E-05 
PALMD  palmdelphin  -2.01  9.40E-07  1.89E-05 
FBN1  fibrillin 1  -1.99  9.42E-07  1.89E-05 
PCM1  pericentriolar material 1  -1.21  9.47E-07  1.90E-05 
NEIL2  nei endonuclease VIII-like 2 (E. coli)  1.38  9.52E-07  1.90E-05 
SHROOM1  shroom family member 1  1.27  9.57E-07  1.91E-05 
FANK1  fibronectin type III and ankyrin repeat domains 1  1.21  9.60E-07  1.92E-05 
ACADS  acyl-CoA dehydrogenase, C-2 to C-3 short chain  2.05  9.70E-07  1.93E-05 
SMAD1  SMAD family member 1  -1.42  9.74E-07  1.94E-05 
CAV2  caveolin 2  -1.33  9.75E-07  1.94E-05 
ATP9A  ATPase, class II, type 9A  1.68  1.01E-06  1.98E-05 
MLANA  melan-A  2.71  1.02E-06  2.01E-05 148	 ﾠ
CLIC4  chloride intracellular channel 4  -1.28  1.02E-06  2.01E-05 
TNS1  tensin 1  1.65  1.03E-06  2.02E-05 
MERTK  c-mer proto-oncogene tyrosine kinase  -1.72  1.03E-06  2.02E-05 
FEM1B  fem-1 homolog b (C. elegans)  -1.37  1.04E-06  2.03E-05 
ELL2  elongation factor, RNA polymerase II, 2  1.32  1.04E-06  2.03E-05 
PRKD1  protein kinase D1  -1.45  1.04E-06  2.03E-05 
C1S  complement component 1, s subcomponent  -1.74  1.05E-06  2.05E-05 
PCDHGA10  SURWRFDGKHULQȖVXEIDPLO\A, 10  1.66  1.07E-06  2.07E-05 
TMEFF1  transmembrane protein with EGF-like and two follistatin-like domains 1  -1.64  1.07E-06  2.08E-05 
SIRT1  sirtuin 1  -1.22  1.11E-06  2.13E-05 
CD38  CD38 molecule  1.54  1.12E-06  2.15E-05 
ARHGAP42  Rho GTPase activating protein 42  -1.26  1.12E-06  2.15E-05 
UNC5B  unc-5 homolog B (C. elegans)  1.62  1.15E-06  2.20E-05 
SSX2IP  synovial sarcoma, X breakpoint 2 interacting protein  1.97  1.16E-06  2.21E-05 
MYC  v-myc myelocytomatosis viral oncogene homolog (avian)  -1.72  1.16E-06  2.22E-05 
PTGES2  prostaglandin E synthase 2  1.46  1.16E-06  2.22E-05 
KLF6  Kruppel-like factor 6  -1.48  1.18E-06  2.24E-05 
DOCK8  dedicator of cytokinesis 8  1.38  1.18E-06  2.25E-05 
CCDC63  coiled-coil domain containing 63  2.02  1.18E-06  2.25E-05 
SLC1A3  solute carrier family 1 (glial high affinity glutamate transporter), member 3  1.64  1.20E-06  2.28E-05 
BMP5  bone morphogenetic protein 5  -1.41  1.24E-06  2.34E-05 
PLXNB1  plexin B1  1.37  1.29E-06  2.40E-05 
PDE4D  phosphodiesterase 4D, cAMP-specific  -1.24  1.30E-06  2.42E-05 
TTC39B  tetratricopeptide repeat domain 39B  -1.35  1.32E-06  2.45E-05 149	 ﾠ
PDZK1  PDZ domain containing 1  2.03  1.34E-06  2.48E-05 
CD274  CD274 molecule  2.01  1.34E-06  2.48E-05 
OSBPL3  oxysterol binding protein-like 3  -1.37  1.35E-06  2.50E-05 
DTX2  deltex homolog 2 (Drosophila)  1.65  1.35E-06  2.50E-05 
IL33  interleukin 33  -2.91  1.37E-06  2.53E-05 
PSTPIP2  proline-serine-threonine phosphatase interacting protein 2  1.31  1.39E-06  2.55E-05 
EPHA1  EPH receptor A1  1.58  1.43E-06  2.60E-05 
SH2B1  SH2B adaptor protein 1  1.85  1.44E-06  2.62E-05 
DPP4  dipeptidyl-peptidase 4  1.59  1.44E-06  2.63E-05 
UNC93B1  unc-93 homolog B1 (C. elegans)  1.25  1.45E-06  2.63E-05 
ARMCX3  armadillo repeat containing, X-linked 3  -1.29  1.47E-06  2.67E-05 
SERPINB11  serpin peptidase inhibitor, clade B (ovalbumin), member 11 (gene/pseudogene)  2.18  1.49E-06  2.69E-05 
NSUN7  NOP2/Sun domain family, member 7  2.37  1.51E-06  2.72E-05 
SLC27A3  solute carrier family 27 (fatty acid transporter), member 3  -1.29  1.52E-06  2.75E-05 
ETS2  v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)  2.01  1.52E-06  2.75E-05 
MCL1  myeloid cell leukemia sequence 1 (BCL2-related)  -1.43  1.54E-06  2.78E-05 
BBS7  Bardet-Biedl syndrome 7  -1.27  1.57E-06  2.81E-05 
CD109  CD109 molecule  -1.37  1.57E-06  2.81E-05 
ANKRD11  ankyrin repeat domain 11  1.50  1.57E-06  2.81E-05 
MAN1A1  PDQQRVLGDVHĮFODVV$PHPEHU  -1.57  1.60E-06  2.86E-05 
ENG  endoglin  -1.43  1.63E-06  2.90E-05 
PSMB8  SURWHDVRPHSURVRPHPDFURSDLQVXEXQLWȕW\SHODUJHPXOWLIXQFWLRQDO
peptidase 7) 
-1.24  1.63E-06  2.90E-05 
ELOVL5  ELOVL family member 5, elongation of long chain fatty acids (FEN1/Elo2,  -1.39  1.67E-06  2.95E-05 150	 ﾠ
SUR4/Elo3-like, yeast) 
CTTN  cortactin  -1.46  1.68E-06  2.97E-05 
ABCC9  ATP-binding cassette, sub-family C (CFTR/MRP), member 9  -2.25  1.68E-06  2.97E-05 
CCL2  chemokine (C-C motif) ligand 2  -2.58  1.71E-06  3.00 E-05 
PTPRB  protein tyrosine phosphatase, receptor type, B  -1.90  1.71E-06  3.00E-05 
ATP2C1  ATPase, Ca
++ transporting, type 2C, member 1  1.58  1.71E-06  3.00E-05 
CHN2  chimerin (chimaerin) 2  -1.42  1.72E-06  3.01E-05 
GUF1  GUF1 GTPase homolog (S. cerevisiae)  -1.34  1.73E-06  3.03E-05 
GLOD5  glyoxalase domain containing 5  1.43  1.73E-06  3.03E-05 
PARP8  poly (ADP-ribose) polymerase family, member 8  -1.81  1.79E-06  3.11E-05 
CLSTN1  calsyntenin 1  -1.68  1.81E-06  3.13E-05 
SLC6A4  solute carrier family 6 (neurotransmitter transporter, serotonin), member 4  2.20  1.82E-06  3.15E-05 
CAB39  Ca
++ binding protein 39  1.51  1.86E-06  3.20E-05 
HLA-DRB1  0+&FODVV,,'/$'5%ȕFKDLQ  -1.80  1.86E-06  3.20E-05 
TTC3  tetratricopeptide repeat domain 3  -1.28  1.88E-06  3.24E-05 
CCRL2  chemokine (C-C motif) receptor-like 2  -1.42  2.03E-06  3.44E-05 
ABCA8  ATP-binding cassette, sub-family A (ABC1), member 8  -1.67  2.07E-06  3.50E-05 
RBMS3  RNA binding motif, single stranded interacting protein 3  -1.69  2.09E-06  3.52E-05 
GPR125  G protein-coupled receptor 125  1.72  2.10E-06  3.53E-05 
PRLR  prolactin receptor  1.70  2.12E-06  3.56E-05 
FAM96B  family with sequence similarity 96, member B  1.24  2.15E-06  3.59E-05 
PIK3R3  phosphoinositide-3-kinase, regulatory VXEXQLWȖ  -1.47  2.18E-06  3.65E-05 
TCEA3  transcription elongation factor A (SII), 3  1.22  2.19E-06  3.66E-05 
PRELP  proline/arginine-rich end leucine-rich repeat protein  -1.56  2.19E-06  3.66E-05 151	 ﾠ
CLINT1  clathrin interactor 1  1.45  2.22E-06  3.69E-05 
ARMCX1  armadillo repeat containing, X-linked 1  -1.43  2.23E-06  3.70E-05 
DENND2D  DENN/MADD domain containing 2D  1.32  2.24E-06  3.72E-05 
SPARCL1  SPARC-like 1 (hevin)  -1.97  2.28E-06  3.76E-05 
CSTB  cystatin B (stefin B)  1.27  2.28E-06  3.77E-05 
ZHX1  Zn
++ fingers and homeoboxes 1  -1.79  2.36E-06  3.87E-05 
ACSS3  acyl-CoA synthetase short-chain family member 3  1.25  2.40E-06  3.92E-05 
ZCCHC11  Zn
++ finger, CCHC domain containing 11  -1.41  2.43E-06  3.95E-05 
ARHGAP25  Rho GTPase activating protein 25  1.74  2.43E-06  3.95E-05 
N4BP2L1  NEDD4 binding protein 2-like 1  -1.30  2.44E-06  3.98E-05 
P4HA3  prolyl 4-K\GUR[\ODVHĮSRO\SHSWLGH,,,  -2.16  2.50E-06  4.04E-05 
S100A1  S100 Ca
++ binding protein A1  2.95  2.50E-06  4.04E-05 
TM4SF18  transmembrane 4 L six family member 18  -1.52  2.55E-06  4.10E-05 
EML1  echinoderm microtubule associated protein like 1  -1.38  2.57E-06  4.12E-05 
RAB22A  RAB22A, member RAS oncogene family  1.32  2.59E-06  4.14E-05 
RHOG  ras homolog gene family, member G (rho G)  1.52  2.62E-06  4.18E-05 
CH25H  cholesterol 25-hydroxylase  -2.95  2.84E-06  4.48E-05 
THBS2  thrombospondin 2  -1.42  2.90E-06  4.55E-05 
TAOK2  TAO kinase 2  1.37  2.91E-06  4.55E-05 
ANKRD29  ankyrin repeat domain 29  -1.42  2.91E-06  4.55E-05 
TNFSF10  tumor necrosis factor (ligand) superfamily, member 10  -1.77  2.93E-06  4.58E-05 
KARS  lysyl-tRNA synthetase  -1.16  2.93E-06  4.58E-05 
SYNE1  spectrin repeat containing, nuclear envelope 1  -1.67  3.06E-06  4.75E-05 
VCAM1  vascular cell adhesion molecule 1  -2.01  3.10E-06  4.80E-05 152	 ﾠ
BACE2, 
LOC478419 
ȕ-site APP-cleaving enzyme 2, similar to Protein FAM3B precursor (Cytokine-
like protein 2-21) 
-1.52  3.16E-06  4.87E-05 
OSTF1  osteoclast stimulating factor 1  1.24  3.17E-06  4.88E-05 
SLC46A3  solute carrier family 46, member 3  -1.26  3.17E-06  4.88E-05 
GOLIM4  golgi integral membrane protein 4  -1.44  3.25E-06  4.98E-05 
GADD45B  growth arrest and DNA-damage-LQGXFLEOHȕ  -2.04  3.30E-06  5.03E-05 
GJA1  JDSMXQFWLRQSURWHLQĮN'D  -1.97  3.32E-06  5.05E-05 
PRPS2  phosphoribosyl pyrophosphate synthetase 2  -1.58  3.33E-06  5.06E-05 
CXCR4  chemokine (C-X-C motif) receptor 4  -1.69  3.41E-06  5.15E-05 
FOXO1  forkhead box O1  1.32  3.44E-06  5.19E-05 
TMPO  thymopoietin  -1.27  3.56E-06  5.33E-05 
OCA2  oculocutaneous albinism II  1.72  3.58E-06  5.37E-05 
UGGT2  UDP-glucose glycoprotein glucosyltransferase 2  -1.47  3.63E-06  5.42E-05 
EGFR  epidermal growth factor receptor  1.63  3.78E-06  5.58E-05 
CREM  cAMP responsive element modulator  -1.29  3.80E-06  5.62E-05 
SLC1A4  solute carrier family 1 (glutamate/neutral amino acid transporter), member 4  1.56  3.81E-06  5.62E-05 
PON3  paraoxonase 3  -1.80  3.86E-06  5.68E-05 
PRRG1  proline rich Gla (G-carboxyglutamic acid) 1  1.21  3.91E-06  5.74E-05 
SUSD1  sushi domain containing 1  -1.37  3.94E-06  5.77E-05 
SLC15A1  solute carrier family 15 (oligopeptide transporter), member 1  -1.72  4.03E-06  5.86E-05 
FRY  furry homolog (Drosophila)  -1.32  4.09E-06  5.93E-05 
UST  uronyl-2-sulfotransferase  -1.22  4.33E-06  6.19E-05 
SVEP1  sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1  1.41  4.52E-06  6.38E-05 
EPSTI1  epithelial stromal interaction 1 (breast)  -1.33  4.55E-06  6.42E-05 153	 ﾠ
VEGFC  vascular endothelial growth factor C  -1.49  4.57E-06  6.43E-05 
NCOA7  nuclear receptor coactivator 7  -1.46  4.67E-06  6.54E-05 
PLD3  phospholipase D family, member 3  2.65  4.70E-06  6.57E-05 
PQLC3  PQ loop repeat containing 3  -1.57  4.70E-06  6.57E-05 
NR1D2  nuclear receptor subfamily 1, group D, member 2  -1.36  4.72E-06  6.58E-05 
RAB31  RAB31, member RAS oncogene family  -1.27  4.72E-06  6.58E-05 
DAPL1  death associated protein-like 1  1.90  4.75E-06  6.61E-05 
SLMAP  sarcolemma associated protein  1.34  4.80E-06  6.66E-05 
RRAD  Ras-related associated with diabetes  -1.57  4.83E-06  6.69E-05 
KIFC3  kinesin family member C3  2.08  4.85E-06  6.71E-05 
USP33  ubiquitin specific peptidase 33  1.48  4.86E-06  6.72E-05 
ZSWIM6  Zn
++  finger, SWIM-type containing 6  1.54  4.88E-06  6.75E-05 
NOC3L  nucleolar complex associated 3 homolog (S. cerevisiae)  1.51  4.98E-06  6.85E-05 
SLC31A2  solute carrier family 31 (Cu
++ transporters), member 2  1.39  5.09E-06  6.96E-05 
RAB25  RAB25, member RAS oncogene family  1.36  5.12E-06  7.00E-05 
B4GALT1  UDP-*DOȕ*OF1$Fȕ- galactosyltransferase, polypeptide 1  1.36  5.20E-06  7.08E-05 
AGPAT4  1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid 
acyltransferase, ') 
-1.76  5.23E-06  7.11E-05 
STK25  serine/threonine-protein kinase 25  1.57  5.31E-06  7.17E-05 
SLTM  SAFB-like, transcription modulator  -1.21  5.32E-06  7.18E-05 
SDR16C5  short chain dehydrogenase/reductase family 16C, member 5  1.35  5.33E-06  7.19E-05 
PEG3  paternally expressed 3  -1.42  5.40E-06  7.27E-05 
FICD  FIC domain containing  1.53  5.40E-06  7.27E-05 
STARD6  StAR-related lipid transfer (START) domain containing 6  -1.22  5.45E-06  7.32E-05 154	 ﾠ
SNX25  sorting nexin 25  -1.34  5.54E-06  7.41E-05 
ISG20  interferon stimulated exonuclease gene 20kDa  1.45  5.60E-06  7.48E-05 
AMPD3  adenosine monophosphate deaminase 3  1.41  5.68E-06  7.56E-05 
LGALS12  lectin, galactoside-binding, soluble, 12  1.23  5.76E-06  7.64E-05 
ASB9  ankyrin repeat and SOCS box-containing 9  -1.27  5.84E-06  7.73E-05 
PKD2L1  polycystic kidney disease 2-like 1  2.35  5.84E-06  7.74E-05 
SERPING1  serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  -1.69  5.97E-06  7.86E-05 
RBM47  RNA binding motif protein 47  1.42  6.09E-06  7.99E-05 
NBEA  neurobeachin  -1.29  6.10E-06  7.99E-05 
FMO2  flavin containing monooxygenase 2 (non-functional)  1.80  6.13E-06  8.03E-05 
RBM11  RNA binding motif protein 11  1.38  6.25E-06  8.14E-05 
RRAGD  Ras-related GTP binding D  2.31  6.42E-06  8.30E-05 
DLA-DRA  0+&FODVV,,'5ĮFKDLQ  -1.87  6.483E-
06 
8.36E-05 
BICD1  bicaudal D homolog 1 (Drosophila)  1.65  6.50E-06  8.38E-05 
RCL1  RNA terminal phosphate cyclase-like 1  1.35  6.53E-06  8.41E-05 
GPR116  G protein-coupled receptor 116  -1.36  6.58E-06  8.46E-05 
SPATA6  spermatogenesis associated 6  -1.46  6.77E-06  8.63E-05 
GAS6  growth arrest-specific 6  -1.63  6.85E-06  8.72E-05 
CTSL2  cathepsin L2  1.70  6.88E-06  8.75E-05 
CD200  CD200 molecule  -1.32  6.99E-06  8.87E-05 
TMEFF2  transmembrane protein with EGF-like and two follistatin-like domains 2  -1.30  7.05E-06  8.94E-05 
DCAF4  DDB1 and CUL4 associated factor 4  1.55  7.08E-06  8.97E-05 
HERC5  hect domain and RLD 5  2.14  7.18E-06  9.06E-05 155	 ﾠ
RGS10  regulator of G-protein signaling 10  -1.22  7.35E-06  9.20E-05 
TRA2A  WUDQVIRUPHUĮKRPRORJ'URVRSKLOD  -1.21  7.38E-06  9.23E-05 
FGF9  fibroblast growth factor 9 (glia-activating factor)  2.01  7.52E-06  9.36E-05 
PPP2R2B  SURWHLQSKRVSKDWDVHUHJXODWRU\VXEXQLW%ȕ  1.50  7.61E-06  9.45E-05 
AP1AR  adaptor-related protein complex 1 associated regulatory protein  -1.32  7.68E-06  9.51E-05 
FOLR1  folate receptor 1 (adult)  2.02  7.78E-06  9.61E-05 
HIP1  huntingtin interacting protein 1  -1.21  7.83E-06  9.66E-05 
NCSTN  nicastrin  1.67  7.90E-06  9.72E-05 
MBOAT2  membrane bound O-acyltransferase domain containing 2  -1.49  7.98E-06  9.80E-05 
MLF2  myeloid leukemia factor 2  1.21  8.57E-06  0.0001 
TDRD6  tudor domain containing 6  1.42  8.65E-06  0.0001 
PPP4R1  protein phosphatase 4, regulatory subunit 1  -1.31  8.67E-06  0.0001 
FKBP7  FK506 binding protein 7  -1.43  8.81E-06  0.0001 
GOLM1  golgi membrane protein 1  -2.06  8.96E-06  0.0001 
WARS  tryptophanyl-tRNA synthetase  -1.82  9.21E-06  0.0001 
GPER  G protein-coupled estrogen receptor 1  1.35  9.23E-06  0.0001 
NPNT  nephronectin  2.29  9.69E-06  0.0001 
SNRNP40  small nuclear ribonucleoprotein 40kDa (U5)  -1.33  9.90E-06  0.0001 
GPATCH1  G patch domain containing 1  1.32  9.92E-06  0.0001 
EGF  epidermal growth factor  2.96  9.96E-06  0.0001 
LIPH  lipase, member H  1.71  9.98E-06  0.0001 
HMOX1  heme oxygenase (decycling) 1  2.19  9.98E-06  0.0001 
GATA2  GATA binding protein 2  1.55  1.03E-05  0.0001 
RALBP1  ralA binding protein 1  1.22  1.05E-05  0.0001 156	 ﾠ
SNCAIP  V\QXFOHLQĮLQWHUDFWLQJSURWHLQ  -1.28  1.07E-05  0.0001 
ST8SIA6  ST8 Į-N-acetyl-QHXUDPLQLGHĮ-2,8-sialyltransferase 6  1.41  1.10E-05  0.0001 
NAMPT  Nicotinamide phosphoribosyltransferase  1.53  1.10E-05  0.0001 
SDC4  syndecan 4  1.41  1.12E-05  0.0001 
MAP2  microtubule-associated protein 2  -1.26  1.13E-05  0.0001 
ARL15  ADP-ribosylation factor-like 15  -1.22  1.15E-05  0.0001 
SLC16A10  solute carrier family 16, member 10 (aromatic amino acid transporter)  -1.46  1.18E-05  0.0001 
HNMT  histamine N-methyltransferase  -1.26  1.19E-05  0.0001 
SP1  Sp1 transcription factor  1.32  1.25E-05  0.0001 
LAMB1  ODPLQLQȕ  1.76  1.26E-05  0.0001 
FGR  Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog  -1.24  1.29E-05  0.0001 
TPM4  tropomyosin 4  -1.80  1.32E-05  0.0002 
LATS1  LATS, large tumor suppressor, homolog 1 (Drosophila)  1.37  1.32E-05  0.0002 
DUSP7  dual specificity phosphatase 7  1.73  1.34E-05  0.0002 
SLC6A2  solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2  1.44  1.38E-05  0.0002 
HOXD10  homeobox D10  -1.27  1.38E-05  0.0002 
BIN2  bridging integrator 2  1.85  1.39E-05  0.0002 
SERPINF1  VHUSLQSHSWLGDVHLQKLELWRUFODGH)Į-2 antiplasmin, pigment epithelium derived 
factor), member 1 
-1.42  1.43E-05  0.0002 
NUP50  nucleoporin 50kDa  1.30  1.47E-05  0.0002 
TSPAN2  tetraspanin 2  -1.76  1.54E-05  0.0002 
PHYHIP  phytanoyl-CoA 2-hydroxylase interacting protein  3.26  1.56E-05  0.0002 
KDM6B  lysine (K)-specific demethylase 6B  1.52  1.65E-05  0.0002 
GPD1  glycerol-3-phosphate dehydrogenase 1 (soluble)  2.19  1.65E-05  0.0002 157	 ﾠ
DOCK9  dedicator of cytokinesis 9  -1.23  1.68E-05  0.0002 
PTPN6  protein tyrosine phosphatase, non-receptor type 6  1.22  1.70E-05  0.0002 
OAS1  2',5'-oligoadenylate synthetase 1, 40/46kDa  -1.37  1.71E-05  0.0002 
CFH  complement factor H  -1.82  1.71E-05  0.0002 
IL20RA  LQWHUOHXNLQUHFHSWRUĮ  -1.28  1.72E-05  0.0002 
STK17B  serine/threonine kinase 17b  -1.22  1.72E-05  0.0002 
CERK  ceramide kinase  1.40  1.74E-05  0.0002 
LMCD1  LIM and cysteine-rich domains 1  -1.33  1.75E-05  0.0002 
TEX12  testis expressed 12  1.22  1.75E-05  0.0002 
USP5  ubiquitin specific peptidase 5 (isopeptidase T)  1.40  1.75E-05  0.0002 
COL12A1  FROODJHQW\SH;,,Į  -1.30  1.90E-05  0.0002 
CDH6  cadherin 6, type 2, K-cadherin (fetal kidney)  -1.51  1.96E-05  0.0002 
APOL5  apolipoprotein L, 5  -1.36  1.98E-05  0.0002 
SLC44A3  solute carrier family 44, member 3  1.40  2.01E-05  0.0002 
FAR1  fatty acyl CoA reductase 1  -1.21  2.02E-05  0.0002 
TMEM156  transmembrane protein 156  -1.31  2.02E-05  0.0002 
TRIB2  tribbles homolog 2 (Drosophila)  -1.21  2.08E-05  0.0002 
FKBP8  FK506 binding protein 8, 38kDa  1.45  2.09E-05  0.0002 
CEP192  centrosomal protein 192kDa  -1.21  2.12E-05  0.0002 
ME2  malic enzyme 2, NAD(+)-dependent, mitochondrial  -1.22  2.12E-05  0.0002 
TIMP1  TIMP metallopeptidase inhibitor 1  -1.32  2.18E-05  0.0002 
IFT81  intraflagellar transport 81 homolog (Chlamydomonas)  -1.26  2.25E-05  0.0002 
NDE1  nudE nuclear distribution gene E homolog 1 (A. nidulans)  1.25  2.28E-05  0.0002 
MCAM  melanoma cell adhesion molecule  -1.36  2.32E-05  0.0002 158	 ﾠ
PIM1  pim-1 oncogene  1.25  2.50E-05  0.0003 
CYR61  cysteine-rich, angiogenic inducer, 61  -2.69  2.52E-05  0.0003 
YTHDC1  YTH domain containing 1  1.55  2.53E-05  0.0003 
UHRF2  ubiquitin-like with PHD and ring finger domains 2  -1.38  2.54E-05  0.0003 
ST3GAL5  67ȕ-JDODFWRVLGHĮ-2,3-sialyltransferase 5  -1.62  2.55E-05  0.0003 
FTSJD2  FtsJ methyltransferase domain containing 2  1.74  2.60E-05  0.0003 
ACSL5  acyl-CoA synthetase long-chain family member 5  -1.58  2.64E-05  0.0003 
VANGL1  vang-like 1 (van gogh, Drosophila)  1.47  2.65E-05  0.0003 
ICA1  islet cell autoantigen 1, 69kDa  -1.38  2.66E-05  0.0003 
OAS2  2'-5'-oligoadenylate synthetase 2, 69/71kDa  -1.23  2.67E-05  0.0003 
ZNF182  Zn
++  finger protein 182  -1.30  2.68E-05  0.0003 
CXCR7  chemokine (C-X-C motif) receptor 7  -1.40  2.72E-05  0.0003 
ABHD3  abhydrolase domain containing 3  -1.55  2.75E-05  0.0003 
CIRBP  cold inducible RNA binding protein  -1.23  2.78E-05  0.0003 
FGF13  fibroblast growth factor 13  -1.47  2.84E-05  0.0003 
BMX  BMX non-receptor tyrosine kinase  -1.24  2.85E-05  0.0003 
HBEGF  heparin-binding EGF-like growth factor  -1.45  2.93E-05  0.0003 
CD93  CD93 molecule  -1.24  2.97E-05  0.0003 
ADSS  adenylosuccinate synthase  -1.44  2.97E-05  0.0003 
ACE2  angiotensin I converting enzyme (peptidyl-dipeptidase A) 2  -1.98  2.99E-05  0.0003 
NTN4  netrin 4  -2.13  3.00E-05  0.0003 
MTHFD1  methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase 
-1.27  3.00E-05  0.0003 
ADAMTS6  ADAM metallopeptidase with thrombospondin type 1 motif, 6  -1.88  3.21E-05  0.0003 159	 ﾠ
EXOC5  exocyst complex component 5  -1.23  3.40E-05  0.0003 
DPT  dermatopontin  -1.92  3.45E-05  0.0003 
PKM2  pyruvate kinase, muscle  -1.48  3.51E-05  0.0003 
ODZ3  odz, odd Oz/ten-m homolog 3 (Drosophila)  1.32  3.58E-05  0.0003 
USP11  ubiquitin specific peptidase 11  1.30  3.61E-05  0.0003 
ADCY4  adenylate cyclase 4  -1.25  3.63E-05  0.0003 
MRC1  mannose receptor, C type 1  -1.42  3.65E-05  0.0003 
NPL  N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase)  2.71  3.73E-05  0.0003 
ANXA3  annexin A3  -1.24  3.76E-05  0.0003 
LAMA3  ODPLQLQĮ  -2.16  3.78E-05  0.0003 
SMOC2  SPARC related modular Ca
++ binding 2  -1.31  3.85E-05  0.0004 
CCL8  chemokine (C-C motif) ligand 8  -1.73  3.90E-05  0.0004 
FBLN1  fibulin 1  1.35  3.92E-05  0.0004 
ZYX  zyxin  1.33  3.94E-05  0.0004 
SCMH1  sex comb on midleg homolog 1 (Drosophila)  1.57  4.16E-05  0.0004 
WLS  wntless homolog (Drosophila)  -1.26  4.26E-05  0.0004 
STMN1  stathmin 1  -1.35  4.30E-05  0.0004 
AP1M2  adaptor-related protein complex 1, mu 2 subunit  1.38  4.36E-05  0.0004 
RAB27B  RAB27B, member RAS oncogene family  2.03  4.44E-05  0.0004 
WASF1  WAS protein family, member 1  -1.27  4.53E-05  0.0004 
MTMR7  myotubularin related protein 7  1.63  4.56E-05  0.0004 
DIO3  deiodinase, iodothyronine, type III  -1.35  4.63E-05  0.0004 
TLR4  toll-like receptor 4  -1.45  4.72E-05  0.0004 
ASPA  aspartoacylase  -1.25  4.77E-05  0.0004 160	 ﾠ
CALCRL  calcitonin receptor-like  -1.49  4.78E-05  0.0004 
RREB1  ras responsive element binding protein 1  1.37  5.00E-05  0.0004 
CAPN1  calpain 1, (mu/I) large subunit  -1.67  5.10E-05  0.0004 
TUBA4A  WXEXOLQĮD  1.88  5.12E-05  0.0004 
IL1A  LQWHUOHXNLQĮ  -1.87  5.32E-05  0.0005 
RASSF9  Ras association (RalGDS/AF-6) domain family (N-terminal) member 9  -1.45  5.40E-05  0.0005 
SLC29A1  solute carrier family 29 (nucleoside transporters), member 1  1.23  5.85E-05  0.0005 
ITIH3  inter-ĮJOREXOLQLQKLELWRU+  -1.64  5.92E-05  0.0005 
C1QTNF1  C1q and tumor necrosis factor related protein 1  3.18  6.05E-05  0.0005 
PTPRE  protein tyrosine phosphatase, receptor type, E  1.84  6.08E-05  0.0005 
SBSN  suprabasin  -3.41  6.24E-05  0.0005 
GPRC5A  G protein-coupled receptor, family C, group 5, member A  1.56  6.48E-05  0.0005 
HES6  hairy and enhancer of split 6 (Drosophila)  1.94  6.70E-05  0.0005 
APBB1  DP\ORLGȕ$SUHFXUVRUSURWHLQ-binding, family B, member 1 (Fe65)  1.40  6.80E-05  0.0006 
ABCA5  ATP-binding cassette, sub-family A (ABC1), member 5  -1.30  6.93E-05  0.0006 
LARP6  La ribonucleoprotein domain family, member 6  -1.26  6.97E-05  0.0006 
CCBE1  collagen and Ca
++  binding EGF domains 1  1.45  7.08E-05  0.0006 
ARHGAP8  Rho GTPase activating protein 8  1.50  7.34E-05  0.0006 
CD14  CD14 molecule  -1.33  7.35E-05  0.0006 
AGTRAP  angiotensin II receptor-associated protein  1.63  7.57E-05  0.0006 
GLUL  glutamate-ammonia ligase  1.53  7.66E-05  0.0006 
WFS1  Wolfram syndrome 1 (wolframin)  1.46  7.89E-05  0.0006 
MATN2  matrilin 2  -1.88  8.17E-05  0.0006 
DNAJB1  DnaJ (Hsp40) homolog, subfamily B, member 1  -1.36  8.18E-05  0.0006 161	 ﾠ
IL6  LQWHUOHXNLQLQWHUIHURQȕ  -2.29  8.23E-05  0.0006 
ITGB4  LQWHJULQȕ  1.26  8.48E-05  0.0007 
EML2  echinoderm microtubule associated protein like 2  1.54  8.65E-05  0.0007 
SLC47A1  solute carrier family 47, member 1  1.44  8.72E-05  0.0007 
MADD  MAP-kinase activating death domain  1.23  9.02E-05  0.0007 
TGFB2  WUDQVIRUPLQJJURZWKIDFWRUȕ  -1.66  9.19E-05  0.0007 
CRYM  crystallin, mu  2.23  9.23E-05  0.0007 
TMEM178  transmembrane protein 178  -2.02  9.31E-05  0.0007 
HOXA5  homeobox A5  -1.26  9.39E-05  0.0007 
CFB  complement factor B  -1.67  9.49E-05  0.0007 
STK39  serine threonine kinase 39  1.34  9.53E-05  0.0007 
CD34  CD34 molecule  -1.36  9.55E-05  0.0007 
IL18  interleukin 18 (interferon-Ȗ-inducing factor)  1.32  9.58E-05  0.0007 
RBP7  retinol binding protein 7, cellular  -1.97  9.59E-05  0.0007 
POSTN  periostin, osteoblast specific factor  -1.73  9.86E-05  0.0007 
GSTT1  glutathione S-transferase theta 1  -1.22  0.0001  0.0008 
ZNF300  Zn
++  finger protein 300  -1.45  0.0001  0.0008 
UBA1  ubiquitin-like modifier activating enzyme 1  1.24  0.0001  0.0008 
PLXNA2  plexin A2  -1.34  0.0001  0.0008 
NKX3-1  NK3 homeobox 1  1.43  0.0001  0.0008 
FIBIN  fin bud initiation factor homolog (zebrafish)  1.31  0.0001  0.0008 
FGD6  FYVE, RhoGEF and PH domain containing 6  1.26  0.0001  0.0008 
KLHDC1  kelch domain containing 1  -1.24  0.0001  0.0008 
TMEM100  transmembrane protein 100  -1.21  0.0001  0.0008 162	 ﾠ
FBXW10  F-box and WD repeat domain containing 10  -1.73  0.0001  0.0008 
SRSF7  serine/arginine-rich splicing factor 7  -1.81  0.0001  0.0008 
JUN  jun proto-oncogene  -3.12  0.0001  0.0008 
TRIM3  tripartite motif-containing 3  1.51  0.0001  0.0009 
DLGAP1  discs, large (Drosophila) homolog-associated protein 1  1.42  0.0001  0.0009 
ENPP2  ectonucleotide pyrophosphatase/phosphodiesterase 2  -1.39  0.0001  0.0009 
PARP2  poly (ADP-ribose) polymerase 2  -1.29  0.0001  0.0009 
CLDN10  claudin 10  -1.88  0.0001  0.0009 
BIRC3  baculoviral IAP repeat-containing 3  -1.56  0.0001  0.0009 
NR4A1  nuclear receptor subfamily 4, group A, member 1  -2.17  0.0001  0.0009 
OGT  O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) 
-1.65  0.0001  0.0010 
SAA1  serum amyloid A1  -1.94  0.0001  0.0010 
CA4  carbonic anhydrase IV  -1.89  0.0001  0.0010 
SLC2A3  solute carrier family 2 (facilitated glucose transporter), member 3  -1.93  0.0001  0.0010 
PHLDA1  pleckstrin homology-like domain, family A, member 1  1.63  0.0001  0.0010 
BFAR  bifunctional apoptosis regulator  1.25  0.0001  0.0010 
ABCA6  ATP-binding cassette, sub-family A (ABC1), member 6  -1.40  0.0002  0.0010 
HSP70  heat shock protein 70  -2.18  0.0002  0.0010 
ADAM10  ADAM metallopeptidase domain 10  1.27  0.0002  0.0010 
FLT1  fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular 
permeability factor receptor) 
-1.30  0.0002  0.0010 
ASPM  asp (abnormal spindle) homolog, microcephaly associated (Drosophila)  -1.23  0.0002  0.0011 
NAPA  N-ethylmaleimide-sensitive factor attachment SURWHLQĮ  1.50  0.0002  0.0011 163	 ﾠ
APOC1  apolipoprotein C-I  -1.51  0.0002  0.0011 
CXCL10  chemokine (C-X-C motif) ligand 10  -1.73  0.0002  0.0011 
FEZ2  fasciculation and elongation protein zeta 2 (zygin II)  -1.26  0.0002  0.0011 
FKBP4  FK506 binding protein 4, 59kDa  1.24  0.0002  0.0011 
PLAUR  plasminogen activator, urokinase receptor  -1.29  0.0002  0.0011 
UBL5  ubiquitin-like 5  1.29  0.0002  0.0011 
IQGAP2  IQ motif containing GTPase activating protein 2  -1.22  0.0002  0.0012 
ASPN  asporin  -1.45  0.0002  0.0012 
VPS13D  vacuolar protein sorting 13 homolog D (S. cerevisiae)  1.46  0.0002  0.0012 
TMTC1  transmembrane and tetratricopeptide repeat containing 1  -1.24  0.0002  0.0012 
CCNL1  cyclin L1  -1.94  0.0002  0.0013 
AVPR1A  arginine vasopressin receptor 1A  -1.27  0.0002  0.0013 
COMP  cartilage oligomeric matrix protein  -2.30  0.0002  0.0013 
MAP3K8  mitogen-activated protein kinase kinase kinase 8  -1.31  0.00021  0.0014 
NNAT  neuronatin  -1.44  0.0002  0.0014 
CASC5  cancer susceptibility candidate 5  -1.28  0.0002  0.0014 
MATR3  matrin 3  -1.22  0.0002  0.0014 
WNT5B  wingless-type MMTV integration site family, member 5B  1.58  0.0002  0.0014 
EHMT2  euchromatic histone-lysine N-methyltransferase 2  1.45  0.0002  0.0015 
SGIP1  SH3-domain GRB2-like (endophilin) interacting protein 1  -1.79  0.0003  0.0016 
CHMP4C  chromatin modifying protein 4C  -1.26  0.0003  0.0016 
DDX26B  DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26B  -1.31  0.0003  0.0016 
CPXM1  carboxypeptidase X (M14 family), member 1  2.42  0.0003  0.0016 
PDGFRL  platelet-derived growth factor receptor-like  -1.21  0.0003  0.0017 164	 ﾠ
NXPH2  neurexophilin 2  -1.41  0.0003  0.0017 
PDE6H  phosphodiesterase 6H, cGMP-VSHFLILFFRQHȖ  -1.25  0.0003  0.0017 
SERPINE1  serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 
1), member 1 
-1.66  0.0003  0.0017 
MARK2  MAP/microtubule affinity-regulating kinase 2  2.25  0.0003  0.0018 
ACP5  acid phosphatase 5, tartrate resistant  -1.29  0.0003  0.0018 
THBS1  thrombospondin 1  -1.40  0.0003  0.0019 
CD200R1  CD200 receptor 1  -1.46  0.0003  0.0019 
ATR  ataxia telangiectasia and Rad3 related  -1.26  0.0003  0.0019 
EDNRA  endothelin receptor type A  -1.24  0.0003  0.0019 
PDK4  pyruvate dehydrogenase kinase, isozyme 4  -1.34  0.0003  0.0020 
LRRK2  leucine-rich repeat kinase 2  -1.37  0.0003  0.0020 
ICAM1  intercellular adhesion molecule 1  -1.49  0.0003  0.0020 
MYOM1  myomesin 1, 185kDa  -1.28  0.0003  0.0020 
B3GNT4  UDP-*OF1$Fȕ*DOȕ-1,3-N-acetylglucosaminyltransferase 4  1.27  0.00032  0.0021 
PRKCSH  protein kinase C substrate 80K-H  1.40  0.0004  0.0021 
CTSD  cathepsin D  1.71  0.0004  0.0022 
MLL3  myeloid/lymphoid or mixed-lineage leukemia 3  1.25  0.0004  0.0022 
P4HA1  prolyl 4-K\GUR[\ODVHĮSRO\SHSWLGH,  -1.22  0.0004  0.0023 
SLC39A14  solute carrier family 39 (Zn
++ transporter), member 14  -1.24  0.0004  0.0023 
POLE2  polymerase (DNA directed), epsilon 2 (p59 subunit)  -1.24  0.0004  0.0023 
LAPTM5  lysosomal protein transmembrane 5  -1.55  0.0004  0.0023 
THBS4  thrombospondin 4  -3.42  0.0004  0.0023 
GDI1  GDP dissociation inhibitor 1  1.25  0.0004  0.0023 165	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BCAT1  branched chain amino-acid transaminase 1, cytosolic  -1.59  0.0004  0.0025 
MLLT1  myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); 
translocated to, 1 
2.33  0.0004  0.0025 
COL8A1  FROODJHQW\SH9,,,Į  -1.22  0.0005  0.0026 
NRG1  neuregulin 1  1.80  0.0005  0.0026 
CXCL14  chemokine (C-X-C motif) ligand 14  -1.48  0.0005  0.0027 
ELOVL2  elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2  -1.25  0.0005  0.0027 
TMOD1  tropomodulin 1  -1.22  0.0005  0.0028 
BAIAP2  BAI1-associated protein 2  1.38  0.0005  0.0029 
GTSF1  gametocyte specific factor 1  1.59  0.0005  0.0029 
GNA14  JXDQLQHQXFOHRWLGHELQGLQJSURWHLQ*SURWHLQĮ  1.22  0.0006  0.0031 
ILDR2  immunoglobulin-like domain containing receptor 2  -1.40  0.0006  0.0031 
AASS  aminoadipate-semialdehyde synthase  1.95  0.0007  0.0034 
OMD  osteomodulin  -1.21  0.0007  0.0035 
RAB38  RAB38, member RAS oncogene family  1.38  0.0007  0.0035 
NPY  neuropeptide Y  4.00  0.0007  0.0035 
SSBP2  single-stranded DNA binding protein 2  -1.38  0.0007  0.0035 
KCNS3  potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3  2.20  0.0007  0.0036 
ANKRD45  ankyrin repeat domain 45  1.22  0.0007  0.0036 
SGMS2  sphingomyelin synthase 2  1.36  0.0007  0.0036 
PRKAR2B  protein kinase, cAMP-GHSHQGHQWUHJXODWRU\W\SH,,ȕ  -1.29  0.0007  0.0037 
CDH13  cadherin 13, H-cadherin (heart)  -1.49  0.0007  0.0037 
AKT1S1  AKT1 substrate 1 (proline-rich)  1.90  0.0007  0.0038 
PNLIPRP2  pancreatic lipase-related protein 2  2.08  0.0008  0.0039 166	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IDO1  indoleamine 2,3-dioxygenase 1  -1.98  0.0008  0.0039 
GLCCI1  glucocorticoid induced transcript 1  1.94  0.0008  0.0039 
KIRREL  kin of IRRE like (Drosophila)  1.24  0.0008  0.0040 
EDN1  endothelin 1  -1.69  0.0008  0.0040 
PAQR5  progestin and adipoQ receptor family member V  1.21  0.0008  0.0041 
ZBTB16  Zn
++  finger and BTB domain containing 16  -1.25  0.0008  0.0042 
PDE9A  phosphodiesterase 9A  -1.48  0.0009  0.0044 
CD44  CD44 molecule (Indian blood group)  1.23  0.0009  0.0047 
LYVE1  lymphatic vessel endothelial hyaluronan receptor 1  -1.23  0.0010  0.0048 
PTBP2  polypyrimidine tract binding protein 2  -1.37  0.0010  0.0050 
DUSP5  dual specificity phosphatase 5  -1.35  0.0010  0.0051 
HTR1D  5-hydroxytryptamine (serotonin) receptor 1D  1.46  0.0010  0.0051 
ACPL2  acid phosphatase-like 2  -1.65  0.0011  0.0052 
CLPTM1  cleft lip and palate associated transmembrane protein 1  1.28  0.0011  0.0053 
EFEMP1  EGF-containing fibulin-like extracellular matrix protein 1  1.22  0.0011  0.0055 
ACOXL  acyl-CoA oxidase-like  -1.37  0.0012  0.0057 
LPHN3  latrophilin 3  -1.92  0.0012  0.0057 
ITGB6  LQWHJULQȕ  1.73  0.0012  0.0058 
ISG15  ISG15 ubiquitin-like modifier  -1.46  0.0012  0.0058 
HNRNPUL1  heterogeneous nuclear ribonucleoprotein U-like 1  1.31  0.0013  0.0059 
COCH  coagulation factor C homolog, cochlin (Limulus polyphemus)  -1.91  0.0013  0.0061 
BPIL3  bactericidal/permeability-increasing protein-like 3  2.86  0.0013  0.0062 
DNAH17  dynein, axonemal, heavy chain 17  -1.36  0.0014  0.0063 
TGFB3  WUDQVIRUPLQJJURZWKIDFWRUȕ  -1.37  0.0014  0.0063 167	 ﾠ
KRT7  keratin 7  1.56  0.0014  0.0065 
PLAT  plasminogen activator, tissue  -1.36  0.0015  0.0069 
UCHL1  ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)  -1.45  0.0016  0.0071 
MMP1  matrix metallopeptidase 1 (interstitial collagenase)  -2.70  0.0016  0.0072 
PDGFD  platelet derived growth factor D  -1.45  0.0017  0.0076 
NET1  neuroepithelial cell transforming 1  1.55  0.0018  0.0081 
SCCPDH  saccharopine dehydrogenase (putative)  1.29  0.0019  0.0085 
ST14  suppression of tumorigenicity 14 (colon carcinoma)  1.62  0.0020  0.0088 
MAOB  monoamine oxidase B  -1.31  0.0021  0.0090 
PTGDR  prostaglandin D2 receptor (DP)  -1.38  0.0021  0.0091 
MFAP5  microfibrillar associated protein 5  -2.15  0.0021  0.0092 
PAPPA2  pappalysin 2  1.27  0.0022  0.0093 
OLFML3  olfactomedin-like 3  1.34  0.0022  0.0094 
MYO1E  myosin IE  1.23  0.0022  0.0095 
TAF1D  TATA box binding protein (TBP)-associated factor, RNA polymerase I, D, 
41kDa 
-1.21  0.0023  0.0098 
LAPTM4B  O\VRVRPDOSURWHLQWUDQVPHPEUDQHȕ  -1.33  0.0023  0.0098 
STOM  stomatin  -1.21  0.0026  0.0108 
SPINK5  serine peptidase inhibitor, Kazal type 5  -1.68  0.0026  0.0109 
GP1BA  glycoprotein Ib  -1.44  0.0030  0.0122 
SMPDL3A  sphingomyelin phosphodiesterase, acid-like 3A  -1.60  0.0030  0.0123 
SELE  selectin E  -1.78  0.0031  0.0125 
LARP7  La ribonucleoprotein domain family, member 7  -1.38  0.0035  0.0137 
ANO3  anoctamin 3  -1.79  0.0037  0.0139 168	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RBP4  retinol binding protein 4, plasma  -1.32  0.0042  0.0160 
GADD45G  growth arrest and DNA-damage-LQGXFLEOHȖ  -1.21  0.0043  0.0163 
MAGED2  melanoma antigen family D, 2  -1.47  0.0044  0.0166 
BAI3  brain-specific angiogenesis inhibitor 3  -1.32  0.0045  0.0170 
CLEC1B  C-type lectin domain family 1, member B  -1.22  0.0048  0.0180 
TIA1  TIA1 cytotoxic granule-associated RNA binding protein  -1.22  0.0049  0.0181 
CALB1  calbindin 1, 28kDa  1.56  0.0051  0.0187 
MFGE8  milk fat globule-EGF factor 8 protein  1.58  0.0052  0.0190 
FAH  fumarylacetoacetate hydrolase (fumarylacetoacetase)  1.79  0.0058  0.0208 
GDA  guanine deaminase  -1.30  0.0063  0.0225 
MATN3  matrilin 3  2.22  0.0064  0.0226 
SLC2A9  solute carrier family 2 (facilitated glucose transporter), member 9  -1.81  0.0092  0.0307 
FBN2  fibrillin 2  -1.24  0.0107  0.0346 
ANKRD32  ankyrin repeat domain 32  -1.26  0.0112  0.0360 
FABP5  fatty acid binding protein 5 (psoriasis-associated)  1.54  0.0118  0.0375 
AK3L1, 
LOC475238, 
LOC609761, 
LOC611161, 
LOC611170 
adenylate kinase 3-like 1; similar to ZK84.1; similar to Nascent polypeptide-
DVVRFLDWHGFRPSOH[ĮVXEXQLWPXVFOH-VSHFLILFIRUPĮ-NAC, muscle-specific 
form); hypothetical protein LOC611161; similar to CG13648-PA 
1.25  0.0126  0.0396 
DKK1  dickkopf homolog 1 (Xenopus laevis)  1.70  0.0128  0.0399 
IGSF10  immunoglobulin superfamily, member 10  -1.61  0.0153  0.0463 
CA2  carbonic anhydrase II  1.52  0.0171  0.0508 
ULK4  unc-51-like kinase 4 (C. elegans)  -1.22  0.0176  0.0521 169	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Appendix J.1 Summary 
 
I have been fortunate enough to have the opportunity to present my research at regional, 
national and international conferences throughout my graduate career. 
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Appendix J.2 Accepted Abstract to the 2011 Annual Northwest Reproductive Sciences 
Symposium (Corvallis, OR)  
 
Comparison of RNA Yield Using Two Commercial Kits 
 
Elizabeth Fellows, Timothy Hazzard, Michelle Kutzler 
Department of Animal Science, Oregon State University 
 
Introduction: A wide variety of RNA isolation kits are commercially available.  Several 
investigators  have  reported  that  the  most  effective  method  for  isolating  RNA  utilizes 
TRIzol  (Invitrogen,  Carlsbad,  CA)  followed  by  oligo  (dt)  cellulose  spin  columns.
1,2 
However, there have been no published studies comparing RNA yield and purity using 
only TRIzol or oligo (dt) cellulose spin columns. Therefore, we sought to compare the 
TRIzol Plus RNA Purification Kit (Invitrogen, Carlsbad, CA) that isolates total RNA 
using phenol and guanidine isothiocyanate to the Fast Track 2.0 Kit that isolates mRNA 
using oligo (dt) cellulose.  Both kits use silica based spin columns. We hypothesized that 
1)  the  TRIzol  Plus  RNA  Purification  Kit  would  result  in  a  greater  amount  of  RNA 
isolated and 2) that the Fast Track 2.0 Kit would result in increased purity of the RNA 
sample as determined by the A260/280 ratio.  
 
Methods: Tissues from late gestation canine fetuses were flash frozen in liquid nitrogen. 
Following the Fast Track Kit’s instructions, RNA was isolated from 1000 mg of lung, 
liver and chorioallantois. Following the TRIzol Plus RNA Purification Kit’s instructions, 
RNA was isolated from 100 mg of each type of tissue. A nanophotometer (IMPLEN, 
Munich, Germany) was used to determine the A260 measurement, which was then used to 
determine RNA concentration. The RNA concentration was then used to determine the 
amount of isolated RNA.  The A260/A280 ratio was used to determine RNA purity.  
 
Results: Preliminary results indicate the purity of RNA isolated from each protocol was 
not different, but the RNA yield was higher with the TRIzol Plus RNA Purification Kit 
(Table 1).  
 
Discussion: A significant limitation of the Fast Track 2.0 Kit is that it requires ten times 
the  amount  of  tissue  (1000  mg  versus  100  mg)  compared  to  the  TRIzol  Plus  RNA 
Purification  Kit.    However,  the  Fast  Track  2.0  Kit  has  the  advantage  of  yielding  an 
enriched  mRNA  sample;  whereas  the  TRIzol  Plus  RNA  Purification  Kit  yields  total 
RNA, of which approximately 1-5% is mRNA. The decision regarding what kit to use 
should be based on the amount of tissue available and what type of RNA is needed for 
the experiment. 
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7DEOH51$DPRXQWȝJDQGSXULW\$260/280 ratio) from fetal canine tissues isolated 
using two commercially-available kits. 
 
  TRIzol Plus RNA Purification Kit  FastTrack 2.0 Kit 
Tissue  Total RNA Yield 
ȝJ 
Purity  P51$<LHOGȝJ  Purity 
Liver  109.20  1.947  18.96  2.097 
Lung  80.40  1.985  7.02  1.973 
Chorioallantois  130.50  1.957  41.40  2.025 
 
 
References: 
 
[1] Honscha KU, Schirmer A, Reischauer A, Schoon HA, Einspanier A, Gabel. 
Expression of ABC-transport proteins in canine mammary cancer: consequences for 
chemotherapy. Reprod Dom Anim. 2009. 44 (Suppl. 2): 218-223. 
[2] Wang HB. Wang QG, Zhang XY, Gu XF, Wang SB, Wu SB, Li H. Microarray 
analysis of genes differentially expressed in the liver of lean and fat chickens. Animal. 
2010. 4(4): 513-522.172	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Appendix J.4 Presented at the 2012 Annual Northwest Reproductive Sciences 
Symposium (Beaverton, OR) and the 7
th International Symposium on Canine and Feline 
Reproduction (Whistler, BC, Canada) 
 
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pre-term, 
pre-labor and parturient canine placentas. 
 
Elizabeth J. Fellows, Timothy M. Hazzard, Michelle A. Kutzler
 
Department of Animal Science, Oregon State University, Corvallis, OR USA 97330 
fellowel@onid.orst.edu 
 
INTRODUCTION: Matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) are postulated to be involved in trophoblast differentiation, 
migration and invasion during primate and ruminant placentation (1-3, 5). It has also 
been proposed that MMPs may contribute to rentention of placental membranes in the 
cow (3, 5). Previous studies have reported MMP-2 and MMP-9 expression in the canine 
uterus and pre-implantation embryo (4, 6), but no studies have examined MMP 
expression in the canine placenta. Abnormal expression of these factors at the end of 
canine gestation may contribute to post-parturient trophoblast persistence as in the case of 
subinvolution of placental sites (SIPS). The expression of TIMP-2 has not been described 
in the canine reproductive tract. Therefore, the aim of this study was to examine mRNA 
expression of MMP-2, MMP-9 and TIMP-2 in canine chorioallantois tissue at pre-term, 
pre-labor and during parturition. The hypothesis was that expression of MMP-2, MMP-9 
and TIMP-2 would be lower in parturient canine chorioallantois tissues compared to pre-
labor and pre-term tissues. 
 
METHODS: Following ovariohysterectomy at 61±1 days past the LH surge (pre-term; 
n=4), chorioallantois tissue was collected without the marginal hematoma and flash 
frozen in liquid nitrogen. Chorioallantois tissue was collected in the same manner 
following elective C-section at 64±1 days past the LH surge prior to first stage labor (pre-
labor; n=3) and following natural delivery (parturient; n=3). Total RNA was isolated 
using the TRIzol Plus RNA Purification Kit (Invitrogen, Carlsbad, CA) following the 
manufacturer’s instructions. Quantitative RT-PCR was performed using primers and 
probes developed for canine MMP-2, MMP-9 and TIMP-2 (Applied Biosystems, 
Carlsbad, CA). Gene expression was normalized to 18S rRNA expression and the first 
parturient sample collected was used as a calibrator. Relative expression was calculated 
using the relative quantitation (2
-ǻǻ&W) method. Statisical analysis was performed using a 
one-way ANOVA with Bonferroni corrections using Stata 12.0 software (StataCorp LP, 
College Station, TX). Significance was defined as p<0.05. 
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CONCLUSION: This is the first investigation to report MMP-2, MMP-9 and TIMP-2 
expression in pre-term, pre-labor and parturient canine chorioallantois. The mRNA 
expression of MMP-2 and MMP-9 may related to the onset of labor. This differs from the 
human where MMP-2 and MMP-9 mRNA expression gradually decrease with 
approaching parturition (1). TIMP-2 mRNA expression appears to be constitutive at the 
end of gestation. This is similar to what has been reported in cattle (3). 
 
REFERENCES: 
1. Zhang H, Long Q, Ling L, Gao A, Li A, Lin Q. Elevated expression of KiSS-1 in 
placenta of preeclampsia and its effect on trophoblast. Reprod Biol 2011; 11(2): 99-
115. 
2. Gao F, Chen XL, Gao HJ, Liu YX. Expression of matrix metalloproteinase-2, tissue 
inhibitors of metalloproteinase-1, -3 at the implantation site of rhesus monkey during 
the early stage of pregnancy. Endocrine 2001; 16(1): 47-54. 
3. Walter I, Boos A. Matrix metalloproteinases (MMP-2 and MMP-9) and tissue 
inhibitor-2 of matrix metalloproteinases (TIMP-2) in the placenta and interplacental 
uterine wall in normal cows and in cattle with retention of fetal membranes. Placenta 
2001; 22: 473-483. 
4. Kanca H, Walter I, Miller I, Schafer-Somi S, Izgur H, Aslan S. Expression and activity 
of matrix metalloproteinases in the uterus of bitches after spontaneous and induced 
abortion. Reprod Dom Anim 2011; 46: 197-204. 
5. Dilly M, Hambruch N, Shenavai S, Schuler G, Froehlich R, Haeger JD, Ozalp GR, 
Pfarrer C. Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue 
inhibitor of matrix metalloproteinase (TIMP)-2 during bovine placentation and at term 
with or without placental retention. Theriogenology 2011; 75: 1104-1114. 
6. Beceriklisoy HB, Schafer-Somi S, Miller I, Kanca H, Izgur H, Aslan S. Matrix 
metalloproteinase (MMP)-2 and MMP-9 activity in the canine uterus before and 
during placentation. Reprod Dom Anim 2007; 42: 654-659. 
 
Figure 1. Relative Quantitation (RQ) of 
MMP-9, MMP-2 and TIMP-2 in pre-term, 
pre-labor and parturient samples. MMP-9 
and MMP-2 expression was higher in pre-
labor samples compared to pre-term and 
parturient samples. *p<0.05 
RESULTS: MMP-9 and MMP-2 expression 
was higher in pre-labor samples compared to 
pre-term and parturient samples (Figure 1). 
There was no significant difference between 
TIMP-2 expression among groups. 
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Appendix J.7 Presented at the 2012 Annual Conference for the Society for 
Theriogenology (Baltimore, MD) 
 
Expression of vascular endothelial growth factor A and its receptor Flt-1 in canine 
placenta 
 
Elizabeth J. Fellows, Timothy M. Hazzard, Michelle A. Kutzler
 
Department of Animal Science, Oregon State University, Corvallis, OR USA 97330 
 
INTRODUCTION: Vascular endothelial growth factor A (VEGFA) and its receptor Flt-
1 have been studied extensively in primate placentas, where they have been proposed to 
play a role in trophoblast invasion (1). In addition, placental Flt-1 mRNA expression has 
been shown to increase at term in humans (2). No studies have been performed on the 
expression of these factors in the canine placenta at the time of parturition. Dysregulation 
of these factors could, for example, contribute to abnormal post-partum involution of the 
placental sites (subinvolution of placental sites). Therefore, the aim of this study was to 
examine VEGFA and Flt-1 mRNA expression in canine chorio-allantoic tissue at pre-
term, pre-labor and during parturition. The hypothesis was that expression of VEGFA 
and Flt-1 will be greater in term (pre-labor or parturient) than in pre-term bitches.  
METHODS: Following ovariohysterectomy at 61±1 days past the LH surge (pre-term; 
n=4), chorio-allantoic tissue was collected without the marginal hematoma and flash 
frozen in LN2. Chorio-allantoic tissue was collected in the same manner following 
elective Caesarean section at 64±1 days past the LH surge prior to first stage labor (pre-
labor; n=3) and following natural delivery (parturient; n=3). Total RNA was isolated 
using the TRIzol Plus RNA Purification Kit (Invitrogen, Carlsbad, CA) following the 
manufacturer’s instructions. Quantitative RT-PCR was performed using primers and 
probes developed for canine VEGFA and Flt-1 (Applied Biosystems, Carlsbad, CA). 
Gene expression was normalized to 18S rRNA expression and the first parturient sample 
collected was used as a calibrator. Relative expression was calculated using the relative 
quantitation (2
-ǻǻ&W) method. Statistical analysis was performed using a Student’s t test in 
Excel (Microsoft, Redmond, WA). Significance was defined as p<0.05. 
RESULTS: Flt-1 expression was higher in tissues collected from pre-labor and parturient 
bitches than in tissues from pre-term bitches. However, there were no differences 
between groups in VEGFA expression. 
CONCLUSION: Based on these results, VEGFA mRNA is constitutively expressed 
during late gestation and parturition in the dog. Its receptor, Flt-1 increases in the canine 
chorio-allantois at the time of parturition, similar to what has been reported in primates 
(2). Flt-1 has been reported to be directly up-regulated by hypoxic conditions (2), 
suggesting that placental hypoxia associated with parturition may lead to the observed 
up-regulation of Flt-1 during whelping. 
REFERENCES: 
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pregnancies complicated by hypertensive disorders. BJOG. 2004; 111: 564-570. 
2.  Lee KJ, Shim SH, Kang KM, et al. Global gene expression changes induced in the human 
placenta during labor. Placenta. 2010; 31(8): 698-704. 181	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Objec ves 
•  Compare expression pa erns of MMPͲ2, 
MMPͲ9, TIMPͲ2, VEGFͲA & FltͲ1 in the 
peripartum canine placenta using realͲ
me RTͲPCR 
•  Compare global gene expression pa erns 
in the peripartum canine placenta using 
microarray & iden fy  
candidate genes for future 
studies 
 
Methods 
•  Sample collec on 
– Tissue was flash frozen in LN2 & stored at 
Ͳ80°C un l processing 
– Total RNA was isolated using the TRIzol Plus 
RNA Purifica on Kit (Invitrogen) 
– RNA integrity was confirmed with a 2100 
Agilent Bioanalyzer ͳͺ͵
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Sta s cal Analysis  
•  RealͲ me RTͲPCR 
– Rela ve quan ta on (RQ) or 2ͲȴȴCt method  
– OneͲway ANOVA with Bonferroni correc ons 
•  Microarray analysis  
– Bioconductor so ware with the limma & affy 
packages in the R sta s cal program using a 
false discovery rate (FDR) adjusted p value ч 
0.1 with a log fold change ш 1.2 
•  Significance defined as p ч 0.05 
Smyth, 2004, Sitras et al., 2009; Hoegh 
et al., 2010; Lian et al., 2010   
Hypothesis 1: Results 
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Hypothesis 1: Results 
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0.0
0.5
1.0
1.5 Pre-term (n=4)
Pre-labor (n=4)
Parturient (n=3)
R
Q
PreͲlabor 
Up: 8  
Down: 4  
Parturient 
Up: 12 
Down: 20 
PreͲlabor & 
Parturient 
Up: 1 
Down: 5 
Hypothesis 2: Results  ͳͺͶ
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